Methods and compositions for genetically modifying and amplifying lymphocytes and modulating their activity
Through the binding of replication-deficient recombinant retroviral particles with lymphocytes, pseudotyping components and chimeric antigen receptors, the problem of insensitive cell activation and gene transduction in CAR therapy is solved, and efficient and safe Lymphocyte gene modification and regulation improves the safety and efficiency of treatment.
Patent Information
- Application Number
- CN202410976802.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-09-06
- Filing Date
- 2018-09-17
- Publication Date
- 2024-11-05
AI Technical Summary
Existing CAR therapies have difficulty in cell activation, insensitive gene transduction, cell survival and consistency problems when transducing and genetically modified lymphocytes, and it is difficult to safely control cell propagation rates and target orientation.
Replication-deficient recombinant retroviral particles are used to bind to resting T cells and NK cells, and pseudotyping components such as Src-FLAG-Vpx, measles virus clotting and CD28 binding peptides to promote cell membrane fusion and gene modification, and bind to Chimeric antigen receptors and lymphoproliferative components that control their expression to regulate cellular activity.
It has achieved efficient genetic modification of lymphocytes in a short period of time, improved the growth characteristics and regulation of cells, reduced the inconsistency of cell survival and amplification, and enhanced the safety of tumor target toxicity.
Smart Images

Figure CN118895313A_ABST
Abstract
Description
[0001] This application is a divisional application of the Chinese patent application entitled “Methods and compositions for genetically modifying and expanding lymphocytes and regulating their activity” filed by the applicant Exuma Biotechnology Corporation on September 17, 2018 and with application number 201880060681.7 (PCT / US2018 / 051392).
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application is a continuation-in-part of International Application No. PCT / US2018 / 020818, filed on March 3, 2018, and claims the benefit of U.S. Provisional Application No. 62 / 560,176, filed on September 18, 2017; U.S. Provisional Application No. 62 / 564,253, filed on September 27, 2017; U.S. Provisional Application No. 62 / 564,991, filed on September 28, 2017; and U.S. Provisional Application No. 62 / 728,056, filed on September 6, 2018. International Application No. PCT / US2018 / 020818 is a continuation-in-part of International Application No. PCT / US2017 / 023112, filed on March 19, 2017. Continuation-in-Part; International Application No. PCT / US2017 / 041277, filed July 8, 2017; U.S. Application No. 15 / 462,855, filed March 19, 2017; and U.S. Application No. 15 / 644,778, filed July 8, 2017; and claims the benefit of U.S. Provisional Application No. 62 / 467,039, filed March 3, 2017; U.S. Provisional Application No. 62 / 560,176, filed September 18, 2017; U.S. Provisional Application No. 62 / 564,253, filed September 27, 2017; and U.S. Provisional Application No. 62 / 564,991; International Application No. PCT / US2017 / 023112 claims the benefit of U.S. Provisional Application No. 62 / 390,093, filed March 19, 2016; U.S. Provisional Application No. 62 / 360,041, filed July 8, 2016; and U.S. Provisional Application No. 62 / 467,039, filed March 3, 2017; International Application No. PCT / US2017 / 041277 claims the benefit of International Application No. PCT / US2017 / 023112, filed March 19, 2017; U.S. Patent Application No. 15 / 462,855, filed March 19, 2017; U.S. Provisional Application No. 62 / 360,041, filed July 8, 2016; and U.S. Provisional Application No. 62 / 467,039, filed March 3, 2017; U.S. Application No. 15 / 462,855 claims the benefit of U.S. Provisional Application No. 62 / 390,093, filed March 19, 2016; U.S. Provisional Application No. 62 / 360,041, filed July 8, 2016; and U.S. Provisional Application No. 62 / 467,039, filed March 3, 2017; and U.S. Application No. 15 / 644,778 is a continuation-in-part of International Application No. PCT / US2017 / 023112, filed March 19, 2017;and a continuation-in-part of U.S. Patent Application No. 15 / 462,855, filed on March 19, 2017; and claims the benefit of U.S. Provisional Application No. 62 / 360,041, filed on July 8, 2016, and U.S. Provisional Application No. 62 / 467,039, filed on March 3, 2017. These applications are incorporated herein by reference in their entirety.
[0004] Sequence Listing
[0005] This application incorporates by reference the electronic sequence listing submitted with this application. The electronic sequence listing was submitted as a text (.txt) file titled "F1_001_TW_04_Sequence_Listing_2018_09_17" created on September 17, 2018 (file size: 529KB), and is incorporated herein by reference in its entirety. Technical Field
[0006] The present invention relates to the field of immunology, or more specifically, to gene modification of T lymphocytes or other immune cells, and methods for preparing replication-deficient recombinant retroviral particles and controlling gene expression therein. Background Art
[0007] Lymphocytes isolated from individuals (e.g., patients) can be activated in vitro and genetically modified to express synthetic proteins that are capable of repositioning and binding to other cells and the environment based on the genetic program incorporated therein. An example of this synthetic protein is a chimeric antigen receptor (CAR). A currently used CAR is a fusion of an extracellular recognition domain (e.g., an antigen binding domain), a transmembrane domain, and one or more intracellular signaling domains encoded by a replication-deficient recombinant retrovirus.
[0008] Although recombinant retroviruses have shown efficacy in infecting non-dividing cells, resting CD4 and CD8 lymphocytes are insensitive to gene transduction of these vectors. To overcome these difficulties, stimulators are usually used to activate these cells in vitro before genetic modification of the CAR gene vector can occur. After stimulation and transduction, the genetically modified cells are expanded in vitro and then reintroduced into patients with lympholysis. After antigen engagement in vivo, the intracellular signaling portion of the CAR can start activation-related reactions in immune cells and release cytolytic molecules to induce tumor cell death.
[0009] Such current approaches require extensive manipulation and ex vivo production of proliferative T cells before T cells are reinfused into the patient, as well as lymphodepleting chemotherapy to release cytokines and deplete competing receptors to facilitate T cell engraftment. Once introduced into the body, such CAR therapies are also unable to control the rate of in vivo dissemination and are unable to safely target targets that are also expressed outside the tumor. Therefore, current CAR therapies generally consist of 1×10 5 cells / kg to 1×10 8 The cell infusion of 12 to 28 days of ex vivo expansion of a dose of individual cells / kg, and directed targets (e.g., tumor targets), is generally acceptable for the CAR therapy to leave the tumor in terms of target toxicity. These relatively long ex vivo expansion times produce cell viability and sterility problems, as well as sample consistency issues other than the challenges of adjustability. Therefore, there is a significant need for a safer and more effective adjustable T cell or NK cell therapy.
[0010] Since our understanding of the processes that drive the transduction, proliferation and survival of lymphocytes is at the core of various potential commercial uses involving immune processes, there is a need for improved methods and compositions for studying lymphocytes. For example, it will help identify methods and compositions that can be used to better characterize and understand how lymphocytes can be modified through genetic means and the factors that affect their survival and proliferation. In addition, it will help identify compositions that drive lymphocyte proliferation and survival. These compositions can be used to study the regulation of these processes. In addition to the methods and compositions for studying lymphocytes, there is a need for improved virus packaging cell lines and methods for their manufacture and use. For example, these cell lines and methods will be suitable for analyzing the different components of recombinant viruses (such as recombinant retroviral particles), and for using packaging cell lines for the production of recombinant retroviral particles. Summary of the Invention
[0011] Provided herein are methods, compositions and kits for helping to overcome the effectiveness and safety of transducing and / or genetically modifying lymphocytes (such as T cells and / or NK cells). Certain embodiments of these methods are applicable to performing adoptive cell therapy with these cells. Therefore, in some aspects, provided herein are methods, compositions and kits for genetically modifying and / or transducing lymphocytes (especially T cells and / or NK cells) and / or for regulating transduced and / or genetically modified T cells and / or NK cells. These methods, compositions and kits provide improved efficacy and safety that are superior to current technology, especially with respect to expressing chimeric antigen receptors (CAR) and in illustrative embodiments, microenvironment-restricted T cells and / or NK cells of biological CAR. Transduced and / or genetically modified T cells and / or NK cells produced using the methods provided herein include, in illustrative embodiments, delivery from retroviral (e.g., lentiviral) genomes via retroviral (e.g., lentiviral) particles, functionalities and functional combinations that provide improved characteristics for such cells and for methods utilizing such cells, such as research methods, commercial production methods, and adoptive cell therapy. For example, these cells can be generated ex vivo in a shorter time, and the cells have improved growth characteristics that can be better regulated.
[0012] In some aspects, there is provided herein a regulatory component for regulating CAR, mRNA, inhibitory RNA, and / or lymphoproliferative components in lymphocytes (such as B cells, T cells and NK cells), such as chimeric lymphoproliferative components. In addition, in some aspects, there is provided herein a recombinant retrovirus expressing various functional components and carrying various functional components on its surface, and a method and packaging cell line for producing the recombinant retrovirus. These recombinant retroviruses and methods and cells for producing the same overcome the limitations of prior art on the number and size of genomes, with different functional components providing benefits when delivered to T cells and / or NK cells.
[0013] In some aspects, there is provided a method for transducing and / or genetically modifying lymphocytes (such as T cells and / or NK cells), and in an illustrative embodiment, there is provided an in vitro method for transducing and / or genetically modifying resting T cells and / or NK cells. Some of these aspects can be performed more quickly than previous methods, which can contribute to more efficient research, more efficient commercial production, and improved patient care methods. In addition, provided herein are methods for utilizing in some embodiments a recombinant retrovirus and a pharmaceutical agent provided herein in some aspects to provide an improved safety mechanism to help regulate the activity of transduced and / or genetically modified lymphocytes (such as T cells and / or NK cells). These methods, compositions, and kits can be used as research tools in commercial generation and in adoptive cell therapy with transduced and / or genetically modified T cells and / or NK cells expressing CAR.
[0014] Additional details regarding aspects and embodiments of the invention are provided throughout this patent application.Section and section headings are for ease of reading and are not intended to limit the inventive combinations, such as methods, compositions, and kits, or the functional components thereof throughout the sections. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 A schematic diagram showing an illustrative composition comprising a packaging cell (100) and a replication-defective recombinant retroviral particle (200) produced by the packaging cell (100) according to an exemplary, non-limiting embodiment of the present invention. Figure 1 In the present invention, various vectors encoding aspects of the present invention (referred to as recombinant polynucleotides (110)) are packaged into recombinant retroviral particles (200) that include in their genome a first engineered signaling polypeptide (which includes one or more lymphoproliferative elements) and, in some embodiments, a second engineered signaling polypeptide (which is a chimeric antigen receptor or CAR). The replication-deficient recombinant retroviral particles express on their membrane: a pseudotyping element (in a non-limiting embodiment, measles virus hemagglutinin (H) polypeptide and measles virus fusion (F) polypeptide, or cytoplasmic domain deletion variants thereof) that allows the replication-deficient recombinant retroviral particles to bind to and fuse with target cells (240); an activation element (in a non-limiting embodiment, an activation element having a polypeptide capable of binding to CD28 and a polypeptide capable of binding to CD3) (210 and 220, respectively); and a membrane-bound cytokine (in a non-limiting embodiment, an IL-7DAF fusion polypeptide) (230). The parts marked as (250), (260), (270), (280) and (290) are Src-FLAG-Vpx, HIV gag matrix, HIV gag capsid, RNA and HIV pol, respectively.
[0016] Figure 2 A schematic diagram of a non-limiting illustrative composition comprising a replication-deficient recombinant retroviral particle (200) produced by a packaging cell (100) and a resting T cell (300) transfected with the replication-deficient recombinant retroviral particle (200) is shown. Components on the surface of the replication-deficient recombinant retroviral particle (200) bind to receptors and / or ligands on the surface of the resting T cell. In a non-limiting embodiment, the pseudotyping component may include a binding polypeptide and a fusogenic polypeptide (in a non-limiting embodiment, a measles virus hemagglutinin (H) polypeptide and a measles virus fusion (F) polypeptide, or a cytoplasmic domain deletion variant thereof) that facilitate binding and fusion of the replication-deficient recombinant retroviral particle (200) with the T cell. In a non-limiting embodiment, the replication-deficient recombinant retroviral particle (200) includes on its surface an activation component (in a non-limiting embodiment, an activation component having a polypeptide capable of binding to CD28 and a polypeptide capable of binding to CD3) that is capable of activating resting T cells by engaging the T cell receptor complex and, if present, an auxiliary receptor (320). In addition, the membrane-bound cytokine (in a non-limiting embodiment, an IL-7DAF fusion polypeptide) present on the surface of the replication-deficient recombinant retroviral particle (200) binds to IL-7Rα (310) on the surface of the resting T cell. The replication-deficient recombinant retroviral particle (200) fused with the T cell and the polynucleotide encoding the first engineered signaling polypeptide including the lymphoproliferative component (in an illustrative embodiment, a constitutively active IL-7Rα) (370) is reverse transcribed in the cytosol before migrating to the nucleus to be incorporated into the DNA of the activated T cell. Without being limited by theory, in some non-limiting embodiments, the virally packaged Src-FLAG-Vpx (250) enters the cytosol of the resting T cell and promotes the degradation of SAMHD1 (350), thereby increasing the cytoplasmic dNTP pool available for reverse transcription. In some embodiments, the polynucleotide may also encode a second engineered signaling polypeptide including CAR (360). In some embodiments, the lymphoproliferative component is expressed when the compound is bound to a control component that regulates its expression (in a non-limiting example, the control component is a riboswitch that binds a nucleoside analog). In some embodiments, expression of the CAR is also regulated by the control component. Moiety (330) is SLAM and CD46. Moiety (340) is CD3.
[0017] Figures 3A to 3E Schematic diagrams showing non-limiting, exemplary vector constructs used to transfect packaging cells to produce the replication-defective recombinant retroviral particles described herein. Figure 3ADisplayed are constructs containing polynucleotide sequences encoding the FRB domain fused to the NFκB p65 activation domain (p65AD) and the ZFHD1 DNA binding domain fused to three constitutively expressed FKBP repeats. Figure 3A The construct in also included HIV1 REV and Vpx as a SrcFlagVpx fusion under the rapamycin-inducible ZFHD1 / p65 AD promoter. Figure 3B Displayed are constructs containing a polynucleotide encoding the rtTA sequence under the control of the ZFHD1 / p65 AD promoter. Figure 3C Displayed are constructs containing a polynucleotide encoding a puromycin resistance gene flanked by loxP sites and an extracellular MYC marker flanked by lox2272 sites. Both selectable markers are under the control of the BiTRE promoter flanked by FRT sites. Figure 3D Displayed are constructs containing a polynucleotide encoding RFP flanked by loxP sites under the control of a TRE promoter and a single FRT site between the TRE promoter and the 5' loxP site of RFP. Figure 3E Displayed are constructs containing a polynucleotide encoding GFP flanked by loxP sites under the control of the TRE promoter and a single FRT site between the TRE promoter and the 5' loxP site of GEP. Figures 3C to 3E The construct in serves as a landing site for insertion of other polynucleotide sequences into the genome of the packaging cell line.
[0018] Figures 4A to 4C Schematic diagrams showing non-limiting, exemplary vector constructs used to transfect packaging cells to produce the replication-defective recombinant retroviral particles described herein. Figure 4A Displayed are constructs containing a tricistronic polynucleotide encoding an anti-CD3 (cloned UCHT1) scFvFc with a CD14 GPI anchor, a CD80 extracellular domain (ECD) capable of binding CD28 to a CD16B GPI anchor, and IL-7 fused to a decay-accelerating factor (DAF), with transposon sequences flanking the polynucleotide region for integration into the HEK293S genome. Figure 4B Displayed are constructs containing a polynucleotide having a BiTRE promoter and a polynucleotide region encoding a gag polypeptide and a pol polypeptide in one orientation and a polynucleotide region encoding a measles virus FΔx protein and a HΔy protein in the other orientation. Figure 4CDisplay a construct containing a polynucleotide sequence encoding a CAR and a lymphoproliferative component IL7Rα-insPPCL under the control of a CD3Z promoter (which is not active in HEK293S cells), wherein the CAR and IL7Rα-insPPCL are separated by a polynucleotide sequence encoding a T2A ribosomal skipping sequence, and the IL7Rα-insPPCL has a ribonuclease controlled by an acyclovir riboswitch. The CAR-containing construct further includes a cPPT / CTS, an RRE sequence, and a polynucleotide sequence encoding HIV-1Psi (Ψ). The entire polynucleotide sequence on the CAR-containing construct to be integrated into the genome is flanked by an FRT site.
[0019] Figure 5 A schematic diagram of the lentiviral expression vector encoding GFP, anti-CD19 chimeric antigen receptor, and eTAG (referred to herein as F1-0-03) is shown.
[0020] Figure 6A and 6B Histogram showing the percentage (%) of CD3+GFP+ cells in the total CD3+ population on days 3, 6, 9, 13, and 17, 14 hours after transduction of freshly isolated and unstimulated PBMCs from donor 12M with VSV-G pseudotyped lentiviral particles encoding F1-0-03 and displaying GPI-anchored anti-CD3 scFvFc on their surface as indicated ( Figure 6A ) and histogram of absolute cell counts per well of CD3+GFP+ population ( Figure 6B ). Each bar represents the mean + / - SD of two replicates.
[0021] Figure 7A and 7B Histogram showing the percentage (%) of CD3+GFP+ cells in the total CD3+ population on day 3 and day 6 after freshly isolated and unstimulated PBMCs from donor 13F were transduced with the indicated lentiviral particles encoding F1-0-03 for 14 hours ( Figure 7A ) and histogram of absolute cell counts per well of CD3+GFP+ population ( Figure 7B). Please note that "A" shows the results using VSV-G pseudotyped lentiviral particles (three replicates); "B" shows the results using VSV-G pseudotyped lentiviral particles with the addition of OKT3Ab (1 μg / mL) to the transduction medium (two replicates); "C" shows the results using VSV-G pseudotyped lentiviral particles expressing GPI-anchored UCHT1scFvFc on their surface (three replicates); and "D" shows the results using VSV-G pseudotyped lentiviral particles displaying GPI-anchored UCHT1scFvFc and GPI-anchored CD80 on their surface (two replicates). Each bar represents the mean + / - SD of two or three replicates, as shown in Figure 2. Figure 7A As indicated.
[0022] Figure 8A and 8B Histograms showing the percentage (%) of CD3+GFP+ cells in the total CD3+ population on days 3, 6, and 9 after transduction of freshly isolated and unstimulated PBMCs from donor 12M with VSV-G pseudotyped lentiviral particles encoding F1-0-03 and displaying GPI-anchored UCHT1 scFvFc and GPI-anchored CD80 on their surface as indicated for the indicated exposure times (2 h to 20 h) ( Figure 8A ) and histogram of absolute cell counts per well of CD3+GFP+ population ( Figure 8B ). Transduction was performed in plates or shake flasks as indicated. Each bar represents the mean + / - SD of two replicates of lentiviral particles pseudotyped with VSV-G ("VSV-G"); other experiments did not have replicates.
[0023] Figure 9A and Figure 9B Histogram showing the percentage (%) of CD3+GFP+ cells in the viable CD3+ population of freshly isolated and unstimulated PBMCs from donor 18 on day 3 after transduction with the indicated lentiviral particles encoding F1-0-03 ( Figure 9A ) and histograms of absolute cell counts per microliter of the total viable population ( Figure 9B ). Each bar represents the mean + / - SD of two replicates.
[0024] Figure 10A and Figure 10B Histogram showing the percentage (%) of GFP+ cells in the total viable cell population on day 6 after unstimulated PBMCs were transduced with different replication-defective lentiviral particles at an MOI of 1 for 4 hours ( Figure 10A ) and the number of GFP+ cells per microliter of culture ( Figure 10BVSV-G pseudotyped lentiviral particles encoding F1-0-03 [VSV-G] were visualized with UCHT1 scFvFc-GPI alone [VSV-G+U] or with CD80-GPI [VSV-G+U+CD80] as indicated. Samples were treated with the antiretroviral drugs dapivirine and dolutegravir as indicated. A "cells only" (untransduced) control was included.
[0025] Figure 11A and Figure 11B Histogram showing the percentage (%) of FLAG+ cells in the total viable cell population on day 6 after 4 hours of transduction of unstimulated PBMCs with different replication-defective lentiviral particles ( Figure 11A ) and the number of FLAG+ cells per microliter of culture ( Figure 11B Lentiviral particles encoding F1-3-219 were used at an MOI of 1. Lentiviral particles were pseudotyped with VSV-G [VSV-G], BaEV [BaEV], or BaEV with deletions of the fusion-inhibitory R peptide [BaEVΔR(HA)] and [BaEVΔR(HAM)]. Untransduced PBMCs ("cells") were included as controls.
[0026] Figure 12A and Figure 12B Histogram showing the percentage (%) of CD3+FLAG+ cells in the total viable cell population on day 6 after 4 hours of transduction of unstimulated PBMCs with different replication-defective lentiviral particles ( Figure 12A ) and the number of CD3+FLAG+ cells per microliter of culture ( Figure 12B Lentiviral particles encoding F1-3-451 were used at an MOI of 1. Lentiviral particles were pseudotyped with VSV-G [VSV-G], MuLV [MuLV], or a fusion of UCHT1 scFv and MuLV [U-MuLV]. Lentiviral viruses [VSV-G+U] and [MuLV+U] were pseudotyped with VSV-G and MuLV, respectively, and UCHT1 scFv Fc-GPI was further visualized. Untransduced PBMCs ("cells") were included as controls.
[0027] Figure 13A histogram showing the number of CD3+FLAG+ cells per microliter of culture on day 6 after transduction of unstimulated PBMCs with different replication-defective lentiviral particles at an MOI of 1 for the indicated periods. F1-3-253 encodes an anti-CD19 CAR and F1-3-451 encodes CLE in addition to the same CAR. Lentiviral particles were pseudotyped with VSV-G [VSV-G] and UCHT1 ScFvFc-GPI [VSV-G+U] was developed as indicated. Samples were treated with dapline (an inhibitor of reverse transcription (RT inb)) or dolutegravir (an integration inhibitor (INT inb)) as indicated.
[0028] Figure 14A Provided is a schematic representation of IL7Ra variants tested for lymphoproliferative / survival activity when expressed in PBMCs. Figure 14B A bar graph showing the percentage of viability of PBMCs in the presence and absence of IL-2 is provided.
[0029] Figure 15 Schematic diagram of a non-limiting exemplary transgenic expression cassette containing a polynucleotide sequence encoding a CAR and candidate CLEs of pools 3A, 3B, 3.1A, and 3.1B.
[0030] Figure 16 Schematic diagram of a non-limiting exemplary transgene expression cassette containing polynucleotide sequences encoding CAR and candidate chimeric lymphoproliferative elements (CLEs) of libraries 1A, 1.1A, and 1.1B.
[0031] Figure 17 Schematic diagram of non-limiting exemplary transgenic expression cassettes containing polynucleotide sequences encoding candidate CLEs of libraries 2B and 2.1B.
[0032] Figure 18 Schematic diagram of non-limiting exemplary transgenic expression cassettes containing polynucleotide sequences encoding candidate CLEs of libraries 4B and 4.1B.
[0033] Figure 19 Figure 2 is a graph showing the fold expansion of PBMCs transduced with lentiviral particles encoding individual CLEs and cultured for 35 days in the absence of exogenous cytokines.
[0034] Figure 20 Figure 2 is a graph showing the fold expansion of PBMCs transduced with lentiviral particles encoding anti-CD19 CAR constructs and individual CLEs and cultured for 35 days in the presence of donor-matched PBMCs but without exogenous cytokines.
[0035] Figure 21Graph showing the efficiency of the indicated lentiviral particles in transducing resting PBMCs within 4 hours. In the absence of exogenous cytokines, transduction efficiency was measured in culture as % CAR+PBMC after 6 days, as determined by FACS. Each lentiviral particle encodes CAR and CLE. Lentiviral particles F1-1-228U and F1-3-219U display UCHT1 scFv Fc-GPI on their surface.
[0036] Figure 22A and Figure 22B Graph showing the time course of total viable cell counts after 4 hours of transduction of resting PBMCs with the indicated lentiviral particles and 6 days of in vitro culture in the absence of exogenous cytokines. Each lentiviral particle encodes CAR and CLE. Lentiviral particles F1-1-228U and F1-3-219U display UCHT1 scFv Fc-GPI on their surface.
[0037] Figure 23A 、 Figure 23B and Figure 23C Graph showing the time course of lentiviral genome copies per microgram of genomic DNA from blood of tumor-bearing NSG mice dosed with human PBMCs transduced with the indicated lentiviral particles for 4 hours and injected intravenously without ex vivo expansion of PBMCs. Each lentiviral particle encodes a CAR. F1-1-228, F1-1-228U, F1-3-219, and F1-3-219U also encode CLE. Lentiviral particles F1-1-228U and F1-3-219U also display UCHT1 scFv Fc-GPI on their surface.
[0038] Figure 24 Graph showing the number of CAR+ cells per 200 μl of blood in tumor-bearing NSG mice that were intravenously administered human PBMCs transduced with the indicated lentiviral particles for 4 hours without ex vivo PBMC expansion. Blood was sampled upon euthanasia. Each lentiviral particle encodes a CAR. F1-1-228, F1-1-228U, F1-3-219, and F1-3-219U also encode CLE. Lentiviral particles F1-1-228U and F1-3-219U also display UCHT1 scFv Fc-GPI on their surface.
[0039] Figure 25A Graph showing the mean volume of CHO-ROR2 tumors in NSG mice intravenously dosed with PBS or human PBMCs transduced for 4 hours with the indicated lentiviral particles encoding anti-ROR2 MRB CAR and CLE without ex vivo expansion of PBMCs. Figure 25BFigure 2 shows the mean volume of Raji tumors in NSG mice intravenously dosed with PBS or human PBMCs transduced for 4 hours with the indicated lentiviral particles encoding anti-CD19 CAR and CLE without ex vivo expansion of PBMCs. Lentiviral particles F1-1-228U and F1-3-219U displayed UCHT1 scFv Fc-GPI on their surface.
[0040] Figure 26A Schematic diagram of the lentiviral vector backbone F1-0-02, which includes a transgene expression cassette driving the expression of GFP and eTag, as well as a synthetic EF-1α promoter and intron A upstream of GFP. Figure 26B Insertion of the miRNA into EF1α intron A of the F1-0-02 backbone is shown. "1" indicates the EF1α overlap; "2" indicates the 5' arm; "3" indicates the miRNA1 5' stem; "4" indicates the loop; "5" indicates the miRNA1 3' stem; "6" indicates the 3' arm; "7" indicates the connector; "8" indicates the miRNA2 5' stem; "9" indicates the miRNA2 3' stem; "10" indicates the miRNA3 5' stem; "11" indicates the miRNA3 3' stem; "12" indicates the miRNA4 5' stem; and "13" indicates the miRNA4 3' stem.
[0041] Figure 27 Figure 2 shows that miRNA targeting CD3ζ located in the intron of the EF-1α promoter can block the expression of the CD3 complex.
[0042] Figure 28 Figure 2 is a histogram showing the ΔΔCt values for samples transduced with miR-TCRα containing replication-defective lentiviral particles. ΔΔCt values represent the amount of treated miR-TCRa miRNA in each transduced sample relative to the untransduced control.
[0043] definition
[0044] As used herein, the term "chimeric antigen receptor" or "CAR" or "CARs" refers to an engineered receptor that specifically transplants antigens onto cells, such as T cells, NK cells, macrophages, and stem cells. The CAR of the present invention includes at least one antigen-specific targeting region (ASTR), a transmembrane domain (TM), and an intracellular activation domain (IAD), and may include a handle and one or more costimulatory domains (CSD). In another embodiment, CAR is a bispecific CAR that is specific for two different antigens or antigenic determinants. After the ASTR specifically binds to the target antigen, the IAD activates intracellular signaling. For example, IAD can redirect T cell specificity and reactivity to the selected target in a non-MHC restricted manner, thereby utilizing the antigen binding properties of the antibody. Non-MHC restricted antigen recognition gives CAR-expressing T cells the ability to recognize antigens independently of antigen processing, thereby bypassing the main mechanism of tumor escape. In addition, when expressed in T cells, CAR advantageously does not dimerize with endogenous T cell receptor (TCR) α chain and β chain.
[0045] As used herein, the term "microenvironment" means any part or region of a tissue or body that is physically or chemically distinct from other tissue regions or body regions, whether constant or temporal. For example, as used herein, "tumor microenvironment" refers to the environment in which a tumor resides, which is the non-cellular region within the tumor and the region just outside the tumor tissue that is not part of the intracellular compartment of the cancer cells themselves. The tumor microenvironment can refer to any and all conditions of the tumor environment, including those that create a structural and / or functional environment for malignant processes to survive and / or proliferate and / or spread. For example, the tumor microenvironment can include modifications in conditions such as, but not limited to, pressure, temperature, pH, ionic strength, osmolarity, osmolality, oxidative stress, concentration of one or more solutes, concentration of electrolytes, concentration of glucose, concentration of hyaluronic acid, concentration of lactic acid or lactate, concentration of albumin, levels of adenosine, levels of R-2-hydroxyglutarate, concentration of pyruvate, concentration of oxygen, and / or the presence of oxidants, reducing agents, or cofactors, as well as other conditions that will be understood by those skilled in the art.
[0046] As used interchangeably herein, the terms "polynucleotide" and "nucleic acid" refer to a polymeric form of nucleotides (ribonucleotides or deoxyribonucleotides) of any length. Thus, the term includes, but is not limited to, single-, double-, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or polymers containing purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural, or derived nucleotide bases.
[0047] As used herein, the term "antibody" includes polyclonal and monoclonal antibodies, including intact antibodies and antibody fragments that retain specific antigen binding. Antibody fragments may include, but are not limited to, fragment antigen-binding (Fab) fragments, Fab' fragments, F(ab')2 fragments, Fv fragments, Fab'-SH fragments, (Fab')2Fv fragments, Fd fragments, recombinant IgG (rIgG) fragments, single-chain antibody fragments, including single-chain variable fragments (scFv), bivalent scFv, trivalent scFv, and single-domain antibody fragments (e.g., sdAb, sdFv, nanobodies). The term includes genetically engineered and / or other modified forms of immunoglobulins, such as intrabodies, peptibodies, chimeric antibodies, single-chain antibodies, fully human antibodies, humanized antibodies, fusion proteins comprising antigen-specific targeting regions of antibodies and non-antibody proteins, heterojunction antibodies, multispecific antibodies (e.g., bispecific antibodies, bifunctional antibodies, trifunctional antibodies, and tetrafunctional antibodies), tandem bis-scFv, and tandem tri-scFv. Unless otherwise stated, the term "antibody" should be understood to include functional antibody fragments thereof. The term also includes intact or full-length antibodies, including antibodies of any class or subclass, including IgG and its subclasses, IgM, IgE, IgA and IgD.
[0048] As used herein, the term "antibody fragment" includes a portion of an intact antibody, for example, the antigen binding region or variable region of an intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; bifunctional antibodies; linear antibodies (Zapata et al., Protein Eng. 8(10): 1057-1062 (1995)); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments. Papain digestion of an antibody produces two identical antigen-binding fragments (called "Fab" fragments, each with a single antigen-binding site) and a residual "Fc" fragment (an indicator reflecting the ability to crystallize easily). Pepsin treatment produces an F(ab')2 fragment that has two antigen-binding sites and is still able to cross-link antigen.
[0049] As used interchangeably herein, the terms "single-chain Fv," "scFv," or "sFv" antibody fragments include the V H Domain and V L domains, wherein these domains are present in a single polypeptide chain. In some embodiments, the Fv polypeptide further comprises a V H Domain and V LThe polypeptide connector or spacer between the domains that enables the sFv to form the desired structure for antigen binding. For a review of sFv, see Pluckthun in The Pharmacology of Monoclonal Antibodies, Vol. 113, Rosenburg and Moore, eds., Springer-Verlag, New York, pp. 269-315 (1994).
[0050] As used herein, "naturally occurring" V H Domain and V L A V domain is a V domain that has been isolated from a host without further molecular evolution to alter its affinity when produced in scFv format under specific conditions. H Domain and V L domains, such as those disclosed in U.S. Patent 8,709,755 B2 and application WO / 2016 / 033331 A1.
[0051] As used herein, the term "affinity" refers to the equilibrium constant for the reversible binding of two agents and is expressed as a dissociation constant (Kd). The affinity can be at least 1-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 20-fold, at least 30-fold, at least 40-fold, at least 50-fold, at least 60-fold, at least 70-fold, at least 80-fold, at least 90-fold, at least 100-fold, or at least 1000-fold, or more, higher than the affinity of the antibody for an unrelated amino acid sequence. The affinity of the antibody for the target protein can be, for example, from about 100 nanomolars (nM) to about 0.1 nM, from about 100 nM to about 1 picomole (pM), or from about 100 nM to about 1 femtomolar (fM) or higher. As used herein, the term "avidity" refers to the resistance of a complex of two or more agents to dissociation upon dilution. With respect to antibodies and / or antigen-binding fragments, the terms "immunoreactivity" and "preferential binding" are used interchangeably herein.
[0052] As used herein, the term "binding" refers to the direct association between two molecules due to, for example, covalent interactions, electrostatic interactions, hydrophobic interactions, and ionic interactions and / or hydrogen bonding interactions (including interactions such as salt bridges and water bridges). Non-specific binding shall refer to an affinity of less than about 10 -7 M binding, for example, with an affinity less than 10 -6 M, 10 -5 M, 10 -4 A combination of M et al.
[0053] As used herein, reference to a "cell surface expression system" or "cell surface display system" refers to the display or expression of a protein or portion thereof on the surface of a cell. Typically, cells are generated that express the protein of interest fused to a cell surface protein. For example, the protein is expressed as a fusion protein with a transmembrane domain.
[0054] As used herein, the term "module" includes polypeptides (including fusions of polypeptides, regions of polypeptides, and functional mutants or fragments thereof) and polynucleotides (including microRNAs and shRNAs, and functional mutants or fragments thereof).
[0055] As used herein, the term "region" is any segment of a polypeptide or polynucleotide.
[0056] As used herein, a "domain" is a region of a polypeptide or polynucleotide that has functional and / or structural properties.
[0057] As used herein, the term "handle" or "handle domain" refers to a flexible polypeptide linking region that provides structural flexibility and is separated from the flanking polypeptide regions, and can be composed of natural or synthetic polypeptides. The handle can be derived from the hinge or hinge region of an immunoglobulin (e.g., IgG1), which is generally defined as stretching from Glu216 to Pro230 of human IgG1 (Burton (1985) Molec. Immunol., 22: 161-206). Hinge regions of other IgG isotypes can be aligned with the IgG1 sequence by having the first and last cysteine forming an inter-heavy chain disulfide bond (SS) at the same position. The handle can be naturally occurring or non-naturally occurring, including (but not limited to) an altered hinge region, as disclosed in U.S. Patent No. 5,677,425. The handle can include a complete hinge region derived from an antibody of any class or subclass. The stalk may also include regions derived from CD8, CD28, or other receptors that provide flexibility and serve similar functions in terms of spacing from the flanking regions.
[0058] As used herein, the term "isolated" means that the material is removed from its original environment (e.g., from its natural environment if it occurs in nature). For example, a naturally occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide separated from some or all of the coexisting materials in the natural system is isolated. Such a polynucleotide can be part of a vector, and / or such a polynucleotide or polypeptide can be part of a composition and still be isolated because the vector or composition is not part of its natural environment.
[0059] As used herein, a "polypeptide" is a single chain of amino acid residues linked by peptide bonds. A polypeptide is neither folded into a fixed structure nor undergoes any post-translational modifications. A "protein" is a polypeptide folded into a fixed structure. "Polypeptide" and "protein" are used interchangeably herein.
[0060] As used herein, a polypeptide can be "purified" to remove impurity components of the polypeptide's natural environment, for example, materials such as enzymes, hormones, and other proteinaceous or non-proteinaceous solutes that would interfere with the polypeptide's diagnostic or therapeutic use. The polypeptide can be (1) purified to greater than 90%, greater than 95%, or greater than 98% by weight of the antibody as determined by the Lowry method, for example, greater than 99% by weight, (2) purified by spinning cup sequenator to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence, or (3) purified to homogeneity by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing or non-reducing conditions using Coomassie blue or silver stain.
[0061] As used herein, the term "immune cell" generally includes white blood cells (leukocytes) derived from hematopoietic stem cells (HSCs) produced in the bone marrow."Immune cells" include, for example, lymphocytes (T cells, B cells, natural killer (NK) cells) and cells derived from the bone marrow (neutrophils, eosinophils, basophils, monocytes, macrophages, dendritic cells).
[0062] As used herein, "T cells" include all types of immune cells that express CD3, including helper T cells (CD4 + cells), cytotoxic T cells (CD8 + cells), regulatory T cells (Tregs), and γ-δ T cells.
[0063] As used herein, "cytotoxic cells" include CD8 + T cells, natural killer (NK) cells, NK-T cells, γδT cells (a type of CD4 + cytotoxic cells) and neutrophils, which are cells capable of mediating cytotoxic responses.
[0064] As used herein, the term "stem cell" generally includes pluripotent or multipotent stem cells. "Stem cell" includes, for example, embryonic stem cells (ES), mesenchymal stem cells (MSC), induced pluripotent stem cells (iPS), and committed progenitor cells (hematopoietic stem cells (HSC), bone marrow-derived cells, etc.).
[0065] As used herein, the terms "treatment," "treating," and the like refer to obtaining a desired pharmacological and / or physiological effect. The effect may be prophylactic, in the sense of completely or partially preventing a disease or its symptoms, and / or therapeutic, in the sense of partially or completely curing a disease and / or adverse effects caused by the disease. "Treatment," as used herein, encompasses any treatment of a disease in a mammal (e.g., a human), and includes: (a) preventing the occurrence of a disease in an individual susceptible to the disease but not yet diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., causing regression of the disease.
[0066] As used interchangeably herein, the terms "individual," "subject," "host," and "patient" refer to mammals, including but not limited to humans, murines (e.g., rats, mice), lagomorphs (e.g., rabbits), non-human primates, humans, dogs, cats, ungulates (e.g., horses, cattle, sheep, pigs, goats), and the like.
[0067] As used herein, the term "therapeutically effective amount" or "effective amount" refers to the amount of an agent or a combined amount of two agents that, when administered to a mammal or other individual for the treatment of a disease, is sufficient to affect such treatment of the disease. The "therapeutically effective amount" will vary depending on the agent, the disease and its severity, and the age, weight, etc., of the individual to be treated.
[0068] As used herein, the terms "evolution" and "evolving" refer to the use of one or more mutational methods to generate different polynucleotides encoding otherwise improved polypeptides that are themselves improved biomolecules and / or contribute to the production of another improved biomolecule. "Physiological" or "normal" or "normal physiological" conditions are conditions such as, but not limited to, pressure, temperature, pH, ionic strength, osmotic pressure, osmolality, oxidative stress, concentration of one or more solutes, concentration of electrolytes, concentration of glucose, concentration of hyaluronic acid, concentration of lactic acid or lactate, concentration of albumin, level of adenosine, level of R-2-hydroxyglutarate, concentration of pyruvate, concentration of oxygen, and / or the presence of oxidants, reducing agents, or cofactors, as well as other conditions that would be considered to be within the normal range for a subject at the site of administration or at the tissue or organ at the site of action.
[0069] As used herein, "genetically modified cells" include cells that contain exogenous nucleic acid, whether or not the exogenous nucleic acid is integrated into the genome of the cell.
[0070] As used herein, a "polypeptide" may include a portion of a protein molecule or the entire protein molecule as well as any post-translational or other modifications.
[0071] As used herein, pseudotyping components may include: "binding polypeptides," which include one or more polypeptides (usually glycoproteins) that recognize and bind to target host cells; and one or more "fusogenic polypeptides" that mediate fusion of the retrovirus with the target host cell membrane, thereby allowing the retroviral genome to enter the target host cell. As used herein, "binding polypeptides" may also be referred to as "T cell and / or NK cell binding polypeptides" or "target engagement components," and "fusogenic polypeptides" may also be referred to as "fusogenic components."
[0072] "Resting" lymphocytes, such as resting T cells, are lymphocytes in the G0 phase of the cell cycle that do not express activation markers, such as Ki-67. Resting lymphocytes can include naive T cells that have never been exposed to a specific antigen and memory T cells that have been altered by previous exposure to the antigen. "Resting" lymphocytes may also be referred to as "quiescent" lymphocytes.
[0073] As used herein, "lymphodepletion" refers to a method of reducing the number of lymphocytes in a subject (e.g., by administering a lymphodepleting agent). Partial or whole-body fractionated radiation therapy can also result in lymphodepletion. A lymphodepleting agent can be a chemical compound or composition that is capable of reducing the number of functional lymphocytes in a mammal when administered to the mammal. One example of such an agent is one or more chemotherapeutic agents. Such agents and dosages are known and can be selected by the treating physician depending on the individual to be treated. Examples of lymphodepleting agents may include, but are not limited to, fludarabine, cyclophosphamide, cladribine, denileukin diftitox, or a combination thereof.
[0074] RNA interference (RNAi) is a biological process in which an RNA molecule inhibits gene expression or translation by neutralizing a target RNA molecule. The RNA target may be an mRNA, or it may be any other RNA susceptible to functional inhibition by RNAi. As used herein, an "inhibitory RNA molecule" refers to an RNA molecule whose presence produces RNAi in a cell and causes reduced expression of the transcript targeted by the inhibitory RNA molecule. As used herein, an inhibitory RNA molecule has a 5' stem and a 3' stem that can form an RNA duplex. The inhibitory RNA molecule may be, for example, a miRNA (endogenous or artificial) or shRNA, a precursor of a miRNA (i.e., Pri-miRNA or pre-miRNA) or shRNA, or a dsRNA that is directly transcribed or introduced into a cell or individual as an isolated nucleic acid.
[0075] As used herein, "double-stranded RNA" or "dsRNA" or "RNA duplex" refers to an RNA molecule consisting of two chains. Double-stranded molecules include those consisting of two RNA chains that hybridize to form a double-helical RNA structure, or single-stranded RNA that folds itself to form a double-helical structure. Most, but not necessarily, all bases in the duplex region are base-paired. The duplex region comprises a sequence complementary to the target RNA. The sequence complementary to the target RNA is an antisense sequence, and is typically 18 to 29, 19 to 29, 19 to 21, or 25 to 28 nucleotides long, or in some embodiments, 18, 19, 20, 21, 22, 23, 24, 25 on the low end and 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 on the high end, wherein a given range typically has a low end that is lower than the high end. Such structures typically include a 5' stem, a loop, and a 3' stem connected by a loop adjacent to each stem (which is not part of the duplex). In certain embodiments, the loop comprises at least 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides. In other embodiments, the loop comprises 2 to 40, 3 to 40, 3 to 21, or 19 to 21 nucleotides; or in some embodiments, between 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 on the low end and 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, or 40 on the high end, wherein a given range typically has a lower end than the higher end.
[0076] As used herein, the term "microRNA flanking sequence" refers to a nucleotide sequence comprising a microRNA processing component. The microRNA processing component is a minimal nucleic acid sequence that helps produce a mature microRNA from a precursor microRNA. These components are typically located within a 40 nucleotide sequence flanking the microRNA stem-loop structure. In some cases, the microRNA processing component is found within an extension of a nucleotide sequence between 5 and 4,000 nucleotides flanking the microRNA stem-loop structure.
[0077] The term "linker," when used in reference to multiple inhibitory RNA molecules, refers to a connecting component that joins two inhibitory RNA molecules.
[0078] As used herein, unless explicitly designated as a replication-competent retrovirus, a "recombinant retrovirus" refers to a non-replication or "replication-defective" retrovirus. The terms "recombinant retrovirus" and "recombinant retroviral particle" are used interchangeably herein. Such retroviruses / retroviral particles can be any type of retroviral particle, including, for example, gamma-retroviruses and, in illustrative embodiments, lentiviruses. As is well known, such retroviral particles (e.g., lentiviral particles) are typically formed in packaging cells by transfecting the packaging cells with a plasmid (which includes packaging components such as Gag, Pol, and Rev) and an envelope or pseudotyping plasmid (which encodes the pseudotyping components) and a transfer, genomic, or retroviral (e.g., lentiviral) expression vector (which is typically a plasmid encoding a gene or other relevant coding sequence thereon). Thus, a retroviral (e.g., lentiviral) expression vector includes sequences that facilitate expression and packaging after transfection into the cell (e.g., 5' and 3' LTRs flanking, for example, psi packaging components and a target heterologous coding sequence). The terms "lentivirus" and "lentiviral particle" are used interchangeably herein.
[0079] The "framework" of a miRNA consists of the "5' microRNA flanking sequence" and / or "3' microRNA flanking sequence" surrounding the miRNA and (in some cases) the loop sequence separating the stem of the stem-loop structure in the miRNA. In some examples, the "framework" is derived from a naturally occurring miRNA, such as miR-155. The terms "5' microRNA flanking sequence" and "5' arm" are used interchangeably herein. The terms "3' microRNA flanking sequence" and "3' arm" are used interchangeably herein.
[0080] As used herein, the term "miRNA precursor" refers to an RNA molecule of any length that can be enzymatically processed into a miRNA, such as a primary RNA transcript, pri-miRNA, or pre-miRNA.
[0081] As used herein, the term "construct" refers to an isolated polypeptide or an isolated polynucleotide encoding a polypeptide. A polynucleotide construct can encode a polypeptide, such as a lymphoproliferative component. A skilled artisan will understand that whether a construct refers to an isolated polynucleotide or an isolated polypeptide depends on the context.
[0082] It should be understood that the present invention and the aspects and embodiments provided herein are not limited to the specific examples disclosed, and therefore variations are possible. It should also be understood that the technology used herein is for the purpose of disclosing specific examples and embodiments only and is not intended to be limiting, as the scope of the present invention will be limited only by the appended claims.
[0083] When a range of values is provided, it is understood that each intermediate value between the upper and lower limits of the range (unless the context clearly indicates otherwise, one-tenth of the lower limit unit) and any other value or intermediate value in the stated range are encompassed within the present invention. The upper and lower limits of these smaller ranges may be independently included in the smaller range and are also encompassed within the present invention, except for any specific excluded limits in the stated range. When the stated range includes one or both of the limits, ranges excluding one or both of those included limits are also encompassed within the present invention. When multiple low values and multiple high values that overlap are given for a range, those skilled in the art will recognize that the selected range will include the low value that is lower than the high value. All headings in this specification are for ease of reading and are not restrictive.
[0084] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs. Although any methods similar or equivalent to those described herein can also be used in the practice or testing of the present invention, preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials related to the cited publications.
[0085] It should be noted that, as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, a reference to a "chimeric antigen receptor" includes a plurality of such chimeric antigen receptors and equivalents thereof known to those skilled in the art, and so forth. It should be further noted that the claims may be drafted to exclude any optional element. Therefore, this statement is intended to serve as a precondition for the use of exclusive terminology such as "solely," "only," and the like in connection with the recitation of claim elements, or the use of a "negative" limitation.
[0086] It should be understood that certain features of the present invention that are described for clarity in the context of separate embodiments may also be provided in combination in a single embodiment. Conversely, various features of the present invention that are described for brevity in the context of a single embodiment may also be provided separately or in any suitable subcombination. All combinations of embodiments of the present invention are specifically included in the present invention and are disclosed herein as if each and every combination were individually and clearly disclosed. In addition, all subcombinations of the various embodiments and elements thereof are also specifically included in the present invention and are disclosed herein as if each and every such subcombination were individually and clearly disclosed. DETAILED DESCRIPTION
[0087] The present invention overcomes the challenges of the prior art by providing improved methods and compositions for genetically modifying lymphocytes (e.g., NK cells, and in illustrative embodiments, T cells). For example, some of these methods do not include pre-activation of lymphocytes, and some of these methods are performed in less time than previous methods. In addition, compositions with many uses (including their use in these improved methods) are provided. Some of these compositions are genetically modified lymphocytes with improved proliferation and survival quality, including when cultured in vitro, for example, in the absence of growth factors. These genetically modified lymphocytes will have, for example, the following uses: as research tools to better understand the factors that affect T cell proliferation and survival; and commercial production, for example, the production of certain factors (such as growth factors and immunomodulators) that can be collected and tested or used in commercial products.
[0088] Some embodiments provided herein are methods for performing adoptive cell therapy, which include transducing T cells and / or NK cells ex vivo for a short period of time (e.g., 24 hours, 12 hours, or 8 hours or less), and in some embodiments, no prior ex vivo stimulation is required. These methods are preferably suitable for closed systems that process blood from an individual ex vivo, and can be performed on an individual present in the same room as some embodiments and / or an individual in some embodiments who is within sight of their blood or its separated blood cells at all times during the performance of the method. More specifically, aspects and embodiments of the disclosure herein overcome the problems associated with current adoptive cell therapy by providing methods for transducing resting T cells and / or resting NK cells, which methods typically utilize pseudotyping components that facilitate binding and fusion of replication-defective recombinant retroviral particles with resting T cells and / or resting NK cells to facilitate genetic modification of resting T cells and / or resting NK cells using replication-defective recombinant retroviral particles. Furthermore, the methods provided herein overcome problems in the art by utilizing, in illustrative embodiments, a chimeric antigen receptor and one or more lymphoproliferative components whose expression is under the control of a control component, such that exposure of an individual to a compound that binds the control component, or termination of such exposure, promotes expansion of genetically modified T cells and / or NK cells in vivo.
[0089] Due to these and other improvements disclosed in detail herein, in one aspect, a method for genetically modifying resting T cells and / or resting NK cells of an individual (such as a patient with a disease or disorder) is provided herein, wherein blood from the individual is collected; resting T cells and / or NK cells are genetically modified by contacting them with replication-deficient recombinant retroviral particles; and the genetically modified cells are typically reintroduced into the individual within a shorter period of time (e.g., within 24 hours and in some non-limiting embodiments, within 12 hours) than in prior art methods and / or without further ex vivo amplification of the population of genetically modified T cells and / or NK cells, such that the genetically modified resting T cells and / or NK cells do not undergo more than 4 ex vivo cell divisions. Therefore, the methods provided herein can be performed in a much shorter time than current CAR therapies, thereby providing a method in which an individual can stay in the clinic for the entire time of the ex vivo step. This helps to perform the ex vivo step in a closed system, which reduces the chance of contamination and mixing of patient samples and can be more easily performed by a clinical laboratory.
[0090] therefore, Figure 1 and Figure 2 Schematic block diagrams are provided of illustrative compositions for use in the methods provided herein. Figure 1 A block diagram of a packaging cell (100) and replication-defective recombinant retroviral particles (200) produced by such packaging cells is provided. The packaging cell (100) includes a recombinant polynucleotide (110) incorporated into its genome (which includes recombinant transcriptional components for expressing retroviral proteins) and various membrane-bound polypeptides under the control of an inducible promoter regulated by a transactivator that binds a ligand and is activated by the ligand. These transactivators, inducible promoters, and ligands are used to induce the sequential expression and accumulation of cell membrane-bound polypeptides that will be incorporated into the membrane of the replication-defective recombinant retroviral particles and into the retroviral components necessary for packaging and assembling the replication-defective recombinant retroviral particles.
[0091] As a result of the sequential induction of expression of the various polynucleotides as discussed in detail below, Figure 1 The illustrative packaging cells (100) described in the present invention can be used in the illustrative methods to produce the resting T cells and / or NK cells provided herein for transfection ( Figure 2In a non-limiting embodiment, the packaging cell (100) comprises in its genome a nucleic acid encoding a packageable retroviral RNA genome comprising at least some of the components of the retroviral genome necessary for packaging and assembling the replication-defective recombinant retroviral particles (as non-limiting illustrative examples, the retroviral psi component, the retroviral gag polypeptide, and the retroviral pol polypeptide).
[0092] Some membrane-bound polypeptides that are bound or associated with the cell membrane of the packaging cell will be incorporated or associated with the replication-defective recombinant retroviral particles, but are not encoded by the retroviral genome. For example, the packaging cell and, in particular, the replication-defective recombinant retroviral particles formed may include: a retroviral Vpx polypeptide (250), which in non-limiting embodiments may be expressed as a membrane-associated fusion protein, such as a Src-Flag-Vpx polypeptide; a pseudotyping component (240) that may include binding polypeptides and fusogenic polypeptides, which in non-limiting embodiments may include measles virus hemagglutinin (H) polypeptide and measles virus fusion (F) polypeptide, or cytoplasmic domain deletion variants thereof; one or more activation components (210, 220), which in non-limiting embodiments may include a membrane-bound polypeptide capable of binding to CD3 and a membrane-bound polypeptide capable of binding to CD28; and / or an optional membrane-bound interleukin (230), a non-limiting example of which is a fusion polypeptide comprising IL-7 fused to DAF or a fragment thereof. Various other specificities for these membrane-bound polypeptides are provided herein.
[0093] As a result of expressing the transcription components in sequence by packaging cells, replication-defective recombinant retroviral particles are produced. The RNA retroviral genome that becomes the genome of the packaging cell of the replication-defective recombinant retroviral particles and is usually integrated into therein includes retroviral components (as non-limiting illustrative embodiments, retroviral Gag and Pol polynucleotides) necessary for retroviral production, infection and integration into the genome of the host cell (which is usually resting T cells and / or NK cells). In addition, the retroviral genome further includes a polynucleotide encoding one or usually two engineered signaling polypeptides provided herein. One of the engineered signaling polypeptides usually encodes at least one lymphoproliferative component lymphoproliferative component (in non-limiting examples, constitutive interleukin 7 receptor mutations) and other engineered signaling polypeptides usually encode chimeric antigen receptors.
[0094] Next, the replication-defective recombinant retroviral particles (200) are used to transduce resting T cells and / or resting NK cells (300) using the methods provided herein. Figure 2As shown, after contacting resting T cells and / or NK cells (300) with replication-deficient recombinant retroviral particles (200), the membrane polypeptides discussed above on the surface of the replication-deficient recombinant retroviral particles bind to receptors and / or ligands on the surface of the resting T cells and / or NK cells (300). For example, as indicated above, the pseudotyping component, which may include binding polypeptides and fusogenic polypeptides that bind to molecules on the surface of resting T cells and / or resting NK cells, facilitates binding and fusion of the replication-deficient recombinant retroviral particles (200) with T cell and / or NK cell membranes. The activation component (210, 220) activates the resting T cells and / or NK cells (300) by engaging the T cell receptor complex (a process that occurs during the course of contact or a subsequent incubation). In addition, membrane-bound cytokines (230) may be present on the surface of the replication-deficient recombinant retroviral particles and bind to cytokine receptors (310) on the surface of resting T cells and / or NK cells (300), thereby further promoting binding and activation. Thus, without being limited by theory, in the illustrative embodiments provided herein, due to one or more of the components of the replication-deficient recombinant retroviral particles (200), there is no need for ex vivo stimulation or activation of components that are not already in or on the replication-deficient recombinant retroviral particles (200). This, in turn, helps to reduce the ex vivo time required to complete the methods of the illustrative methods provided herein.
[0095] After binding to T cells and / or NK cells (200), the replication-deficient recombinant retroviral particles then fuse with the T cells and / or NK cells (300), and the polypeptides and nucleic acids in the replication-deficient recombinant retroviral particles enter the T cells and / or NK cells (300). As indicated above, one of these polypeptides in the replication-deficient recombinant retroviral particles is the Vpx polypeptide (250). The Vpx polypeptide (250) binds to the SAMHD1 restriction factor (350) that degrades free dNTPs in the cytoplasm and induces its degradation. Therefore, the concentration of free dNTPs in the cytoplasm increases as Vpx degrades SAMHD1, and increases reverse transcription activity, thereby facilitating reverse transcription of the retroviral genome and integration into the T cell and / or NK cell genome.
[0096] After the retroviral genome is integrated into the T cell and / or NK cell (200), the T cell and / or NK cell genome includes a nucleic acid encoding a signaling polypeptide encoding a lymphoproliferative component (370) and a signaling polypeptide encoding a CAR (360) as appropriate. The expression of the lymphoproliferative component and the CAR as appropriate is under the control of the control component. Exposure to a compound that binds to the control component (which can occur in vitro or in vivo by administering the compound to an individual whose T cells and / or NK cells (300) are transduced) promotes the proliferation of T cells and / or NK cells (300) in vitro or in vivo by expressing the lymphoproliferative component and, as appropriate, by expression of the CAR and binding of the CAR to its target cell. Therefore, herein, T cells and / or NK cells transduced with replication-deficient recombinant retroviral particles have one or more signals that drive proliferation and / or inhibit cell death (in illustrative embodiments, this in turn avoids the need for a previous method to deplete host lymphocytes before returning transduced T cells and / or NK cells to the individual). In illustrative embodiments, this in turn further reduces the number of days required for processing before reintroducing transduced T cells and / or NK cells into the individual. Therefore, in illustrative embodiments, the time required for blood collection from the individual to reintroduction of blood into the individual is no more than 36 hours, 24 hours, 12 hours, or even no more than 8 hours in some cases, which fundamentally changes the CAR-T method from the prior art method. In addition, the control component also provides one of the safety mechanisms provided herein. For example, stopping the administration of the compound can lower or even terminate the expression of the lymphoproliferative component lymphoproliferative component and the optionally selected CAR, thereby ending the proliferation and / or survival signal for transduced T cells and / or NK cells and their progeny.
[0097] Methods for transducing and / or genetically modifying lymphocytes
[0098] In certain aspects, provided herein is a method for transducing and / or genetically modifying peripheral blood mononuclear cells (PBMCs) or lymphocytes, typically T cells and / or NK cells, and in certain illustrative embodiments, typically resting T cells and / or resting NK cells, comprising contacting the lymphocytes with replication-deficient recombinant retroviral particles, wherein the replication-deficient recombinant retroviral particles typically comprise a pseudotyping component on their surface, wherein the contacting (and incubation under contacting conditions) facilitates transduction of the resting T cells and / or NK cells by the replication-deficient recombinant retroviral particles, thereby generating genetically modified T cells and / or NK cells. The pseudotyping component is typically capable of binding to resting T cells and / or NK cells and can facilitate its own membrane fusion or binding to other proteins of the replication-deficient recombinant retroviral particles.
[0099] Various components or steps of such method aspects for transducing and / or genetically modifying PBMCs, lymphocytes, T cells, and / or NK cells are provided herein (e.g., in this section and in the Exemplary Examples section), and as further discussed herein, such methods include the embodiments provided throughout this specification, for example, embodiments of any of the aspects for transducing and / or genetically modifying PBMCs or lymphocytes (e.g., NK cells, or, in illustrative embodiments, T cells) provided for example in this section and in the Exemplary Examples section can include any of the embodiments of replication-defective recombinant retroviral particles provided herein, including those comprising one or more lymphoproliferative components, CARs, pseudotyping components, riboswitches, activation components, membrane-bound cytokines, miRNAs, Kozak-type sequences, WPRE components, triple stop codons, and or other components disclosed herein, and can be combined with the methods herein for producing retroviral particles using packaging cells. In certain illustrative embodiments, the retroviral particles are lentiviral particles. Such methods for genetically modifying and / or transducing PBMCs or lymphocytes (such as T cells and / or NK cells) can be performed in vitro or ex vivo. The skilled artisan will recognize that the details provided herein for transducing and / or genetically modifying PBMCs or lymphocytes (such as T cells and / or NK cells) can be applied to any aspect comprising such steps.
[0100] In some illustrative embodiments, without the need for prior in vivo, in vitro or ex vivo activation or stimulation, genetically modified and / or transduced cells. In some illustrative embodiments, cells are activated during contact and are not activated or activated for more than 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours or 8 hours before contact. In some illustrative embodiments, activation by components not present on the surface of the retroviral particles does not require genetically modified and / or transduced cells. Therefore, before, during or after contact, except on the retroviral particles, such activation or stimulation components are not required. Therefore, as discussed in more detail herein, these illustrative embodiments that do not require pre-activation or stimulation provide the ability to quickly perform in vitro experiments intended to better understand T cells and the biological mechanisms therein. In addition, such methods provide more effective commercial production and the development of such commercial production methods for the biological products produced using PBMC, lymphocytes, T cells or NK cells. Ultimately, such methods provide for faster ex vivo processing of PBMC for adoptive cell therapy, such as by providing a point of care method to substantially simplify the delivery of such therapies.
[0101] The method for transduction provided herein and / or the contact step for the method for genetically modifying generally include initial steps, wherein retroviral particle (usually retroviral particle colony) contacts with cell (usual cell colony) to form transduction reaction mixture when in the liquid buffer and / or culture medium containing suspension, followed by the cultivation period optionally selected in this reaction mixture of the retroviral particle and cell in the suspension. Can, for example, be contacted in the chamber of the closed system suitable for processing PMBC, as discussed in more detail herein. Transduction reaction mixture may include one or more buffers or ions, and in illustrative embodiments, include culture medium, such as those culture mediums for relating to lymphocytic in vitro treatment known in the art, as provided in further detail herein.
[0102] The transduction reaction mixture can be between 23°C and 39°C, and in some illustrative embodiments, incubated at 37°C. In certain embodiments, the transduction reaction can be performed at 37°C to 39°C for faster fusion / transduction. When contacted in the transduction reaction mixture, the cells and retroviral particles can be immediately processed to remove retroviral particles that remain free in the suspension and are not associated with the cells from the cells. Optionally, the cells and retroviral particles in suspension, whether free in the suspension or associated with the cells in the suspension, are incubated for different lengths of time, as provided herein for use in the contacting steps in the methods provided herein. Washing, such as washing in the culture medium used in the transduction reaction, may be performed before other steps, regardless of whether such cells will be studied in vitro, in vitro, or introduced into an individual.
[0103] In some embodiments, the replication-defective recombinant retroviral particle can further comprise an activation module, which can be any activation module provided herein. In illustrative embodiments, the activation module can be anti-CD3, such as anti-CD3 scFv or anti-CD3 scFv Fc.
[0104] In some embodiments, the contacting step in the methods provided herein for transducing and / or genetically modifying PBMCs or lymphocytes (typically T cells and / or NK cells) can be performed (or can occur) for between 1 and 24 hours, for example, between 1 and 12 hours, or between 1 and 6 hours. In some illustrative embodiments, the contacting can be performed for less than 24 hours, for example, less than 12 hours, less than 8 hours, less than 4 hours, less than 2 hours, less than 1 hour, less than 30 minutes, or less than 15 minutes, but in each case, there is at least one initial contacting step in which the retroviral particles are contacted with the cells in suspension in the transduction reaction mixture. Such a suspension can include allowing the cells and retroviral particles to settle, or causing such settling at the bottom of a container or chamber by applying a force such as centrifugal force. Following such initial contact, additional optional incubation can be performed in the reaction mixture (containing the cells and retroviral particles in suspension in the reaction mixture) without removing the retroviral particles that remain free in the solution and are not associated with the cells. In illustrative embodiments, the contacting step may be performed (or occur) for a period of time between 30 seconds or 1 minute, 2 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, or 45 minutes at the low end of the range, or 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, or 8 hours at the high end of the range and 10 minutes, 15 minutes, 30 minutes, or 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 36 hours, 48 hours, and 72 hours at the high end of the range. In certain illustrative embodiments, the contacting step may be performed for a period of time between 30 seconds, 1 minute, 5 minutes, 10 minutes, 15 minutes, or 30 minutes at the low end of the range and 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, or 12 hours at the high end of the range. In some embodiments, the contacting step is performed for a period of time between 30 seconds, 1 minute, and 5 minutes at the high end of the range and 10 minutes at the high end of the range. In another illustrative embodiment, contacting is performed only between the initial contacting steps (without any additional incubation in the reaction mixture comprising free retroviral particles in suspension and cells in suspension) without any additional incubation in the reaction mixture, or between incubations of the reaction mixture for 5 minutes, 10 minutes, 15 minutes, 30 minutes, or 1 hour.
[0105] The methods for genetic modification and / or transduction of cells provided herein generally comprise inserting into a cell a polynucleotide comprising one or more transcriptional units encoding a CAR or a lymphoproliferative component, or in illustrative embodiments, encoding a CAR according to any one of the CAR and lymphoproliferative component embodiments provided herein and a lymphoproliferative component. As illustrated in the examples herein, the lymphoproliferative component promotes survival and / or proliferation, which results in the survival and / or expansion of genetically modified and / or transduced cells under appropriate conditions, including but not limited to those provided in the examples provided herein. Thus, PBMCs, lymphocytes, NK cells, or T cells genetically modified herein with one or more nucleic acids encoding a CAR or both a CAR and a lymphoproliferative component are capable of, suitable for, possess, and / or modified for improved survival or expansion in culture medium ex vivo or in vitro in the absence of one or more added cytokines (such as IL-2, IL-15, or IL-7) or added lymphocyte mitogens, as compared to control cells that are identical to the genetically modified and / or transduced cells before they are genetically modified and / or transduced, or in some embodiments, as compared to control cells modified and / or transduced with the same control recombinant retroviral particles as those used to produce the genetically modified and / or transduced cells capable of improved survival or expansion, except that the control retroviral particles do not comprise a transcription unit encoding a CAR, a lymphoproliferative component, or an intracellular domain thereof, or both a CAR and a lymphoproliferative component, or an intracellular domain thereof. In illustrative examples performed in vitro or ex vivo, the control cells and conditions of culture are selected such that under these conditions, the survival and / or proliferation of the control cells will be promoted by the addition of the one or more cytokines (such as IL-2, IL-15 or IL-7), or the lymphocyte mitogen to the culture medium, even though no such cytokines or mitogens are actually added for comparison.
[0106] Therefore, in an illustrative embodiment, the method for genetically modifying and / or transducing is provided herein as a rapid means for providing new functionality by inserting nucleic acid into cells, wherein the nucleic acid provides the function of CAR and / or lymphoproliferative components as discussed herein when expressed. For example, as provided in the examples herein, such cells can better survive and / or expand in vitro and in vivo compared to control cells, and the control cells are identical to the cells modified by genetic means but do not include nucleic acids encoding lymphoproliferative components and optionally selected CARs. For example, the examples herein demonstrate that, compared to the same control cells not modified by genetic means, after contact in culture for the first 7 days, PBMCs modified by genetic means to express CAR or to express both CAR and lymphoproliferative components survive and / or proliferate more, wherein culture is carried out in the absence of any added cytokines (such as, but not limited to, IL-2, IL-15, or IL-7) or added lymphocyte mitogens. Furthermore, this example demonstrates that T cells genetically modified to express a CAR and a lymphoproliferative component have increased survival between days 7 and 14 or 21 following contact under these conditions compared to the same control cells that have not been genetically modified. In fact, T cells genetically modified to express a CAR (e.g., an anti-CD19 CAR) and a driver (as exemplified for a number of drivers identified herein) have increased survival characteristics between days 7 and 21 following contact under these conditions compared to the same cells genetically modified to express a CAR without a lymphoproliferative component.
[0107] In certain embodiments, the genetically modified and / or transduced cells exhibit, are capable of, are adapted to, possess the following properties, or are modified for improved expansion in culture in the absence of any exogenously added T cell stimulator (e.g., IL-2, IL-7, IL-15, anti-CD3, or anti-CD28) or other exogenously added lymphocyte mitogens, compared to control cells that were genetically modified and / or transduced cells before they were genetically modified and / or transduced. In certain embodiments, the genetically modified cells exhibit, are capable of, are adapted to, possess the following properties, or are modified for better expansion in culture in the absence of exogenously added cytokines, in the absence of an antigen bound by an optional CAR encoded by the genome of a retroviral particle, and / or in the absence of a lymphocyte mitogen, compared to control cells between days 3 and 6 of ex vivo culture after contacting. In certain embodiments, the genetically modified cells exhibit, are capable of, are suitable for, possess, or are modified to expand at least two-fold between days 3 and 6 of ex vivo culture following contacting in the absence of exogenously added cytokines and in the absence of an antigen bound by an optional CAR encoded by the genome of the retroviral particle.
[0108] For example, when cells and retroviral particles are initially contacted with retroviral particles (including retroviral particles and cells in a suspension-containing medium) or thereafter during an optional incubation period, the culture medium that may be included in the contacting step or that may be used during cell culture and / or during various washing steps may include a basal culture medium, such as a commercially available culture medium for ex vivo T cell and / or NK cell culture. Non-limiting examples of such culture media include: X-VIVO TM 15 Chemically Defined Serum-Free Hematopoietic Cell Culture Medium (Lonza) (2018 Catalog No. BE02-060F, BE02-00Q, BE-02-061Q, 04-744Q, or 04-418Q), ImmunoCult TM -XF T Cell Expansion Medium (STEMCELL Technologies) (2018 Catalog No. 10981), T cell expansion XSFM (Irvine Scientific) (2018 catalog number 91141), CTS culture medium TM (Therapeutic Grade) (Thermo Fisher Scientific (herein referred to as "Thermo Fisher") or CTS TM Optimizer TMMedia (Thermo Fisher) (2018 Catalog Nos. A10221-01 (basal medium (bottle)) and A10484-02 (supplements), A10221-03 (basal medium (bag)), A1048501 (basal medium and supplement kit (bottle)), and A1048503 (basal medium and supplement kit (bag)). Such media can be chemically defined serum-free formulations manufactured in compliance with cGMP. The media can be xeno-free and complete. In some embodiments, the basal media has been cleared by a regulatory agency for use in ex vivo cell processing, such as an FDA 510(k) cleared device. In some embodiments, the media is 2018 Catalog No. A1048501 (CTS®) with or without PBS, both available from Thermo Fisher (Waltham, MA). TM OpTmizer TM T cell expansion SFM, bottle format) or A1048503 (CTS TM OpTmizer TM The transduction reaction mixture may be supplemented with a T cell expansion supplement (T cell expansion SFM, bag format). Additives such as human serum albumin, human AB+ serum, and / or serum derived from an individual may be added to the transduction reaction mixture. Supporting cytokines such as IL2, IL7, or IL15, or those found in human serum, may be added to the transduction reaction mixture. dGTP may be added to the transduction reaction mixture in certain embodiments.
[0109] In exemplary embodiments of such methods, genetically modified T cells or NK cells can be transplanted into mice in vivo and / or enriched in mice in vivo for at least 7 days, 14 days, or 28 days. The skilled artisan will recognize that such mice can be treated or otherwise genetically modified such that any immunological differences between the genetically modified T cells and / or NK cells do not result in an immune response in the mice directed against any component of the lymphocytes transduced by the replication-defective recombinant retroviral particles.
[0110] Packaging cells (and in illustrative embodiments, packaging cell lines, and in certain illustrative embodiments, packaging cells provided herein in certain aspects) are used to produce replication-defective recombinant retroviral particles. In some embodiments, the packaging cell line can be a suspension cell line. In illustrative embodiments, the packaging cell line can be grown in serum-free medium. In some embodiments, the lymphocytes can be derived from an individual. In illustrative embodiments, the lymphocytes can be derived from the blood of an individual.
[0111] Thus, in one aspect, provided herein is a method for transducing (and / or genetically modifying) lymphocytes (typically resting T cells and / or resting NK cells from separated blood), the method comprising:
[0112] A. Collect blood from individuals;
[0113] B. isolating peripheral blood mononuclear cells (PBMCs) containing resting T cells and / or resting NK cells; and
[0114] C. contacting the individual's resting T cells and / or resting NK cells ex vivo with non-replicating recombinant retroviral particles, wherein the non-replicating recombinant retroviral particles comprise a pseudotyping component on their surface that is capable of binding to resting T cells and / or resting NK cells and facilitating fusion of the non-replicating recombinant retroviral particles with their membranes, wherein the contacting facilitates transduction of at least 5% of the resting T cells and / or resting NK cells with the non-replicating recombinant retroviral particles, thereby generating genetically modified T cells and / or NK cells, thereby transducing resting T cells and / or NK cells.
[0115] In some embodiments of any method herein comprising the step of transducing T cells and / or NK cells, cells can be contacted with retroviral particles without prior activation. In some embodiments of any method herein comprising the step of transducing T cells and / or NK cells, prior to transduction, T cells and / or NK cells are cultivated on a matrix adhered to monocytes for more than 4 hours in one embodiment, or more than 6 hours in another embodiment, or more than 8 hours in another embodiment. In an illustrative embodiment, prior to transduction, T cells and / or NK cells are cultivated overnight on an adhesive matrix to remove monocytes. In another embodiment, the method may include cultivating T cells and / or NK cells on an adhesive matrix in conjunction with monocytes for no more than 30 minutes, 1 hour, or 2 hours before transduction. In another embodiment, prior to this transduction step, T cells and / or NK cells are not exposed to the step of removing monocytes by cultivating on an adhesive matrix. In another embodiment, the T cells and / or NK cells are not cultured with or exposed to bovine serum (such as cell culture bovine serum, e.g., fetal bovine serum) prior to or during transduction.
[0116] Thus, in another aspect, provided herein is a method for genetically modifying or transducing lymphocytes (in illustrative embodiments, T cells and / or NK cells, or a population of T cells and / or NK cells) of an individual, the method comprising contacting T cells and / or NK cells of a general individual ex vivo with a replication-defective recombinant retroviral particle, the replication-defective recombinant retroviral particle comprising a polynucleotide in its genome comprising one or more nucleic acid sequences operably linked to a promoter active in T cells and / or NK cells, wherein a first nucleic acid sequence of the one or more nucleic acid sequences encodes two or more inhibitory RNA molecules against one or more RNA targets, and a second nucleic acid sequence of the one or more nucleic acid sequences encodes a chimeric antigen receptor (CAR) comprising an antigen-specific targeting region (ASTR), a transmembrane domain, and an intracellular activation domain, wherein the contacting facilitates transduction of resting T cells and / or NK cells, or at least some of the resting T cells and / or NK cells, with the replication-defective recombinant retroviral particle, thereby generating genetically modified T cells and / or NK cells.
[0117] In another aspect, provided herein is a method for genetically modifying or transducing lymphocytes (e.g., T cells and / or NK cells) or a population thereof of an individual, the method comprising contacting lymphocytes (e.g., T cells and / or NK cells) or a population thereof of the individual ex vivo with a replication-defective recombinant retroviral particle, the replication-defective recombinant retroviral particle comprising a polynucleotide in its genome comprising one or more nucleic acid sequences operably linked to a promoter active in lymphocytes (e.g., T cells and / or NK cells), wherein a first nucleic acid sequence of the one or more nucleic acid sequences encodes One or more (e.g., two or more) inhibitory RNA molecules directed against one or more RNA targets, and a second nucleic acid sequence among the one or more nucleic acid sequences encodes a chimeric antigen receptor (CAR) comprising an antigen-specific targeting region (ASTR), a transmembrane domain, and an intracellular activation domain, wherein the contact facilitates genetic modification and / or transduction of lymphocytes (e.g., T cells and / or NK cells) or at least some of the lymphocytes (e.g., T cells and / or NK cells) using replication-defective recombinant retroviral particles, thereby producing genetically modified and / or transduced lymphocytes (e.g., T cells and / or NK cells).
[0118] In some embodiments of the method immediately following the above, lymphocytes (e.g., T cells and / or NK cells) or a colony thereof modified by gene mode and / or transduced are introduced into an individual. In certain embodiments, lymphocytes (e.g., T cells and / or NK cells) or a colony thereof modified by gene mode and / or transduced are introduced into an individual before being introduced or reintroduced into an individual, undergoing 4 or fewer cell divisions in vitro. In certain embodiments, lymphocytes are resting T cells and / or resting NK cells between 1 and 12 hours of contact with replication-deficient recombinant retroviral particles. In certain embodiments, the time of blood collection from an individual is no more than 8 hours between the time of T cells and / or NK cells modified by gene mode and reintroduced into an individual. In certain embodiments, all steps after blood collection and before blood reintroduction are performed in a closed system, and people monitor the closed system during the entire treatment period.
[0119] In any of the method aspects including polynucleotides provided immediately above, the polynucleotides include one or more nucleic acid sequences operably linked to a promoter active in T cells and / or NK cells, wherein the first nucleic acid sequence in the one or more nucleic acid sequences encodes one or more (e.g., two or more) inhibitory RNA molecules for one or more RNA targets, and the second nucleic acid sequence in the one or more nucleic acid sequences encodes a chimeric antigen receptor (CAR) comprising an antigen-specific targeting region (ASTR), a transmembrane domain, and an intracellular activation domain, the polynucleotides may further include a third nucleic acid sequence encoding at least one lymphoproliferative component lymphoproliferative component that is not an inhibitory RNA molecule. In some embodiments, the lymphoproliferative component lymphoproliferative component may be a cytokine or cytokine receptor polypeptide, or a fragment thereof comprising a signaling domain. In some embodiments, the lymphoproliferative component lymphoproliferative component is constitutively active. In certain embodiments, the lymphoproliferative component lymphoproliferative component may be an IL-7 receptor or a fragment thereof. In illustrative embodiments, the lymphoproliferative element can be a constitutively active IL-7 receptor or a constitutively active fragment thereof.
[0120] In any one of the method aspects including polynucleotides provided immediately above, the polynucleotides include one or more nucleic acid sequences operably connected to a promoter active in T cells and / or NK cells, wherein the first nucleic acid sequence in the one or more nucleic acid sequences encodes one or more (e.g., two or more) inhibitory RNA molecules for one or more RNA targets, inhibitory RNA molecules may include in some embodiments 5' chains and 3' chains that are partially or completely complementary to each other, wherein the 5' chain and the 3' chain can form 18 to 25 nucleotide RNA duplexes. In certain embodiments, the 5' chain length may be 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides, and the 3' chain length may be 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides. In certain embodiments, the 5' chain and the 3' chain length may be the same or different. In certain embodiments, the RNA duplex may include one or more mispairings. In alternative embodiments, the RNA duplex does not have a mispairing.
[0121] In any one of the method aspects including polynucleotides provided immediately above, the polynucleotides include one or more nucleic acid sequences operably linked to a promoter active in T cells and / or NK cells, wherein the first nucleic acid sequence in the one or more nucleic acid sequences encodes one or more (e.g., two or more) inhibitory RNA molecules for one or more RNA targets, and the inhibitory RNA molecules may be miRNA or shRNA. In some embodiments, the inhibitory molecule may be a precursor of miRNA, such as Pri-miRNA or Pre-miRNA, or a precursor of shRNA. In some embodiments, the inhibitory molecule may be an artificially derived miRNA or shRNA. In other embodiments, the inhibitory RNA molecule may be a dsRNA (transcribed or artificially introduced) or siRNA itself that is processed into siRNA. In some embodiments, the inhibitory RNA molecule may be a miRNA or shRNA having a sequence not found in nature, or having at least one functional fragment not found in nature, or having a combination of functional segments not found in nature. In illustrative embodiments, at least one or all of the inhibitory RNA molecules are miR-155.
[0122] In any of the method aspects including polynucleotides (including one or more nucleic acid sequences operably linked to promoters active in T cells and / or NK cells) provided immediately above, wherein the first nucleic acid sequence in the one or more nucleic acid sequences encodes one or more (e.g., two or more) inhibitory RNA molecules directed against one or more RNA targets, in some embodiments, the inhibitory RNA molecule may be oriented from 5' to 3' to include: a 5' arm, a 5' stem, a loop, a 3' stem partially or completely complementary to the 5' stem, and a 3' arm. In some embodiments, at least one of the two or more inhibitory RNA molecules has this arrangement. In other embodiments, all of the two or more inhibitory RNA molecules have this arrangement. In some embodiments, the 5' stem length may be 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the 3' stem length may be 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the loop length may be 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides. In some embodiments, the 5' arm, the 3' arm, or both are derived from naturally occurring miRNAs. In some embodiments, the 5' arm, the 3' arm, or both are derived from naturally occurring miRNAs selected from the group consisting of miR-155, miR-30, miR-17-92, miR-122, and miR-21. In illustrative embodiments, the 5' arm, the 3' arm, or both are derived from miR-155. In some embodiments, the 5' arm, the 3' arm, or both are derived from Mus musculus miR-155 or Homo sapiens miR-155. In some embodiments, the 5'-arm has a sequence set forth in SEQ ID NO: 256 or a functional variant thereof, such as the same length as SEQ ID NO: 256, or 95%, 90%, 85%, 80%, 75%, or 50% of the length of SEQ ID NO: 256, or a sequence of 100 nucleotides or less, 95 nucleotides or less, 90 nucleotides or less, 85 nucleotides or less, 80 nucleotides or less, 75 nucleotides or less, 70 nucleotides or less, 45 nucleotides or less, 40 nucleotides or less, 35 nucleotides or less, 30 nucleotides or less, or 25 nucleotides or less; and is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% identical to SEQ ID NO: 256.In some embodiments, the 3' arm has a sequence set forth in SEQ ID NO: 260, or a functional variant thereof, such as the same length as SEQ ID NO: 260, or 95%, 90%, 85%, 80%, 75%, or 50% of the length of SEQ ID NO: 260, or a sequence of 100 nucleotides or less, 95 nucleotides or less, 90 nucleotides or less, 85 nucleotides or less, 80 nucleotides or less, 75 nucleotides or less, 70 nucleotides or less, 65 nucleotides or less, 60 nucleotides or less, 55 nucleotides or less, 50 nucleotides or less, 45 nucleotides or less, 40 nucleotides or less, 35 nucleotides or less, 30 nucleotides or less, or 25 nucleotides or less; and at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% identical to SEQ ID NO: 260. In some embodiments, the 3' arm comprises nucleotides 221 to 283 of the Mus musculus BIC.
[0123] In any of the method aspects provided immediately above including a polynucleotide comprising one or more nucleic acid sequences operably linked to a promoter active in T cells and / or NK cells, wherein the first nucleic acid sequence in the one or more nucleic acid sequences encodes two or more inhibitory RNA molecules for one or more RNA targets, in some embodiments, the two or more inhibitory RNA molecules may be located continuously in the first nucleic acid sequence. In some embodiments, the inhibitory RNA molecules may be directly or indirectly linked to each other using a non-functional connector sequence. In some embodiments, the connector sequence may be between 5 and 120 nucleotides in length, or between 10 and 40 nucleotides in length.
[0124] In any of the method aspects provided immediately above comprising a polynucleotide comprising one or more nucleic acid sequences operably linked to a promoter active in T cells and / or NK cells, wherein the first nucleic acid sequence in the one or more nucleic acid sequences encodes two or more inhibitory RNA molecules for one or more RNA targets, in some embodiments, the first nucleic acid sequence encodes two to four inhibitory RNA molecules. In illustrative embodiments, the first nucleic acid sequence includes between 2 and 10, between 2 and 8, between 2 and 6, between 2 and 5, between 2 and 4, between 3 and 5, or between 3 and 6 inhibitory RNA molecules. In an illustrative embodiment, the first nucleic acid sequence includes four inhibitory RNA molecules.
[0125] In any of the method aspects including polynucleotides provided immediately above (comprising one or more nucleic acid sequences operably linked to a promoter active in T cells and / or NK cells), wherein the first nucleic acid sequence in the one or more nucleic acid sequences encodes one or more (e.g., two or more) inhibitory RNA molecules directed against one or more RNA targets, the one or more (e.g., two or more) inhibitory RNA molecules may be in an intron. In some embodiments, the intron is in the promoter. In illustrative embodiments, the intron is EF-1α intron A. In some embodiments, the intron is adjacent to the promoter and downstream of the promoter, and in illustrative embodiments, the intron is inactive in packaging cells for producing replication-defective recombinant retroviral particles.
[0126] In any of the method aspects provided immediately above comprising a polynucleotide comprising one or more nucleic acid sequences operably linked to a promoter active in T cells and / or NK cells, wherein a first nucleic acid sequence in the one or more nucleic acid sequences encodes two or more inhibitory RNA molecules directed against one or more RNA targets, in some embodiments, the two or more inhibitory RNA molecules may be directed against different targets. In an alternative embodiment, the two or more inhibitory RNA molecules are directed against the same target. In some embodiments, the RNA target is an mRNA transcribed from a gene expressed by free T cells, such as, but not limited to: PD-1 (prevents inactivation); CTLA4 (prevents inactivation); TCRα (safely prevents autoimmunity); TCRb (safety-prevents autoimmunity); CD3Z (safety-prevents autoimmunity); SOCS1 (prevents inactivation); SMAD2 (prevents inactivation); miR-155 target (promotes activation); IFNγ (reduces CRS); cCBL (prolongs signaling); TRAIL2 (prevents death); PP2A (prolongs signaling); ABCG1 (increases cholesterol micro-levels by limiting cholesterol clearance). In some embodiments, the RNA target is an mRNA transcribed from a gene encoding a component of the T cell receptor (TCR) complex. In some embodiments, at least one of the two or more inhibitory RNA molecules can reduce the expression of a T cell receptor (in illustrative embodiments, one or more endogenous T cell receptors of a T cell). In certain embodiments, the RNA target may be an mRNA transcribed from an endogenous TCRα or TCRβ gene of a T cell whose genome comprises a first nucleic acid sequence encoding one or more miRNAs. In an illustrative embodiment, the RNA target is an mRNA transcribed from a TCRα gene.
[0127] In any of the method aspects provided immediately above including a polynucleotide comprising one or more nucleic acid sequences operably linked to a promoter active in T cells and / or NK cells, wherein the first nucleic acid sequence in the one or more nucleic acid sequences encodes one or more (e.g., two or more) inhibitory RNA molecules directed against one or more RNA targets, and the second nucleic acid sequence in the one or more nucleic acid sequences encodes a chimeric antigen receptor (CAR) comprising an antigen-specific targeting region (ASTR), a transmembrane domain, and an intracellular activation domain, in some embodiments, CAR is a microenvironmentally restricted organism (MRB)-CAR. In other embodiments, the ASTR of CAR binds to tumor-associated antigens. In other embodiments, the ASTR of CAR is a microenvironmentally restricted organism (MRB)-ASTR. In any of the aspects and embodiments comprising MRB-ASTR or MRB-CAR disclosed herein, MRB-ASTR preferably or only binds to its cognate antigen under certain abnormal conditions, such as those present in the tumor microenvironment. MRB-ASTRs that bind better or exclusively under abnormal conditions of the tumor microenvironment can provide reduced on-target off-tumor effects because binding to the antigen under normal physiological conditions is reduced, in some cases to levels below that detected by immunoassays. Normal physiological conditions can include those that are considered to be within the normal range for an individual at the site of administration or in the tissue or organ at the site of action, such as temperature, pH, osmotic pressure, osmolality, oxidative stress, and electrolyte concentration. Abnormal conditions are conditions that deviate from the normal acceptable range. In some embodiments, the MRB-ASTR is reversibly or irreversibly inactivated under normal conditions. As used herein, an MRB-ASTR can be an antibody, an antigen, a ligand, a receptor binding domain of a ligand, a receptor, a ligand binding domain of a receptor, or an affinity. In embodiments where the MRB-ASTR is an antibody, the MRB-ASTR can be a full-length antibody, a single-chain antibody, a Fab fragment, a Fab' fragment, a (Fab')2 fragment, an Fv fragment, a bivalent single-chain antibody, or a diabody, wherein the ASTR comprises a heavy chain and a light chain from an antibody. In some embodiments, the MRB-ASTR is a single chain variable fragment.
[0128] In any of the method aspects provided immediately above including a polynucleotide comprising one or more nucleic acid sequences operably linked to a promoter active in T cells and / or NK cells, wherein the first nucleic acid sequence in the one or more nucleic acid sequences encodes one or more (e.g., two or more) inhibitory RNA molecules directed against one or more RNA targets, and the second nucleic acid sequence in the one or more nucleic acid sequences encodes a chimeric antigen receptor (CAR) comprising an antigen-specific targeting region (ASTR), a transmembrane domain, and an intracellular activation domain, and in some cases, the third nucleic acid sequence in the one or more nucleic acid sequences encodes at least one lymphoproliferative component that is not an inhibitory RNA molecule. In some embodiments, any one or all of the first nucleic acid sequence, the second nucleic acid sequence, and the third nucleic acid sequence are operably linked to a riboswitch. In some embodiments, a riboswitch is capable of binding nucleoside analogs. In some embodiments, nucleoside analogs are antiviral drugs.
[0129] In some embodiments, methods are provided for activating and / or genetically modifying, and typically transducing, resting T cells or NK cells (in illustrative embodiments, resting T cells) by contacting the cells with a retroviral particle disclosed herein and a soluble anti-CD3 antibody at 25 ng / ml to 200 ng / ml, 50 ng / ml to 150 ng / ml, 75 ng / ml to 125 ng / ml, or 100 ng / ml. In illustrative embodiments, these methods are performed without prior activation and can be performed, for example, for 8 hours or less, 4 hours or less, or between 2 and 8 hours, 2 and 4 hours, or between 2 and 3 hours.
[0130] In certain aspects, provided herein are methods for performing adoptive cell therapy on an individual. As an illustrative example, the method may include the following:
[0131] A. Collect blood from individuals;
[0132] B. Isolating peripheral blood mononuclear cells (PBMCs) containing resting T cells and / or resting NK cells;
[0133] C. contacting resting T cells and / or resting NK cells of the individual ex vivo with replication-defective recombinant retroviral particles, wherein the replication-defective recombinant retroviral particles comprise a pseudotyping component on their surface that is capable of binding to resting T cells and / or NK cells and facilitating fusion of the replication-defective recombinant retroviral particles with their membranes, wherein the contacting facilitates transduction of the resting T cells and / or NK cells with the replication-defective recombinant retroviral particles, thereby generating genetically modified T cells and / or NK cells; and
[0134] D. Reintroducing the genetically modified cells into the individual within 36 hours, 24 hours, 12 hours, or even 8 hours of collecting blood from the individual, thereby performing adoptive cell therapy in the individual.
[0135] In some aspects provided herein, methods having similar steps are referred to as methods for genetically modifying and expanding lymphocytes of an individual. A skilled artisan will appreciate that the discussion herein, as applied to methods and compositions for performing adoptive cell therapy, also applies to methods for genetically modifying and expanding lymphocytes of an individual.
[0136] Generally, the adoptive cell therapy of the present invention is to utilize autologous transfer to carry out, wherein cells are separated and / or otherwise prepared from the individual receiving cell therapy or from the sample derived from such individual. Therefore, in some aspects, cells are derived from the individual (for example, patient) in need of treatment and the cells after separation and treatment of the same individual. In some embodiments of the methods and compositions disclosed herein, the individual suffering from disease or illness enters a medical institution where the blood of the individual is extracted using known methods (such as venipuncture). In certain embodiments, the volume of the blood extracted from the individual is 10ml, 15ml, 20ml, 25ml, 30ml, 35ml, 40ml, 50ml, 75ml or 100ml at the low end of the range and 200ml, 250ml, 300ml, 350ml, 400ml, 500ml, 750ml, 1000ml, 2000ml or 2500ml at the high end of the range. In certain embodiments, blood between 10ml and 400ml is extracted from the individual. In some embodiments, between 20 ml and 250 ml of blood is drawn from a subject. In some embodiments, the blood is fresh at the time of processing. In any of the embodiments disclosed herein, fresh blood can be blood drawn from a subject less than 15 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, or 180 minutes previously. In some embodiments, blood is processed using the methods provided herein without storage.
[0137] Contact between T cells and / or NK cells and replication-deficient recombinant retroviral particles generally facilitates transduction of T cells and / or NK cells using replication-deficient recombinant retroviral particles. Throughout the present invention, transduced T cells and / or NK cells include at least some of the progeny of nucleic acids or polynucleotides that are incorporated into cells during ex vivo transduction of transduced cells. In the methods herein where "reintroduction" of transduced cells is cited, it should be understood that such cells are generally not in a transduced state when collected from the blood of an individual. The individual in any one of the aspects disclosed herein can be, for example, an animal, a mammal, and, in illustrative embodiments, a human.
[0138] Without being limited by theory, in a non-limiting illustrative method, ex vivo delivery of a polynucleotide encoding a lymphoproliferative component (such as a constitutively active mutant of IL7) to resting T cells and / or NK cells, which can be integrated into the genome of T cells and / or NK cells, provides cells with drivers for in vivo expansion without requiring host lymphodepletion. Thus, in illustrative embodiments, the individual is not exposed to a lymphodepleting agent within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 14 days, 21 days, or 28 days, or 1 month, 2 months, 3 months, or 6 months of performing the contacting, during the contacting, and / or within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 14 days, 21 days, or 28 days, or 1 month, 2 months, 3 months, or 6 months after the modified T cells and / or NK cells are reintroduced into the individual. Furthermore, in non-limiting embodiments, the methods provided herein can be performed without exposing the individual to a lymphodepleting agent during the step in which the replication-defective recombinant retroviral particles are contacted with resting T cells and / or NK cells of the individual or during the entire ex vivo method.
[0139] Thus, in vivo expansion of genetically modified T cells and / or NK cells in an individual is a feature of some embodiments of the invention.In illustrative embodiments, these methods are ex vivo transmission-free or substantially transmission-free.
[0140] In the non-limiting illustrative embodiments herein, the entire method / process from the extraction of blood from the individual to the reintroduction of the blood back into the individual following ex vivo transduction of T cells and / or NK cells can occur in a timeframe of less than 48 hours, less than 36 hours, less than 24 hours, less than 12 hours, less than 11 hours, less than 10 hours, less than 9 hours, less than 8 hours, less than 7 hours, less than 6 hours, less than 5 hours, less than 4 hours, less than 3 hours, 2 hours, or less than 2 hours. In other embodiments, the entire method / process from the extraction / collection of blood from the individual to the ex vivo transduction (in the non-limiting illustrative embodiments herein) of T cells and / or NK cells and the reintroduction of the blood back into the individual occurs in a timeframe of between 1 hour and 12 hours, or between 2 hours and 8 hours, or between 1 hour and 3 hours, or between 2 hours and 4 hours, or between 2 hours and 6 hours, or between 4 hours and 12 hours, or between 4 hours and 24 hours, or between 8 hours and 24 hours. , or between 8 hours and 36 hours, or between 8 hours and 48 hours, or between 12 hours and 24 hours, or between 12 hours and 36 hours, or between 12 hours and 48 hours; or occurs within the following time periods: 15 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 180 minutes and 240 minutes at the low end of the range and 120 minutes, 180 minutes, 240 minutes, 300 minutes, 360 minutes, 420 minutes and 480 minutes at the high end of the range. In other embodiments, the entire method / process from drawing / collecting blood from a subject to ex vivo transduction of T cells and / or NK cells and reintroducing the blood back into the subject occurs within a timeframe of between 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, and 12 hours at the low end of the range and 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 18 hours, 24 hours, 36 hours, or 48 hours at the high end of the range. In some embodiments, the genetically modified T cells and / or NK cells are isolated from the replication-defective recombinant retroviral particles after the contacting period.
[0141] In some embodiments of any of the methods herein (which include the steps of blood collection and transduction of lymphocytes (in illustrative embodiments, T cells and / or NK cells, including resting T cells and NK cells)), the method of collecting blood to transduce T cells and / or NK cells does not include the step of removing monocytes by culturing on an adhesive matrix for more than 4 hours in one embodiment, or more than 6 hours in another embodiment, or more than 8 hours in yet another embodiment. In an illustrative embodiment, the method of collecting blood to transduce T cells and / or NK cells does not include overnight culturing on an adhesive matrix to remove monocytes. In another embodiment, the method of collecting blood to transduce T cells and / or NK cells includes the step of removing monocytes by culturing on an adhesive matrix for no more than 30 minutes, 1 hour, or 2 hours. In another embodiment, the method of collecting blood from an individual to transduce lymphocytes (in illustrative embodiments, T cells and / or NK cells, including resting T cells and / or NK cells) does not include the step of removing monocytes by culturing on an adhesive matrix. In another embodiment, a method of collecting blood from an individual to transduce lymphocytes (in illustrative embodiments, T cells and / or NK cells, including resting T cells and / or NK cells) includes not incubating the T cells and / or NK cells with or exposing them to bovine serum (such as cell culture bovine serum, e.g., fetal bovine serum) during the method.
[0142] In some embodiments of any of the methods herein (which include the steps of blood collection and transduction of lymphocytes (in illustrative embodiments, T cells and / or NK cells, including resting T cells and NK cells)), the method of collecting blood from an individual to reintroducing T cells and / or NK cells into the individual does not include the step of removing monocytes by incubating on an adhesive matrix for more than 4 hours in one embodiment, or more than 6 hours in another embodiment, or more than 8 hours in yet another embodiment. In an illustrative embodiment, the method of collecting blood from an individual to reintroducing T cells and / or NK cells into the individual does not include incubating on an adhesive matrix overnight to remove monocytes. In another embodiment, the method of collecting blood from an individual to reintroducing T cells and / or NK cells includes the step of removing monocytes by incubating on an adhesive matrix for no more than 30 minutes, 1 hour, or 2 hours. In another embodiment, the method of collecting blood from an individual to reintroducing T cells and / or NK cells into the individual does not include the step of removing monocytes by incubating on an adhesive matrix overnight. In another embodiment, a method is performed to collect blood from an individual and reintroduce T cells and / or NK cells into the individual, during which the T cells and / or NK cells are not cultured with or exposed to bovine serum (such as cell culture bovine serum, e.g., fetal bovine serum).
[0143] Because the method for adoptive cell therapy provided herein, and the related method for modifying the resting T cells and / or NK cells in vitro before amplifying T cells and / or NK cells in vivo, can be performed in a significantly shorter time than the previous method, making it possible to carry out the basic improvement of patient care and safety and product manufacturing. Therefore, in the eyes of the regulatory agencies responsible for approving such methods for therapeutic purposes in vivo, such methods are expected to be advantageous. For example, in a non-limiting example, before modified T cells and / or NK cells are reintroduced into the patient, the individual can stay in the same building (such as an infusion clinic) or room of the institution that processes their blood or sample during the entire time of sample processing. In a non-limiting illustrative embodiment, after blood is extracted / collected from the individual to transduce T cells and / or NK cells in vitro, the blood is reintroduced into the entire method / process of the individual, and the individual remains within the position line and / or within 100, 50, 25 or 12 feet or arm's length of the blood or cells being processed. In other non-limiting illustrative embodiments, after individual blood is drawn / collected to ex vivo transduction T cells and / or NK cells, blood is reintroduced into the whole method / process of individuality and / or continuously, individuality keeps awake and / or at least one person can continue to monitor the blood or cells being processed of individuality. Because of the improvements provided herein, for adoptive cell therapy and / or transduction of resting T cells and / or NK cells, after individual blood is drawn / collected to ex vivo transduction T cells and / or NK cells, blood is reintroduced into the whole method / process of individuality, can be performed together with the continuous monitoring of mankind. In other non-limiting illustrative embodiments, after individual blood is drawn / collected to ex vivo transduction T cells and / or NK cells, blood is reintroduced into any point of the whole method / process of individuality, blood cells are not cultivated in a room without individual presence. In other non-limiting illustrative embodiments, the entire method / process from individual blood extraction / collection to ex vivo transduction of T cells and / or NK cells followed by reintroduction of blood into the individual is performed right next to the individual and / or in the same room as the individual and / or right next to the individual's bed or chair. Thus, sample consistency confusion can be avoided, as well as long and expensive cultivation over several days or weeks. This advantage is further demonstrated by the fact that the methods provided herein are readily applicable to closed and automated blood processing systems, in which the blood sample and its components reintroduced into the individual are contacted only with single, disposable components.
[0144] The method for performing the adoptive cell therapy provided herein generally includes 1) a method for transducing lymphocytes (such as T cells and / or NK cells, which are resting T cells and / or NK cells in illustrative embodiments), and / or includes 2) a method for genetically modifying lymphocytes (such as T cells and / or NK cells, which are resting T cells and / or NK cells in illustrative embodiments), both of which (1 and 2) themselves form different aspects of the present invention. Such methods can be performed with or without other steps identified herein for performing adoptive cell therapy. In any method including ex vivo transduction of resting T cells and / or resting NK cells provided herein, neutrophils / granulocytes are typically separated from blood cells before cells are contacted with replication-deficient recombinant retroviral particles. In some embodiments, peripheral blood mononuclear cells (PBMCs) including peripheral blood lymphocytes (PBL) (such as T cells and / or NK cells) are separated from other components of a blood sample using, for example, hemacytesis and / or density gradient centrifugation. In some embodiments, neutrophils are removed before PBMCs and / or T cells and / or NK cells are processed, contacted with replication-defective recombinant retroviral particles, transduced or transfected.With respect to the individual to be treated, the cells may be allogeneic and / or autologous.
[0145] As a non-limiting example, in some embodiments of the methods for transduction or genetic modification herein, PBMCs are separated using a Sepax or Sepax 2 cell processing system (BioSafe). In some embodiments, PBMCs are separated using a CliniMACS Prodigy cell processor (Miltenyi Biotec). In some embodiments, an automatic blood cell separator is used to collect blood from an individual, pass the blood through a device that selects peripheral cell types (such as PBMCs), and return the remainder to the individual. Density gradient centrifugation can be performed after blood cell separation. In some embodiments, PBMCs are separated using a filter device that removes leukocytes. In some embodiments, magnetic bead-activated cell sorting is then used to purify specific cell populations from PBMCs (such as PBLs or their subsets) based on cell phenotype (i.e., positive selection). Other methods for purification can also be used, such as matrix adhesion, which utilizes a matrix that simulates the environment encountered by T cells during supplementation, thereby causing them to adhere and migrate, or negative selection, in which unwanted cells are removed using antibody complexes (targeting unwanted cells). In some embodiments, erythrocyte rosetting can be used for purifying cells.
[0146] In some illustrative embodiments of any of the related aspects herein, the PBLs include T cells and / or NK cells. During certain embodiments herein, such as in methods of modifying lymphocytes and methods of performing adoptive cell therapy, the T cells and / or NK cells contacted with the replication-defective recombinant retroviral particles of the invention are primarily resting T cells. In some embodiments, the T cells and / or NK cells comprise between 95% and 100% resting cells (Ki-67 - In some embodiments, the T cells and / or NK cells contacted with the replication-defective recombinant retroviral particles comprise between 90%, 91%, 92%, 93%, 94%, and 95% resting cells at the low end of the range and 96%, 97%, 98%, 99%, or 100% resting cells at the high end of the range. In some embodiments, the T cells and / or NK cells comprise naive cells.
[0147] In some embodiments of the methods and compositions disclosed herein, T cells and / or NK cells are contacted ex vivo with replication-deficient recombinant retroviral particles to genetically modify T cells and / or NK cells to induce a targeted immune response in the individual when reintroduced into the individual. During the contact period, the replication-deficient recombinant retroviral particles recognize T cells and / or NK cells and bind to them, at which point the retrovirus begins to fuse with the host cell membrane. Then, via a transduction procedure, the genetic material from the replication-deficient recombinant retroviral particles enters the T cells and / or NK cells and is incorporated into the host cell DNA. The method of lentiviral transduction is known. Exemplary methods are described in, e.g., Wang et al. (2012) J. Immunother. 35(9):689-701, Cooper et al. (2003) Blood. 101:1637-1644, Verhoeyen et al. (2009) Methods Mol Biol. 506:97-114, and Cavalieri et al. (2003) Blood. 102(2):497-505.
[0148] Many methods in the method provided herein include transduction T cells and / or NK cells. It is known in the art to be used for ex vivo transduction of T cells and / or NK cells with replication defective recombinant retroviral particles (such as replication defective recombinant lentiviral particles). In illustrative embodiments, the method provided herein does not require ex vivo stimulation or activation. Therefore, this conventional step in the previous method can be avoided in this method, but ex vivo stimulating molecules (such as anti-CD3 and / or anti-CD28 beads) may be present during transduction. However, utilizing the illustrative method provided herein, ex vivo stimulation is not required. In some exemplary methods, between 3 and 10 heavy infections (MOI), and in some embodiments, the replication defective recombinant retroviral particles of the unit between 5MOI and 10MOI, such as lentivirus, can be used.
[0149] The transduction reaction can be performed in a closed system (such as the Sepax system as discussed herein), wherein the transduction reaction can be performed in a disposable bag loaded on the system. Once blood cells (such as PBMCs) from a blood sample collected from an individual are separated, isolated, and / or purified from granulocytes (including neutrophils), these blood cells can be contacted with the replication-defective recombinant retroviral particles disclosed herein in the bag, wherein the granulocytes are generally not present during the contacting step (i.e., the transduction reaction).
[0150] The replication-defective recombinant retroviral particles can be reintroduced into the bag containing the isolated PBMCs, thereby contacting the PBMCs. The time from the time blood is collected from the individual to the time blood cells (such as PBMCs) are added to the transduction reaction bag can be between 30 minutes and 4 hours, between 30 minutes and 2 hours, or in some examples, about 1 hour.
[0151] In certain embodiments in which cells are infused into an individual, after transduction, before the transduced T cells and / or NK cells are infused back into the individual, the cells are washed to remove the transduction reaction mixture before infusion back into the individual. For example, before the transduced cells are infused back into the individual, a system (such as a Sepax instrument) can be used to wash the cells, for example, with 10 ml to 50 ml of washing solution. In some embodiments, neutrophils are removed before PBMCs and / or T cells and / or NK cells are treated, contacted with replication-defective recombinant retroviral particles, transduced, or transfected.
[0152] In an illustrative embodiment for performing adoptive cell therapy, blood is collected in a blood bag from an individual, and the blood bag is connected to a cell processing system, such as a Sepax cell processing system. The PBMC separated using the cell processing system is collected in a bag, and the PBMC is contacted with replication-deficient recombinant retroviral particles under conditions sufficient to transduce T cells and / or NK cells, and cultivated. After cultivation, a bag containing a mixture of PBMC and replication-deficient recombinant retroviral particles is connected to the cell processing system, and the PBMC is washed. The washed PBMC is collected in a bag and re-infused into the individual. In certain embodiments, the entire method from collecting blood to re-infusing transduced T cells and / or NK cells is performed within 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 15 hours, 18 hours or 24 hours. In an illustrative embodiment, the entire method is performed within 12 hours.
[0153] In some embodiments, the target cell of the replication-defective recombinant retroviral particle is a PBL. In some embodiments, the target cell is a T cell and / or a NK cell. In some embodiments, the T cell is a helper T cell and / or a killer T cell.
[0154] In some embodiments, the replication-deficient recombinant retroviral particles provided herein have pseudotyped components on their surface, which can bind to T cells and / or NK cells and contribute to membrane fusion with replication-deficient recombinant retroviral particles. In other embodiments, the replication-deficient recombinant retroviral particles have activation components on their surface that can bind to resting T cells and / or NK cells. In yet other embodiments, the replication-deficient recombinant retroviral particles have membrane-bound cytokines on their surface. In some embodiments, the replication-deficient recombinant retroviral particles include polynucleotides having one or more transcription units encoding one or more engineered signaling polypeptides, one or more of which include one or more lymphoproliferative components lymphoproliferative components. In other embodiments, when two signaling polypeptides are utilized, one includes at least one lymphoproliferative component lymphoproliferative component, and the other is typically a chimeric antigen receptor (CAR) including an antigen-specific targeting region (ASTR), a transmembrane domain, and an intracellular activation domain. As indicated herein, the activation assembly typically associated with the surface of the replication-deficient recombinant retroviral particles provided herein is capable of contacting resting T cells and / or NK cells for a sufficient period of time, and due to the contact and activation of resting T cells and / or NK cells under appropriate conditions. It should be understood that this activation occurs over time during the contact step of the method herein. In addition, it should be understood that in some embodiments where the pseudotyped assembly is found on the surface of the replication-deficient recombinant retroviral particles that bind T cells and / or NK cells, in the method herein, activation can be induced by binding the pseudotyped assembly. The activation assembly is optionally present in those embodiments.
[0155] Additional descriptions of pseudotyping components, activation components, membrane-bound cytokines, engineered signaling polypeptides, lymphoproliferative components, and CARs are provided elsewhere herein.
[0156] In some embodiments of the methods and compositions disclosed herein, between 5% and 90% of the total lymphocytes collected from the blood are transduced. In certain embodiments, the percentage of transduced lymphocytes is between 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, and 60% at the low end of the range and 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, and 90% at the high end of the range. In some embodiments, the percentage of transduced lymphocytes is at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, or at least 60%.
[0157] In some embodiments of the methods and compositions disclosed herein, genetically modified T cells and / or NK cells are introduced back, reintroduced or re-infused into an individual without the need for additional ex vivo manipulation, such as stimulation and / or activation of T cells and / or NK cells. In prior art methods, ex vivo manipulation is used to stimulate / activate T cells and / or NK cells, and for amplifying genetically modified T cells and / or NK cells before genetically modified T cells and / or NK cells are introduced into an individual. In prior art methods, this typically takes several days or weeks, and requires the individual to return to the clinic for several days or weeks of blood transfusion after initial blood draw. In some embodiments of the methods and compositions disclosed herein, before T cells and / or NK cells contact with replication-defective recombinant retroviral particles, T cells and / or NK cells are not stimulated in vitro by exposure to anti-CD3 / anti-CD28 solid carriers (such as, coated with anti-CD3 / anti-CD28 beads). Therefore, a method for ex vivo transmission-free is provided herein. In other embodiments, the genetically modified T cells and / or NK cells are not expanded in vitro, or only expand a smaller number of cell divisions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 rounds of cell division), but instead refer to in vivo (i.e., within an individual) expansion or primarily in vivo expansion. In some embodiments, no additional medium is added to allow for additional expansion of the cells. In some embodiments, when PBLs are contacted with replication-deficient recombinant retroviral particles, cell production of PBLs does not occur. In illustrative embodiments, cell production of PBLs does not occur when PBLs are ex vivo. In previous methods of adoptive cell therapy, individuals undergo lympholysis prior to reinfusion of genetically modified T cells and / or NK cells. In some embodiments, patients or individuals do not undergo lympholysis prior to blood draw. In some embodiments, patients or individuals do not undergo lympholysis prior to reinfusion of genetically modified T cells and / or NK cells. However, embodiments of the methods and compositions disclosed herein may also be used for pre-activated or pre-stimulated T cells and / or NK cells. In some embodiments, T cells and / or NK cells can be stimulated ex vivo by exposing them to an anti-CD3 / anti-CD28 solid support prior to contacting them with the replication-defective recombinant retroviral particles. In some embodiments, the T cells and / or NK cells can be exposed to the anti-CD3 / anti-CD28 solid support for less than 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, or 24 hours prior to contacting them with the replication-defective recombinant retroviral particles.In illustrative embodiments, the T cells and / or NK cells can be exposed to the anti-CD3 / anti-CD28 solid support for less than 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, or 8 hours prior to contacting the T cells and / or NK cells with the replication-defective recombinant retroviral particles.
[0158] In any of the embodiments disclosed herein, the number of T cells and / or NK cells to be reinfused into the subject may be at the low end of the range of 1×10 3 , 2.5×10 3 , 5×10 3 , 1×10 4 , 2.5×10 4 , 5×10 4 , 1×10 5 , 2.5×10 5 , 5×10 5 , 1×10 6 , 2.5×10 6 , 5×10 6 and 1×10 7 cells / kg with the high end of the range being 5×10 4 , 1×10 5 , 2.5×10 5 , 5×10 5 , 1×10 6 , 2.5×10 6 , 5×10 6 , 1×10 7 , 2.5×10 7 , 5×10 7 and 1×10 8 In an illustrative embodiment, the number of T cells and / or NK cells to be reinfused into an individual may be 1×10 cells / kg at the low end of the range. 4 , 2.5×10 4 , 5×10 4 and 1×10 5 cells / kg with the high end of the range being 2.5 × 10 4 , 5×10 4 , 1×10 5 , 2.5×10 5 , 5×10 5 and 1×10 6 In some embodiments, the number of PBLs to be reinfused into an individual may be less than 5×10 cells / kg at the low end of the range. 5 , 1×10 6 , 2.5×10 6 , 5×10 6 , 1×10 7, 2.5×10 7 , 5×10 7 and 1×10 8 cells, with the high end of the range being 2.5 × 10 6 , 5×10 6 , 1×10 7 , 2.5×10 7 , 5×10 7 , 1×10 8 , 2.5×10 8 , 5×10 8 and 1×10 9 In some embodiments, the number of T cells and / or NK cells that can be used for reinfusion into a 70 kg individual or patient is 7×10 5 cells and 2.5×10 8 In other embodiments, the number of T cells and / or NK cells that can be transduced is approximately 7×10 6 plus or minus 10%.
[0159] In the methods disclosed herein, the entire adoptive cell therapy procedure (from blood withdrawal to reinfusion of genetically modified T cells and / or NK cells) can advantageously be performed in a shorter time than previous methods. In some embodiments, the entire adoptive cell therapy procedure can be performed in less than 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 15 hours, 18 hours, or 24 hours. In illustrative embodiments, the entire adoptive cell therapy procedure can be performed in less than 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours. In some embodiments, the entire adoptive cell therapy procedure may be performed between 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, or 15 hours at the low end of the range and 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 15 hours, 18 hours, or 24 hours at the high end of the range.
[0160] In some embodiments herein, a closed system is used to process PBMCs, for example, in methods comprising genetically modifying PBMCs, NK cells, and in illustrative embodiments, T cells, for example, by transducing PBMCs or a subset thereof. These methods can be used to genetically modify lymphocytes to be used in scientific research, commercial production, or therapeutic methods. For example, these methods can include transferring peripheral blood mononuclear cells (PBMCs) (including NK cells, T cells, or both, and in some embodiments, resting T cells and / or resting NK cells) from a container to a transduction reaction mixture within a closed system, which therefore does not require environmental exposure. The container can be, for example, a tube, bag, syringe, or other container. In some embodiments, the container is a container for a research facility. In some embodiments, the container is a container for commercial production. In other embodiments, the container can be a collection container for an overnight blood collection process. The methods herein for genetically modifying generally involve a contact step in which lymphocytes are contacted with replication-deficient recombinant retroviral particles. In some embodiments, the contact can be performed in a container (e.g., in a blood bag). In other embodiments, PBMCs or a sub-portion thereof can be transferred from a container to another container within a closed system (e.g., from a first container to a second container) for contacting. The second container can be a cell processing compartment of a closed device (such as a G-Rex device). In some embodiments, after contacting, the genetically modified (e.g., transduced) cells can be transferred to a different container within a closed system (i.e., without exposure to the environment). Before or after such transfer, the cells are typically washed within the closed system to substantially remove In some embodiments, the process disclosed in this paragraph is performed within 12 hours after contacting by transferring the PBMCs or a portion thereof to a container where contacting (e.g., transduction) occurs via washing the cells. In some embodiments, this is performed between 1 hour, 2 hours, 3 hours, or 4 hours at the low end of the range and 4 hours, 8 hours, 10 hours, or 12 hours at the high end of the range.
[0161] In some embodiments provided herein, the steps of extracting a blood sample from an individual, contacting T cells and / or NK cells with replication-deficient recombinant retroviral particles, and / or introducing genetically modified T cells and / or NK cells into an individual occur in a closed system. A closed system is a culture method that is generally closed or completely closed to contamination. Therefore, this system or process does not expose cells to the environment. One advantage of the present invention is that a method for performing CAR therapy in a closed system is provided herein. One of the highest risks for safety and regulation in cell processing procedures is the risk of contamination through frequent exposure to the environment, as found in traditional open cell culture systems. In order to mitigate this risk, especially in the absence of antibiotics, some commercial methods dedicated to the use of disposable (single-use) equipment have been developed. However, even when used under sterile conditions, there is always a risk of contamination when opening a flask to sample or add additional growth medium. To overcome this problem, a closed system method is provided herein, a method that is designed and can be operated so that the product is not exposed to the external environment. This is important because the external environment is generally not sterile. Material transfer is performed via sterile connections or welded tubes. The air used for gas exchange is passed through a breathable membrane or similar other additives through a 0.2 μm filter to prevent environmental exposure.
[0162] In some embodiments, the closed system comprises an ex vivo circulatory system connected to the individual's in vivo circulatory system such that blood is withdrawn and then circulated to the ex vivo circulatory system before being introduced back into the individual. In some embodiments, the ex vivo circulatory system comprises a system or device for isolating PBLs and / or a system or device for isolating T cells and / or NK cells in combination with a system or device for exposing cells to replication-defective recombinant retroviral particles. In some embodiments, the closed system does not allow T cells and / or NK cells to be exposed to air.
[0163] Such closed system methods can be performed using commercially available devices. For example, the method can be performed in devices suitable for closed system T cell production. Such devices include G-Rex TM 、WAVE Bioreactor TM 、OriGenPermaLife TM Bags and bag.
[0164] In some embodiments of the methods and compositions disclosed herein, genetically modified T cells and / or NK cells in an individual are exposed to a compound that binds to an in vivo control component present therein, wherein the control component is a portion of the genetic material introduced by a replication-defective recombinant retroviral particle. In some embodiments, the control component may be a riboswitch, and the compound may bind to the aptamer domain of the riboswitch. In some embodiments, the control component may be a molecular chaperone. A molecular chaperone is a compound that directly affects the activity of other components of the lymphoproliferative component or the first or second engineered signaling polypeptide herein, typically by binding. In any of the embodiments disclosed herein, the compound may be a nucleoside analog. In some embodiments, the nucleoside analog may be a nucleoside analog antiviral drug, wherein the antiviral drug is a compound approved by the Food and Drug Administration for antiviral therapy or a compound in a U.S. antiviral clinical trial. In illustrative embodiments, the compound may be acyclovir or penciclovir. In some embodiments, the compound may be famciclovir (an oral prodrug of penciclovir) or valaciclovir (an oral prodrug of acyclovir). The combination of the compound and the control component affects the expression of the introduced genetic material and, therefore, the propagation of the genetically modified T cells and / or NK cells.
[0165] In some embodiments, a nucleoside analog antiviral drug or prodrug (e.g., acyclovir, valacyclovir, penciclovir, or famciclovir) is administered to the subject before, simultaneously with, and / or after isolating PBLs from the subject's blood and before contacting the T cells and / or NK cells with the replication-defective recombinant retroviral particles. In some embodiments, a nucleoside analog antiviral drug or prodrug is administered to the subject between 5 minutes, 10 minutes, 15 minutes, 30 minutes, and 60 minutes at the low end of the range and 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours, or 24 hours at the high end of the range before isolating PBLs from the blood or before contacting the T cells and / or NK cells with the replication-defective recombinant retroviral particles. In other embodiments, the nucleoside analog antiviral drug or prodrug is administered to the subject between 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours, or 24 hours at the low end of the range and 1 / 2 day, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 14 days, 21 days, or 28 days at the high end of the range after PBLs are isolated from the blood and after the T cells and / or NK cells are contacted with the replication-defective recombinant retroviral particles in the methods provided herein. In some embodiments, the nucleoside analog antiviral drug or prodrug is administered to the subject at least 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours, or 24 hours, or at least 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 14 days, 21 days, or 28 days after PBLs are isolated from the blood and after the T cells and / or NK cells are contacted with the replication-defective recombinant retroviral particles in the methods provided herein. In some embodiments, a nucleoside analog antiviral drug or prodrug is administered to the subject at least 1 day, 2 days, 3 days, 4 days, 5 days, 7 days, 10 days, 14 days, 21 days, 28 days, 30 days, 60 days, 90 days, or 120 days, or 5 months, 6 months, 9 months, 12 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 120 months, or indefinitely after PBLs have been reinfused into the subject. In any of the embodiments disclosed herein, a nucleoside analog antiviral drug or prodrug can be administered before and / or during and / or after PBLs have been reinfused.
[0166] In some embodiments, the compound bound to the control component is administered to the subject once, twice, three times, or four times daily. In some embodiments, the compound is provided at daily doses for 1 week, 2 weeks, 4 weeks, 3 months, 6 months, 1 year, until the subject is disease-free (such as cancer-free) or indefinitely. In illustrative embodiments, the drug is a nucleoside analog antiviral drug bound to a nucleoside analog, such as a riboswitch, as further disclosed in WO2017 / 165245A2, WO2018 / 009923A1, and WO2018 / 161064A1.
[0167] Methods for delivering drugs are known in the art, whether small molecules or biologics and can be used in the methods provided herein. Any such method can be used to deliver drugs or candidate compounds or antibodies for use in the methods of the present invention. For example, conventional routes of administration include non-invasive oral (via mouth), topical (skin), transmucosal (nose, cheek / sublingual, vaginal, eye and rectal) and inhalation routes. Many protein and peptide drugs (such as monoclonal antibodies) must be delivered by injection or nanoneedle arrays. For example, many immunizations are based on the delivery of protein drugs and are typically performed by injection.
[0168] Engineered signaling peptides
[0169] In some embodiments, the replication-deficient recombinant retroviral particles for contacting T cells and / or NK cells have a polynucleotide having one or more transcription units encoding one or more engineered signaling polypeptides. In some embodiments, the engineered signaling polypeptide includes any combination of an extracellular domain (e.g., an antigen-specific targeting region or ASTR), a handle, and a transmembrane domain, in combination with one or more intracellular activation domains, one or more regulatory domains (such as costimulatory domains) and one or more T cell survival primitives selected as appropriate. In illustrative embodiments, at least one, both, or all of the engineered signaling polypeptides are chimeric antigen receptors (CARs) or lymphoproliferative components (LEs) (such as chimeric lymphoproliferative components (CLEs)). In some embodiments, when two signaling polypeptides are utilized, one encodes a lymphoproliferative component and the other encodes a chimeric antigen receptor (CAR) comprising an antigen-specific targeting region (ASTR), a transmembrane domain, and an intracellular activation domain. One skilled in the art will be able to configure the system to place the lymphoproliferative element and CAR on different polynucleotides using similar or dissimilar control elements for the methods and compositions disclosed herein. One skilled in the art will recognize that engineered polypeptides may also be referred to as recombinant polypeptides.
[0170] Extracellular domain
[0171] In some embodiments, the engineered signaling polypeptide includes an extracellular domain that is a member of a specific binding pair. For example, in some embodiments, the extracellular domain may be an extracellular domain of a cytokine receptor or a mutant thereof or a hormone receptor or a mutant thereof. This mutant extracellular domain has been reported in some embodiments to be constitutively active when expressed in at least some cell types. In illustrative embodiments, this extracellular domain and transmembrane domain do not include a ligand binding region. It is believed that these domains do not bind to ligands when present in an engineered signaling polypeptide and expressed in B cells, T cells, and / or NK cells. Mutations in these receptor mutants may occur in the extracellular juxtamembrane region. Without being limited by theory, mutations in at least some extracellular domains (and some extracellular-transmembrane domains) of the engineered signaling polypeptides provided herein are responsible for signal transduction of the engineered signaling polypeptide in the absence of a ligand by bringing together activation chains that are not normally together. Additional embodiments of extracellular domains comprising mutations in the extracellular domain can be found, for example, in the lymphoproliferative component section herein.
[0172] In certain illustrative embodiments, the extracellular domain comprises a dimerization motif. In one illustrative embodiment, the dimerization motif comprises a leucine zipper. In some embodiments, the leucine zipper is from a Jun polypeptide, such as c-Jun. Additional examples of extracellular domains comprising a dimerization motif can be found, for example, in the Lymphoproliferative Module section herein.
[0173] In certain embodiments, the extracellular domain is an antigen-specific targeting region (ASTR), sometimes referred to herein as an antigen-binding domain. Specific binding pairs include, but are not limited to, antigen-antibody binding pairs; ligand-receptor binding pairs; and the like. Thus, members of specific binding pairs suitable for use in the engineered signaling polypeptides of the present invention include ASTRs that are antibodies, antigens, ligands, receptor-binding domains of ligands, receptors, ligand-binding domains of receptors, and affibodies.
[0174] ASTRs suitable for use in the engineered signaling polypeptides of the present invention can be any antigen-binding polypeptide. In certain embodiments, the ASTRs are antibodies, such as full-length antibodies, single-chain antibodies, Fab fragments, Fab' fragments, (Fab')2 fragments, Fv fragments, and bivalent single-chain antibodies or bifunctional antibodies.
[0175] In some embodiments, the ASTR is a single-chain Fv (scFv). In some embodiments, the heavy chain is located N-terminally to the light chain in the engineered signaling polypeptide. In other embodiments, the light chain is located N-terminally to the heavy chain in the engineered signaling polypeptide. In any of the disclosed embodiments, the heavy and light chains can be separated by a linker, as discussed in more detail herein. In any of the disclosed embodiments, the heavy or light chain can be N-terminal to the engineered signaling polypeptide and typically C-terminal to another domain, such as a signal sequence or signal peptide.
[0176] Other antibody-based recognition domains (cAb VHH (camelid antibody variable domain) and humanized versions, IgNAR VH (shark antibody variable domain) and humanized versions, sdAb VH (single domain antibody variable domain) and "camelized" antibody variable domain) are suitable for use with engineered signaling polypeptides and are suitable for use in the methods of using the engineered signaling polypeptides of the present invention. In some cases, T cell (TCR)-based recognition domains, such as single-chain TCRs (scTv, a single-chain two-domain TCR containing VαVβ), are also suitable for use.
[0177] In some embodiments, ASTRs may be multispecific, such as bispecific antibodies. Multispecific antibodies possess binding specificities for at least two different sites. In certain embodiments, one of the binding specificities is for one target antigen and the other is for a different target antigen. In certain embodiments, bispecific antibodies can bind to two different antigenic determinants of a target antigen. Bispecific antibodies can also be used to localize cytotoxic agents to cells expressing the target antigen. Bispecific antibodies can be prepared as full-length antibodies or antibody fragments.
[0178] ASTRs suitable for use in the engineered signaling polypeptides of the present invention may have a variety of antigen binding specificities. In some cases, the antigen binding domain is specific for an antigenic determinant present in an antigen expressed (synthesized) by a target cell. In one example, the target cell is an antigen associated with a cancer cell. Cancer cell-associated antigens may be antigens associated with, for example, breast cancer cells, B-cell lymphomas, Hodgkin's lymphoma cells, ovarian cancer cells, prostate cancer cells, mesothelioma cells, lung cancer cells (e.g., small cell lung cancer cells), non-Hodgkin's B-cell lymphoma (B-NHL) cells, ovarian cancer cells, prostate cancer cells, mesothelioma cells, lung cancer cells (e.g., small cell lung cancer cells), melanoma cells, chronic lymphocytic leukemia cells, acute lymphocytic leukemia cells, neuroblastoma cells, gliomas, glioblastomas, medulloblastomas, colon cancer cells, and the like. Cancer cell-associated antigens may also be expressed by non-cancerous cells.
[0179] Non-limiting examples of antigens to which the ASTRs of engineered signaling polypeptides can bind include, e.g., CD19, CD20, CD38, CD30, ERBB2, CA125, MUC-1, prostate-specific membrane antigen (PSMA), CD44 surface adhesion molecule, mesothelin, carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), EGFRvIII, vascular endothelial growth factor receptor-2 (VEGFR2), high molecular weight melanoma-associated antigen (HMW-MAA), MAGE-A1, IL-13R-a2, GD2, Axl, Ror2, and the like.
[0180] In some cases, the member of the specific binding pair suitable for use in engineered signaling polypeptides is an ASTR that is a ligand for a receptor. Ligands include, but are not limited to, hormones (e.g., erythropoietin, growth hormone, leptin, etc.); cytokines (e.g., interferons, interleukins, certain hormones, etc.); growth factors (e.g., regulatory proteins; vascular endothelial growth factor (VEGF); and the like); integrin binding peptides (e.g., peptides comprising the sequence Arg-Gly-Asp); and the like.
[0181] When the member of the specific binding pair in the engineered signaling polypeptide is a ligand, the engineered signaling polypeptide can be activated in the presence of a second member of the specific binding pair, wherein the second member of the specific binding pair is a receptor for the ligand. For example, when the ligand is VEGF, the second member of the specific binding pair can be a VEGF receptor, including a soluble VEGF receptor.
[0182] As mentioned above, in some cases, the member of the specific binding pair included in the engineered signaling polypeptide is an ASTR, which is a receptor, such as a receptor for a ligand, a co-receptor, etc. The receptor can be a ligand-binding fragment of a receptor. Suitable receptors include, but are not limited to, growth factor receptors (e.g., VEGF receptor); killer cell lectin-like receptor subfamily K; member 1 (NKG2D) polypeptide (receptor for MICA, MICB, and ULB6); cytokine receptors (e.g., IL-13 receptor; IL-2 receptor, etc.); CD27; natural cytotoxicity receptors (NCRs) (e.g., NKP30 (NCR3 / CD337) polypeptide (receptor for HLA-B associated transcript 3 (BAT3) and B7-H6), etc.), etc.
[0183] In certain embodiments of any of the aspects provided herein that include an ASTR, the ASTR can be located as an intermediate protein that connects the ASTR to a targeting molecule expressed on a target cell. The intermediate protein can be endogenously expressed or exogenously introduced and can be naturally occurring, engineered, or chemically modified. In certain embodiments, the ASTR can be an anti-labeled ASTR, such that at least one labeled intermediate (typically an anti-labeled conjugate) is included between a label recognized by the ASTR and a targeting molecule (typically a protein target expressed on a target cell). Thus, in these embodiments, the ASTR binds to a label and the label is conjugated to an antibody directed against an antigen on a target cell (such as a cancer cell). Non-limiting examples of labels include fluorescein isothiocyanate (FITC), streptavidin, biotin, histidine, dinitrophenol, peridinin chlorophyll protein complex, green fluorescent protein, phycoerythrin (PE), horseradish peroxidase, palmitoylation, nitrosylation, alkaline phosphatase, glucose oxidase, and maltose binding protein. Thus, the ASTR includes molecules that bind to a label.
[0184] handle
[0185] In some embodiments, the engineered signaling polypeptide includes a stalk located in the portion of the engineered signaling polypeptide that is located outside the cell and is inserted between the ASTR and the transmembrane domain. In some cases, the stalk is at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the wild-type CD8 stalk region (TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGG AVHTRGLDFA (SEQ ID NO: 79)), at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the wild-type CD28 stalk region (FCKIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP (SEQ ID NO: 80)), or at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a wild-type immunoglobulin heavy chain stalk region. In engineered signaling polypeptides, the handle employed allows the antigen-specific targeting region, and often the entire engineered signaling polypeptide, to retain increased binding to the target antigen.
[0186] The stalk region can be about 4 to about 50 amino acids in length, e.g., about 4 amino acids to about 10 amino acids, about 10 amino acids to about 15 amino acids, about 15 amino acids to about 20 amino acids, about 20 amino acids to about 25 amino acids, about 25 amino acids to about 30 amino acids, about 30 amino acids to about 40 amino acids, or about 40 amino acids to about 50 amino acids.
[0187] In some cases, the handle of the engineered signaling polypeptide includes at least one cysteine. For example, in some cases, the handle can include the sequence Cys-Pro-Pro-Cys (SEQ ID NO: 62). If present, the cysteine in the handle of the first engineered signaling polypeptide can be capable of forming a disulfide bond with the handle in the second engineered signaling polypeptide.
[0188] The handle may include an immunoglobulin hinge region amino acid sequence known in the art; see, eg, Tan et al. (1990) Proc. Natl. Acad. Sci. USA 87:162; and Huck et al. (1986) Nucl. Acids Res. 14:1779. As non-limiting examples, an immunoglobulin hinge region can include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a stretch of at least 10, 15, 20 or all amino acids of any of the following amino acid sequences: DKTHT (SEQ ID NO:63); CPPC (SEQ ID NO:62); CPEPKSCDTPPPCPR (SEQ ID NO:64); (see, e.g., Glaser et al. (2005) J. Biol. Chem. 280:41494); ELKTPLGDTTHT (SEQ ID NO:65); KSCDKTHTCP (SEQ ID NO:66); KCCVDCP (SEQ ID NO:67); KYGPPCP (SEQ ID NO:68); EPKSCDKTHTCPPCP (SEQ ID NO:69); NO: 69) (human IgG1 hinge); ERKCCVECPPCP (SEQ ID NO: 70) (human IgG2 hinge); ELKTPLGDTTHTCPRCP (SEQ ID NO: 71) (human IgG3 hinge); SPNMVPHAHHAQ (SEQ ID NO: 72) (human IgG4 hinge); and the like. The handle may comprise a hinge region having the amino acid sequence of a human IgG1, IgG2, IgG3, or IgG4 hinge region. The handle may comprise one or more amino acid substitutions and / or insertions and / or deletions compared to a wild-type (naturally occurring) hinge region. For example, His229 of the human IgG1 hinge may be substituted with Tyr such that the handle comprises the sequence EPKSCDKTYTCPPCP (see, e.g., Yan et al. (2012) J. Biol. Chem. 287: 5891). The handle may comprise an amino acid sequence derived from human CD8; for example, the handle may comprise the amino acid sequence:
[0189] TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD (SEQ ID NO: 73), or a variant thereof.
[0190] transmembrane domain
[0191] The engineered signaling polypeptides of the present invention may include a transmembrane domain for insertion into a eukaryotic cell membrane. The transmembrane domain may be inserted between the ASTR and the costimulatory domain. The transmembrane domain may be inserted between the stalk and the costimulatory domain, such that the chimeric antigen receptor comprises, from the amino terminus (N-terminus) to the carboxyl terminus (C-terminus), the ASTR, the stalk, the transmembrane domain, and the activation domain.
[0192] Any transmembrane (TM) domain that provides for insertion of a polypeptide into the cell membrane of a eukaryotic (eg, mammalian) cell is suitable for use with the aspects and embodiments disclosed herein. Non-limiting examples of TM domains suitable for use in any of the aspects or embodiments provided herein include domains having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a stretch of at least 10, 15, 20 or all amino acids of any of the following TM domains, or combined handle and TM domains: a) CD8α TM (SEQ ID NO: 46); b) CD8β TM (SEQ ID NO: 47); c) CD4 handle (SEQ ID NO: 48); d) CD3Z TM (SEQ ID NO: 49); e) CD28 TM (SEQ ID NO: 50); f) CD134 (OX40) TM (SEQ ID NO: 51); g) CD7 TM (SEQ ID NO: 52); h) CD8 handle and TM (SEQ ID NO: 53). NO:75); and i) CD28 stalk and TM (SEQ ID NO:76).
[0193] As non-limiting examples, the transmembrane domain of one aspect of the invention may have at least 80%, 90% or 95% or may have 100% sequence identity with the transmembrane domain of SEQ ID NO: 46, or may have 100% sequence identity with any one of the transmembrane domains from the following genes: CD8β transmembrane domain, CD4 transmembrane domain, CD3ζ transmembrane domain, CD28 transmembrane domain, CD134 transmembrane domain, or CD7 transmembrane domain, respectively.
[0194] intracellular activation domain
[0195] The intracellular activation domains in the engineered signaling polypeptides suitable for use in the present invention typically induce the production of one or more cytokines upon activation; increase cell death; and / or increase CD8 + T cells, CD4 +The proliferation of T cells, NKT cells, γδT cells and / or neutrophils. The activation domain may also be referred to herein as the activation domain. The activation domain can be used in the CAR provided herein or in the lymphoproliferative component lymphoproliferative component.
[0196] In some embodiments, the intracellular activation domain comprises at least one (e.g., one, two, three, four, five, six, etc.) ITAM motif as described below. In some embodiments, the intracellular activation domain may have at least 80%, 90%, or 95%, or may have 100% sequence identity to a CD3Z, CD3D, CD3E, CD3G, CD79A, CD79B, DAP12, FCER1G, FCGR2A, FCGR2C, DAP10 / CD28, or ZAP70 domain as described below.
[0197] The intracellular activation domains suitable for use in the engineered signaling polypeptides of the present invention include intracellular signaling polypeptides containing an immunotyrosine-based activation motif (ITAM). The ITAM motif is YX1X2L / I, wherein X1 and X2 are independently any amino acids. In some cases, the intracellular activation domain of the engineered signaling polypeptide comprises 1, 2, 3, 4 or 5 ITAM motifs. In some cases, the ITAM motif is repeated twice in the intracellular activation domain, wherein the first and second instances of the ITAM motif are separated by 6 to 8 amino acids (e.g., (YX1X2L / I)(X3)n(YX1X2L / I), wherein n is an integer from 6 to 8, and each of the 6 to 8 X3 can be any amino acid). In some cases, the intracellular activation domain of the engineered signaling polypeptide comprises 3 ITAM motifs.
[0198] A suitable intracellular activation domain may be a portion containing an ITAM motif that is derived from a polypeptide containing an ITAM motif. For example, a suitable intracellular activation domain may be a domain containing an ITAM motif from any protein containing an ITAM motif. Therefore, a suitable intracellular activation domain does not need to contain the entire sequence of the entire protein from which it is derived. Examples of suitable polypeptides containing ITAM motifs include, but are not limited to: CD3Z (CD3ζ); CD3D (CD3δ); CD3E (CD3ε); CD3G (CD3γ); CD79A (antigen receptor complex-associated protein α chain); CD79B (antigen receptor complex-associated protein β chain); DAP12; and FCER1G (Fcε receptor I γ chain).
[0199] In some embodiments, the intracellular activation domain is derived from the T cell surface glycoprotein CD3 zeta chain (also known as CD3Z, T cell receptor T3 zeta chain, CD247, CD3-zeta, CD3H, CD3Q, T3Z, TCRZ, etc.). For example, suitable intracellular activation domains can include domains having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the following sequences, or to a continuous stretch of about 100 amino acids to about 110 amino acids (aa), about 110 aa to about 115 aa, about 115 aa to about 120 aa, about 120 aa to about 130 aa, about 130 aa to about 140 aa, about 140 aa to about 150 aa, or about 150 aa to about 160 aa of any of the following amino acid sequences (2 isoforms):
[0200] MKWKALFTAAILQAQLPITEAQSFGLLDPKLCYLLDGILFIYGVILTALFLRVKFSRSADAPAYQQGQNQL[YNELNLGRREEYDVL]DKRRGRDPEMGGKPRRKNPQEGL[YNELQKDKMA EAYSEI]GMKGERRRGKGHDGL[YQGLSTATKDTYDAL]HMQALPPR(SEQ ID NO:11) or MKWKALFTAAILQAQLPITEAQSFGLLDPKLCYLLDGILFIYGVILTALFLRVKFSRSADAPA YQQGQNQL[YNELNLGRREEYDVL]DKRRGRDPEMGGKPQRRKNPQEGL[YNELQKDKM AEAYSEI]GMKGERRRGKGHDGL[YQGLSTATKDTYDAL]HMQALPPR(SEQ ID NO:12), wherein the ITAM elements are enclosed in brackets.
[0201] Likewise, suitable intracellular activation domain polypeptides may include portions of the full-length CD3 zeta amino acid sequence that contain ITAM motifs. Thus, suitable intracellular activation domains may include a stretch of at least 10, 15, 20, or all of the amino acids in the following sequences, or a continuous stretch of about 100 amino acids to about 110 amino acids (aa), about 110 aa to about 115 aa, about 115 aa to about 120 aa, about 120 aa to about 130 aa, about 130 aa to about 140 aa, about 140 aa to about 150 aa, or about 150 aa to about 160 aa of any of the following amino acid sequences having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity:
[0202] RVKFSRSADAPAYQQGQNQL[YNELNLGRREEYDVL]DKRRGRDPEMGGKPRRKNPQEGL[YNELQKDKMAEAYSEI]GMKGERRRGKGHDGL[YQGLSTATKDTYDAL]HMQALPPR(SEQ ID NO:13); RVKFSRSADAPAYQQGQNQL[YNELNLGRREEYDVL]DKRRGRDPEMGGKPQRRKNPQEGL[YNELQKDKMAEAYSEI]GMKGERRRGKGHDGL[YQGLSTATKDTYDAL]HMQALPPR(SEQ ID NO:81); NQL[YNELNLGRREEYDVL]DKR(SEQ ID NO:14);EGL[YNELQKDKMAEAYSEI]GMK(SEQ ID NO: 15); or DGL[YQGLSTATKDTYDAL]HMQ (SEQ ID NO: 16), wherein the ITAM motif is enclosed in brackets.
[0203] In some cases, the intracellular activation domain is derived from the T cell surface glycoprotein CD3 delta chain (also known as CD3D, CD3-delta, T3D, CD3 antigen, delta subunit, CD3delta, CD3d antigen, delta polypeptide (TiT3 complex), OKT3, delta chain, T cell receptor T3 delta chain, T cell surface glycoprotein CD3 delta chain, etc.). Thus, suitable intracellular activation domains can include domains having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the following sequences, or to a continuous stretch of about 100 amino acids to about 110 amino acids (aa), about 110 aa to about 115 aa, about 115 aa to about 120 aa, about 120 aa to about 130 aa, about 130 aa to about 140 aa, about 140 aa to about 150 aa, or about 150 aa to about 160 aa of any of the following amino acid sequences:
[0204] or
[0205] MEHSTFLSGLVLATLLSQVSPFKIPIEELEDRVFVNCNTSITWVEGTVGTLLSDITRLDLGKRILDPRGIYRCNGTDIYKDKESTVQVHYRTADTQALLRNDQV[YQPLRDRDDAQYSHL]GGNWARNK (SEQ ID NO: 18), wherein the ITAM motif is enclosed in brackets.
[0206] Likewise, suitable intracellular activation domain polypeptides may comprise a portion of the full-length CD3δ amino acid sequence that contains an ITAM motif. Thus, suitable intracellular activation domains may include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all amino acids of the following sequence: DQV[YQPLRDRDDAQYSHL]GGN (SEQ ID NO: 19), wherein the ITAM motif is enclosed in brackets.
[0207] In some cases, the intracellular activation domain is derived from the T cell surface glycoprotein CD3ε chain (also known as CD3e, T cell surface antigen T3 / Leu-4ε chain, T cell surface glycoprotein CD3ε chain, AI504783, CD3, CD3ε, T3e, etc.). Thus, suitable intracellular activation domains can include domains having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the following sequence, or to a continuous stretch of about 100 amino acids to about 110 amino acids (aa), about 110 aa to about 115 aa, about 115 aa to about 120 aa, about 120 aa to about 130 aa, about 130 aa to about 140 aa, about 140 aa to about 150 aa, or about 150 aa to about 160 aa of the following amino acid sequence:
[0208] MQSGTHWRVLGLCLLSVGVWGQDGNEEMGGITQTPYKVSISGTTVILTCPQYPGSEILWQH
[0209] NDKNIGGDEDDKNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRARVCENC
[0210] MEMDMSVATIVIVDICITGGLLLLVYYWSKNRKAKAKPVTRGAGAGGRQRGQNKERPPPVPNPD[YEPIRKGQRDLYSGL]NQRRI (SEQ ID NO: 20), wherein the ITAM motif is enclosed in brackets.
[0211] Likewise, suitable intracellular activation domain polypeptides may comprise portions of the full-length CD3ε amino acid sequence that contain ITAM motifs. Thus, suitable intracellular activation domains may include domains having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a stretch of at least 10, 15, 20 or all amino acids of the following sequence: NPD[YEPIRKGQRDLYSGL ] NQR (SEQ ID NO: 21), wherein the ITAM motif is enclosed in brackets.
[0212] In some cases, the intracellular activation domain is derived from the T cell surface glycoprotein CD3 gamma chain (also known as CD3G, T cell receptor T3 gamma chain, CD3-γ, T3G, gamma polypeptide (TiT3 complex), etc.). Thus, a suitable intracellular activation domain may include a stretch of at least 10, 15, 20, or all of the amino acids in the following sequence, or a continuous stretch of about 100 amino acids to about 110 amino acids (aa), about 110 aa to about 115 aa, about 115 aa to about 120 aa, about 120 aa to about 130 aa, about 130 aa to about 140 aa, about 140 aa to about 150 aa, or about 150 aa to about 160 aa of the following amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity:
[0213] MEQGKGLAVLILAIILLQGTLAQSIKGNHLVKVYDYQEDGSVLLTCDAEAKNITWFKDGKMIGFLTEDKKKWNLGSNAKDPRGMYQCKGSQNKSKPLQVYYRMCQNCIELNAATISGFLFAEIVSIFVLAVGVYFIAGQDGVRQSRASDKQTLLPNDQL[YQPLKDREDDQYSHL]QGNQLRRN (SEQ ID NO: 22), wherein the ITAM motif is enclosed in brackets.
[0214] Likewise, suitable intracellular activation domain polypeptides may comprise portions of the full-length CD3γ amino acid sequence that contain ITAM motifs. Thus, suitable intracellular activation domains may include domains having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a stretch of at least 10, 15, 20 or all amino acids of the following sequence: DQL[YQPLKDREDDQYSHL ] QGN (SEQ ID NO: 23), wherein the ITAM motif is enclosed in brackets.
[0215] In some cases, the intracellular activation domain is derived from CD79A (also known as B-cell antigen receptor complex-associated protein alpha chain; CD79a antigen (immunoglobulin-related alpha); MB-1 membrane glycoprotein; Ig-alpha; membrane-bound immunoglobulin-related protein; surface IgM-related protein, etc.). Thus, suitable intracellular activation domains can include domains having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the following sequences, or to a continuous stretch of about 100 amino acids to about 110 amino acids (aa), about 110 aa to about 115 aa, about 115 aa to about 120 aa, about 120 aa to about 130 aa, about 130 aa to about 140 aa, about 140 aa to about 150 aa, or about 150 aa to about 160 aa of any of the following amino acid sequences:
[0216] MPGGPGVLQALPATIFLLFLLSAVYLGPGCQALWMHKVPASLMMVSLGEDAHFQCPHNSSNN
[0217] ANVTWWRVLHGNYTWPPEFLGPGEDPNGTLIIQNVNKSHGGIYVCRVQEGNESYQQSCGT
[0218] YLRVRQPPPRPFLMGEGTKNRIITAEGIILLFCAVVPGTLLLFRKRWQNEKLGLDAGDEYEDENL[YEGLNLDDCSMYEDI]SRGLQGTYQDVGSLNIGDVQLEKP(SEQ ID NO:24) or MPGGPGVLQALPATIFLLFLLSAVYLGPGCQALWMHKVPASLMMVSLGEDAHFQCPHNSSNN ANVTWWRVLHGNYTWPPEFLGPGEDPNEPPPRPFLDMGEGTKNRIITAEGIILLFCAVVPGT LLLFRKRWQNEKLGLDAGDEYEDENL[YEGLNLDDCSMYEDI]SRGLQGTYQDVGSLNIGD VQLEKP (SEQ ID NO:25), where the ITAM primitive is enclosed in parentheses.
[0219] Similarly, suitable intracellular activation domain polypeptides may comprise a portion of the full-length CD79A amino acid sequence that contains an ITAM motif. Thus, suitable intracellular activation domains may include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a stretch of at least 10, 15, 20 or all amino acids in the following sequence: ENL[YEGLNLDDCSMYEDI]SRG (SEQ ID NO: 26), wherein the ITAM motif is enclosed in brackets.
[0220] In some cases, the intracellular activation domain is derived from DAP12 (also known as TYROBP; TYRO protein tyrosine kinase-binding protein; KARAP; PLOSL; DNAX-activating protein 12; KAR-associated protein; TYRO protein tyrosine kinase-binding protein; killer-activated receptor-associated protein; killer-activated receptor-associated protein, etc.). For example, a suitable intracellular activation domain can include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the following sequence, or to a continuous stretch of about 100 amino acids to about 110 amino acids (aa), about 110 aa to about 115 aa, about 115 aa to about 120 aa, about 120 aa to about 130 aa, about 130 aa to about 140 aa, about 140 aa to about 150 aa, or about 150 aa to about 160 aa of any of the following amino acid sequences (4 isoforms): MGGLEPCSRLLLLPLLLAVSGLRPVQAQAQSDCSCSTVSPGVLAGIVMGDLVLTVLIALAVY FLGRLVPRGRGAAEAATRKQRITETESP[YQELQGQRSDVYSDL]NTQRPYYK(SEQ ID NO:27),MGGLEPCSRLLLLPLLLAVSGLRPVQAQAQSDCSCSTVSPGVLAGIVMGDLVLTVLIALAVY FLGRLVPRGRGAAEATRKQRITETESP[YQELQGQRSDVYSDL]NTQ(SEQ ID NO:28), MGGLEPCSRLLLLPLLLAVSDCSCSTVSPGVLAGIVMGDLVLTVLIALAVYFLGRLVPRGRG AAEAATRKQRITETESP[YQELQGQRSDVYSDL]NTQRPYYK(SEQ ID NO:29) or MGGLEPCSRLLLLPLLLAVSDCSCSTVSPGVLAGIVMGDLVLTVLIALAVYFLGRLVPRGRG AAEATRKQRITETESP[YQELQGQRSDVYSDL]NTQRPYYK (SEQ ID NO: 30), wherein the ITAM motif is enclosed in brackets.
[0221] Likewise, suitable intracellular activation domain polypeptides may comprise portions of the full-length DAP12 amino acid sequence that contain ITAM motifs. Thus, suitable intracellular activation domains may include domains having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the amino acids in the following sequence: ESP[YQELQGQRSDVYSDL ] NTQ (SEQ ID NO: 31), wherein the ITAM motif is enclosed in brackets.
[0222] In some cases, the intracellular activation domain is derived from FCER1G (also known as FCRG; Fcε receptor I gamma chain; Fc receptor gamma chain; fc-εRI-γ; fcRγ; fceRIγ; high affinity immunoglobulin epsilon receptor subunit gamma; immunoglobulin E receptor, high affinity gamma chain, etc.). For example, a suitable intracellular activation domain can include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the following sequence, or to a contiguous stretch of about 50 amino acids to about 60 amino acids (aa), about 60 aa to about 70 aa, about 70 aa to about 80 aa, or about 80 aa to about 88 aa of the following amino acid sequence: MIPAVVLLLLLLVEQAAALGEPQLCYILDAILFLYGIVLTLLYCRLKIQVRKAAITSYEKSDG V[YTGLSTRNQETYETL]KHEKPPQ (SEQ ID NO: 32), wherein the ITAM motif is enclosed in brackets.
[0223] Likewise, suitable intracellular activation domain polypeptides may comprise portions of the full-length FCER1G amino acid sequence that contain ITAM motifs. Thus, suitable intracellular activation domains may include domains having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the amino acids in the following sequence: DGV[YTGLSTRNQETYETL ] KHE (SEQ ID NO: 33), wherein the ITAM motif is enclosed in brackets.
[0224] Intracellular activation domains suitable for use in engineered signaling polypeptides of the present invention include DAP10 / CD28-type signaling chains. An example of a DAP10 signaling chain is the amino acid sequence of SEQ ID NO: 34. In some embodiments, suitable intracellular activation domains may include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the amino acids in SEQ ID NO: 34.
[0225] An example of a CD28 signaling chain is amino acid SEQ ID NO: 35. In some embodiments, a suitable intracellular activation domain may include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the amino acids in SEQ ID NO: 35.
[0226] Intracellular activation domains suitable for use in engineered signaling polypeptides of the present invention include ZAP70 polypeptides. For example, suitable intracellular activation domains may include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the amino acids in SEQ ID NO: 36, or to a continuous stretch of about 300 amino acids to about 400 amino acids, about 400 amino acids to about 500 amino acids, or about 500 amino acids to about 619 amino acids of the following amino acid sequence.
[0227] Regulatory domain
[0228] The regulatory domain can change the effect of the intracellular activation domain in the engineered signal transduction polypeptide, including enhancing or inhibiting the downstream effects of the activation domain or changing the nature of the reaction. The regulatory domain suitable for the engineered signal transduction polypeptide of the present invention includes a costimulatory domain. The length of the regulatory domain suitable for the inclusion body in the engineered signal transduction polypeptide can be about 30 amino acids to about 70 amino acids (aa), for example, the length of the regulatory domain can be about 30aa to about 35aa, about 35aa to about 40aa, about 40aa to about 45aa, about 45aa to about 50aa, about 50aa to about 55aa, about 55aa to about 60aa, about 60aa to about 65aa or about 65aa to about 70aa. In other cases, the length of the regulatory domain can be about 70aa to about 100aa, about 100aa to about 200aa, or greater than 200aa.
[0229] Costimulatory domains generally enhance and / or change the properties of the response of the activation domain. Costimulatory domains suitable for use in the engineered signaling polypeptides of the present invention are generally polypeptides derived from receptors. In some embodiments, costimulatory domains are homodimerized. Individual costimulatory domains may be the intracellular portion of a transmembrane protein (i.e., the costimulatory domain may be derived from a transmembrane protein). Non-limiting examples of suitable costimulatory polypeptides include, but are not limited to, 4-1BB (CD137), CD27, CD28, CD28 for Lck binding (ICΔ) deletion, ICOS, OX40, BTLA, CD27, CD30, GITR, and HVEM. For example, the costimulatory domains of the aspects of the present invention may have at least 80%, 90%, or 95% sequence identity with the costimulatory domains of 4-1BB (CD137), CD27, CD28, CD28 for Lck binding (ICΔ) deletion, ICOS, OX40, BTLA, CD27, CD30, GITR, or HVEM. For example, the costimulatory domains of aspects of the present invention can have at least 80%, 90%, or 95% sequence identity with the costimulatory domains of non-limiting examples of suitable costimulatory polypeptides, including but not limited to 4-1BB (CD137), CD27, CD28, CD28 deleted for Lck binding (ICΔ), ICOS, OX40, BTLA, CD27, CD30, GITR, and HVEM. For example, the costimulatory domains of aspects of the present invention can have at least 80%, 90%, or 95% sequence identity with the costimulatory domains of 4-1BB (CD137), CD27, CD28, CD28 deleted for Lck binding (ICΔ), ICOS, OX40, BTLA, CD27, CD30, GITR, or HVEM.
[0230] The length of the costimulatory domain suitable for inclusion in the engineered signaling polypeptide can be from about 30 amino acids to about 70 amino acids (aa), for example, the length of the costimulatory domain can be from about 30 aa to about 35 aa, from about 35 aa to about 40 aa, from about 40 aa to about 45 aa, from about 45 aa to about 50 aa, from about 50 aa to about 55 aa, from about 55 aa to about 60 aa, from about 60 aa to about 65 aa, or from about 65 aa to about 70 aa. In other cases, the length of the costimulatory domain can be from about 70 aa to about 100 aa, from about 100 aa to about 200 aa, or greater than 200 aa.
[0231] In some cases, the costimulatory domain is derived from the intracellular portion of the transmembrane protein CD137 (also known as TNFRSF9; CD137; 4-1BB; CDwl37; ILA, etc.). For example, a suitable costimulatory domain may include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the amino acids in SEQ ID NO: 1. In some of these embodiments, the length of the costimulatory domain is about 30 aa to about 35 aa, about 35 aa to about 40 aa, about 40 aa to about 45 aa, about 45 aa to about 50 aa, about 50 aa to about 55 aa, about 55 aa to about 60 aa, about 60 aa to about 65 aa, or about 65 aa to about 70 aa.
[0232] In some cases, the costimulatory domain is derived from the intracellular portion of the transmembrane protein CD28 (also known as Tp44). For example, a suitable costimulatory domain may include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the amino acids in SEQ ID NO: 2. In some of these embodiments, the costimulatory domain is about 30 aa to about 35 aa, about 35 aa to about 40 aa, about 40 aa to about 45 aa, about 45 aa to about 50 aa, about 50 aa to about 55 aa, about 55 aa to about 60 aa, about 60 aa to about 65 aa, or about 65 aa to about 70 aa in length.
[0233] In some cases, the costimulatory domain is derived from the intracellular portion of the transmembrane protein CD28 deleted for Lck binding (ICΔ). For example, a suitable costimulatory domain may include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a stretch of at least 10, 15, 20 or all amino acids in SEQ ID NO: 3. In some of these embodiments, the length of the costimulatory domain is about 30aa to about 35aa, about 35aa to about 40aa, about 40aa to about 45aa, about 45aa to about 50aa, about 50aa to about 55aa, about 55aa to about 60aa, about 60aa to about 65aa or about 65aa to about 70aa.
[0234] In some cases, the costimulatory domain is derived from the intracellular portion of the transmembrane protein ICOS (also known as AILIM, CD278, and CVID1). For example, a suitable costimulatory domain may include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the amino acids in SEQ ID NO: 4. In some of these embodiments, the costimulatory domain is about 30 aa to about 35 aa, about 35 aa to about 40 aa, about 40 aa to about 45 aa, about 45 aa to about 50 aa, about 50 aa to about 55 aa, about 55 aa to about 60 aa, about 60 aa to about 65 aa, or about 65 aa to about 70 aa in length.
[0235] In some cases, the costimulatory domain is derived from the intracellular portion of the transmembrane protein OX40 (also known as TNFRSF4, RP5-902P8.3, ACT35, CD134, OX-40, TXGP1L). OX40 contains a p85 PI3K binding motif at each residue 34 to 57 of SEQ ID NO: 504 and a TRAF binding motif at residues 76 to 102. In some embodiments, the costimulatory domain may include the p85 PI3K binding motif of OX40. In some embodiments, the costimulatory domain may include the TRAF binding motif of OX40. The lysines corresponding to amino acids 17 and 41 of SEQ ID NO: 504 are potential negative regulatory sites that act as part of the ubiquitin targeting motif. In some embodiments, one or both of these lysines in the costimulatory domain of OX40 are mutated arginine or another amino acid. In some embodiments, suitable costimulatory domains may include domains having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the amino acids in SEQ ID NO: 5. In some of these embodiments, the costimulatory domain is about 20 aa to about 25 aa, about 25 aa to about 30 aa, 30 aa to about 35 aa, about 35 aa to about 40 aa, about 40 aa to about 45 aa, or about 45 aa to about 50 aa in length. In illustrative embodiments, the costimulatory domain is 20 aa to about 50 aa in length, e.g., 20 aa to 45 aa or 20 aa to 42 aa.
[0236] In some cases, the costimulatory domain is derived from the intracellular portion of the transmembrane protein CD27 (also known as S152, T14, TNFRSF7, and Tp55). For example, a suitable costimulatory domain may include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the amino acids in SEQ ID NO: 6. In some of these embodiments, the costimulatory domain is about 30 aa to about 35 aa, about 35 aa to about 40 aa, about 40 aa to about 45 aa, or about 45 aa to about 50 aa in length.
[0237] In some cases, the costimulatory domain is derived from the intracellular portion of the transmembrane protein BTLA (also known as BTLA1 and CD272). For example, a suitable costimulatory domain may include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all of amino acids in SEQ ID NO: 7.
[0238] In some cases, the costimulatory domain is derived from the intracellular portion of the transmembrane protein CD30 (also known as TNFRSF8, D1S166E, and Ki-1). For example, a suitable costimulatory domain can include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of about 100 amino acids to about 110 amino acids (aa), about 110 aa to about 115 aa, about 115 aa to about 120 aa, about 120 aa to about 130 aa, about 130 aa to about 140 aa, about 140 aa to about 150 aa, about 150 aa to about 160 aa, or about 160 aa to about 185 aa of SEQ ID NO: 8.
[0239] In some cases, the costimulatory domain is derived from the intracellular portion of the transmembrane protein GITR (also known as TNFRSF18, RP5-902P8.2, AITR, CD357, and GITR-D). For example, a suitable costimulatory domain may include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the amino acids in SEQ ID NO: 9. In some of these embodiments, the costimulatory domain is about 30 aa to about 35 aa, about 35 aa to about 40 aa, about 40 aa to about 45 aa, about 45 aa to about 50 aa, about 50 aa to about 55 aa, about 55 aa to about 60 aa, about 60 aa to about 65 aa, or about 65 aa to about 70 aa in length.
[0240] In some cases, the costimulatory domain is derived from the intracellular portion of the transmembrane protein HVEM (also known as TNFRSF14, RP3-395M20.6, ATAR, CD270, HVEA, HVEM, LIGHTR, and TR2). For example, a suitable costimulatory domain may include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all of amino acids in SEQ ID NO: 10. In some of these embodiments, the costimulatory domains of the first and second polypeptides are about 30 aa to about 35 aa, about 35 aa to about 40 aa, about 40 aa to about 45 aa, about 45 aa to about 50 aa, about 50 aa to about 55 aa, about 55 aa to about 60 aa, about 60 aa to about 65 aa, or about 65 aa to about 70 aa in length.
[0241] Connectors
[0242] In some cases, the engineered signaling polypeptide includes a linker between any two adjacent domains. For example, a linker can be between a transmembrane domain and a first stimulatory domain. As another example, the ASTR can be an antibody, and the linker can be between the heavy chain and the light chain. As another example, a linker can be between the ASTR and the transmembrane domain and the costimulatory domain. As another example, a linker can be between the costimulatory domain and the intracellular activation domain of a second polypeptide. As another example, a linker can be between the ASTR and the intracellular signaling domain.
[0243] The connector peptide can have any of a variety of amino acid sequences. Proteins can be connected by spacer peptides that are generally flexible, but other chemical bonds are not excluded. The connector can be a peptide with a length between about 1 and about 100 amino acids, or a length between about 1 and about 25 amino acids. These connectors can be produced by coupling the protein using synthetic oligonucleotides encoding the connector. Peptide connectors with a certain degree of flexibility can be used. The connecting peptide can actually have any amino acid sequence, considering that a suitable connector will have a sequence that produces a generally flexible peptide. The use of smaller amino acids (such as glycine and alanine) is for creating flexible peptides. The creation of such sequences is conventional for those familiar with the technology.
[0244] Suitable linkers can be readily selected and can be any of a variety of suitable lengths, such as 1 amino acid (e.g., Gly) to 20 amino acids, 2 amino acids to 15 amino acids, 3 amino acids to 12 amino acids, including 4 amino acids to 10 amino acids, 5 amino acids to 9 amino acids, 6 amino acids to 8 amino acids, or 7 amino acids to 8 amino acids, and can be 1, 2, 3, 4, 5, 6, or 7 amino acids.
[0245] Exemplary flexible linkers include glycine polymers (G)n, glycine-serine polymers (including, for example, (GS)n, GSGGS n 、GGGS n and GGGGS n, where n is an integer of at least one), glycine-alanine polymers, alanine-serine polymers, and other flexible linkers known in the art. Glycine and glycine-serine polymers are of interest because both of these amino acids are relatively unstructured and can therefore serve as neutral links between components. Glycine polymers are particularly interesting because glycine has significantly more phi-psi space than even alanine and is less constrained than residues with longer side chains (see Scheraga, Rev. Computational Chem. 11173-142 (1992)). Exemplary flexible linkers include, but are not limited to, GGGGSGGGGSGGGGS (SEQ ID NO: 53), GGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 54), GGGGSGGGSGGGGS (SEQ ID NO: 55), GGSG (SEQ ID NO: 56), GGSGG (SEQ ID NO: 57), GSGSG (SEQ ID NO: 58), GSGGG (SEQ ID NO: 59), GGGSG (SEQ ID NO: 60), GSSSG (SEQ ID NO: 61), and the like. One of ordinary skill in the art will recognize that the design of peptide conjugation to any of the components described above can include linkers that are fully or partially flexible, such that a linker can include a flexible linker and one or more portions that confer a less flexible structure.
[0246] combination
[0247] In some embodiments, the polynucleotide provided by the replication-deficient recombinant retroviral particle has one or more transcription units encoding certain combinations of one or more engineered signaling polypeptides. In some methods and compositions provided herein, after transcription of the T cells by the replication-deficient recombinant retroviral particle, the genetically modified T cells include a combination of one or more engineered signaling polypeptides. It will be understood that reference to a first polypeptide, a second polypeptide, a third polypeptide, etc. is for convenience, and that references to components on a "first polypeptide" and those on a "second polypeptide" mean that the components are on different polypeptides, and that the polypeptides are referred to as first or second for reference and convenience only, typically in relation to other components or steps in a specific polypeptide.
[0248] In some embodiments, the first engineered signaling polypeptide comprises an extracellular antigen binding domain capable of binding an antigen, and an intracellular signaling domain. In other embodiments, the first engineered signaling polypeptide also comprises a T cell survival motif and / or a transmembrane domain. In some embodiments, the first engineered signaling polypeptide does not comprise a costimulatory domain, while in other embodiments, the first engineered signaling polypeptide does comprise a costimulatory domain.
[0249] In some embodiments, the second engineered signaling polypeptide comprises a lymphoproliferative gene product and an optional extracellular antigen binding domain. In some embodiments, the second engineered signaling polypeptide also comprises one or more of the following: a T cell survival motif, an intracellular signaling domain, and one or more costimulatory domains. In other embodiments, when two engineered signaling polypeptides are used, at least one is a CAR.
[0250] In one embodiment, one or more engineered signaling polypeptides are expressed under a T cell-specific promoter or a general promoter in the same transcript, wherein the nucleic acid encoding the engineered signaling polypeptide is separated in the transcript by nucleic acid encoding one or more internal ribosome entry sites (IREs) or one or more protease cleavage peptides.
[0251] In certain embodiments, the polynucleotide encodes two engineered signaling polypeptides, wherein the first engineered signaling polypeptide comprises a first extracellular antigen binding domain capable of binding to a first antigen and a first intracellular signaling domain other than a co-stimulatory domain, and the second engineered signaling polypeptide comprises a second extracellular antigen binding domain capable of binding to VEGF and a second intracellular signaling domain, such as the signaling domain of a co-stimulatory molecule. In certain embodiments, the first antigen is PSCA, PSMA, or BCMA. In certain embodiments, the first extracellular antigen binding domain comprises an antibody or fragment thereof (e.g., scFv), such as an antibody or fragment thereof specific for PSCA, PSMA, or BCMA. In certain embodiments, the second extracellular antigen binding domain that binds to VEGF is a receptor for VEGF, i.e., VEGFR. In certain embodiments, VEGFR is VEGFR1, VEGFR2, or VEGFR3. In certain embodiments, VEGFR is VEGFR2.
[0252] In certain embodiments, the polynucleotide encodes two engineered signaling polypeptides, wherein the first engineered signaling polypeptide comprises an extracellular tumor antigen binding domain and a CD3 zeta signaling domain, and the second engineered signaling polypeptide comprises an antigen binding domain (wherein the antigen is an angiogenic or angiogenic factor), and one or more costimulatory molecule signaling domains. The angiogenic factor may be, for example, VEGF. The one or more costimulatory molecule signaling motifs may comprise, for example, a costimulatory signaling domain from each of CD27, CD28, OX40, ICOS, and 4-1BB.
[0253] In certain embodiments, the polynucleotide encodes two engineered signaling polypeptides, wherein the first engineered signaling polypeptide comprises an extracellular tumor antigen binding domain and a CD3ζ signaling domain, and the second polypeptide comprises an antigen binding domain capable of binding to an antigen binding domain of VEGF and a co-stimulatory signaling domain from each of CD27, CD28, OX40, ICOS, and 4-1BB. In another embodiment, the first signaling polypeptide or the second signaling polypeptide also comprises a T cell survival motif. In some embodiments, the T cell survival motif is the intracellular signaling domain of the IL-7 receptor (IL-7R), the intracellular signaling domain of the IL-12 receptor, the intracellular signaling domain of the IL-15 receptor, the intracellular signaling domain of the IL-21 receptor, or the intracellular signaling domain of the transforming growth factor β (TGFβ) receptor or the TGFβ decoy receptor (TGF-β—dominant-negative receptor II (DNRII)), or is derived therefrom.
[0254] In certain embodiments, the polynucleotide encodes two engineered signaling polypeptides, wherein the first engineered signaling polypeptide comprises an extracellular tumor antigen binding domain and a CD3 zeta signaling domain, and the second engineered signaling polypeptide comprises an antigen binding domain capable of binding VEGF, an IL-7 receptor intracellular T cell survival motif, and a costimulatory signaling domain from each of CD27, CD28, OX40, ICOS, and 4-1BB.
[0255] In some embodiments, more than two signaling polypeptides are encoded by a polynucleotide. In certain embodiments, only one of the engineered signaling polypeptides comprises an antigen binding domain that binds to a tumor-associated antigen or a tumor-specific antigen; each of the remaining engineered signaling polypeptides comprises an antigen binding domain that binds to a non-tumor-associated antigen or a non-tumor-specific antigen. In other embodiments, two or more of the engineered signaling polypeptides comprise an antigen binding domain that binds to one or more tumor-associated antigens or tumor-specific antigens, wherein at least one of the engineered signaling polypeptides comprises an antigen binding domain that does not bind to a tumor-associated antigen or a tumor-specific antigen.
[0256] In some embodiments, the tumor-associated antigen or tumor-specific antigen is Her2, prostate stem cell antigen (PSCA), PSMA (prostate-specific membrane antigen), B cell maturation antigen (BCMA) alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen-125 (CA-125), CA19-9, calretinin, MUC-1, epithelial membrane protein (EMA), epithelial tumor antigen (ETA), tyrosinase, melanoma-associated antigen (MAGE), CD34, CD45, CD99, CD117, chromogranin, cytokeratin, desmin, glial fibrillary acidic protein (GFAP), large cystic disease fluid protein (GCDFP-15), HMB-45 antigen, protein Melanin A (melanoma antigen recognized by T lymphocytes; MART-1), myosin-D1, muscle-specific actin (MSA), neuropil, neuron-specific enolase (NSE), placental alkaline phosphatase, synaptophysin, thyroglobulin, thyroid transcription factor-1, pyruvate kinase isoenzyme M2 (tumor M2-PK), CD19, CD22, CD27, CD30, CD70, GD2 (ganglioside G2), EphA2, CSPG4, CD138, FAP (fibroblast activation protein), CD171, kappa integrin, lambda integrin, 5T4 integrin, αvβ6 integrin, integrin αvβ3 (CD61), prolactin K-Ras (V-Ki-ras2) Kirsten rat sarcoma viral oncogene), Ral-B, B7-H3, B7-H6, CAIX, CD20, CD33, CD44, CD44v6, CD44v7 / 8, CD123, EGFR, EGP2, EGP40, EpCAM, embryonic AchR, FRα, GD3, HLA-A1+MAGE1, HLA-A1+NY-ESO-1, IL-11Rα, IL-13Rα2, Lewis-Y, Mu c16, NCAM, NKG2D ligand, NY-ESO-1, PRAME, ROR1, survivin, TAG72, TEMs, VEGFR2, EGFRvIII (epidermal growth factor variant III, sperm protein 17 (Sp17), mesothelin, PAP (prostatic acid phosphatase), prostate protein, TARP (T cell receptor gamma alternative reading frame protein), Trp-p8, STEAP1 (six transmembrane epithelial antigen of the prostate 1), abnormal mouse protein or abnormal p53 protein.
[0257] In some embodiments, the first engineered signaling polypeptide comprises a first extracellular antigen binding domain that binds to a first antigen, and a first intracellular signaling domain; and the second engineered signaling polypeptide comprises a second extracellular antigen binding domain that binds to a second antigen or a receptor that binds to a second antigen, and a second intracellular signaling domain, wherein the second engineered signaling polypeptide does not comprise a co-stimulatory domain. In a certain embodiment, the first antigen binding domain and the second antigen binding domain are independently an antigen binding portion of a receptor or an antigen binding portion of an antibody. In a certain embodiment, the second antigen binding domain or one or both of the second antigen binding domains are scFv antibody fragments. In certain embodiments, the first engineered signaling polypeptide and / or the second engineered signaling polypeptide additionally comprise a transmembrane domain. In a certain embodiment, the first engineered signaling polypeptide or the second engineered signaling polypeptide comprises a T cell survival motif, such as any of the T cell survival motifs described herein.
[0258] In another embodiment, the first engineered signaling polypeptide comprises a first extracellular antigen binding domain that binds HER2, and the second engineered signaling polypeptide comprises a second extracellular antigen binding domain that binds MUC-1.
[0259] In another embodiment, the second extracellular antigen binding domain of the second engineered signaling polypeptide binds interleukin.
[0260] In another embodiment, the second extracellular antigen binding domain of the second engineered signaling polypeptide binds to a damage-associated molecular pattern molecule (DAMP; also known as an alarmin). In another embodiment, the DAMP is a heat shock protein, a chromatin-associated protein high mobility group box 1 (HMGB1), S100A8 (also known as MRP8 or calgranulin A), S100A9 (also known as MRP14 or calgranulin B), serum amyloid A (SAA), deoxyribonucleic acid, adenosine triphosphate, uric acid, or heparin sulfate.
[0261] In certain embodiments, the second antigen is an antigen on an antibody that binds to an antigen presented by a tumor cell.
[0262] In some embodiments, the signal transduction activation via the second engineered signaling polypeptide is non-antigenic but is associated with hypoxia. In certain embodiments, hypoxia is induced by activation of hypoxia-inducible factor-1α (HIF-1α), HIF-1β, HIF-2α, HIF-2β, HIF-3α, or HIF-3β.
[0263] In some embodiments, expression of one or more engineered signaling polypeptides is regulated by control elements disclosed in more detail herein.
[0264] Additional Sequence
[0265] Engineered signaling polypeptides (such as CARs) may further include one or more additional polypeptide domains, wherein such domains include, but are not limited to, signal sequences, antigenic determinant tags, affinity domains, and polypeptides whose presence or activity can be detected, for example, by antibody assays or because they are polypeptides that produce detectable signals (detectable markers). Non-limiting examples of additional domains for any of the aspects or embodiments provided herein include domains having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of the following sequences as described below: signal sequences, antigenic determinant tags, affinity domains, or polypeptides that produce detectable signals.
[0266] Suitable signal sequences for use in an individual CAR (e.g., the first polypeptide of an individual CAR) include any eukaryotic signal sequence, including naturally occurring signal sequences, synthetic (e.g., artificial) signal sequences, etc. In some embodiments, for example, the signal sequence can be the CD8 signal sequence MALPVTALLLPLALLLHAARP (SEQ ID NO: 74).
[0267] Suitable epitope tags include, but are not limited to, hemagglutinin (HA; e.g., YPYDVPDYA; SEQ ID NO: 37), FLAG (e.g., DYKDDDDK; SEQ ID NO: 38), c-myc (e.g., EQKLISEEDL; SEQ ID NO: 39), and the like.
[0268] Affinity domains include peptide sequences suitable for identification or purification that can interact with a binding partner (e.g., one immobilized on a solid support). DNA sequences encoding multiple consecutive single amino acids (e.g., histidine) when fused to the expressed protein can be used for one-step purification of recombinant proteins by high-affinity binding to resin columns (such as agarose gel). Exemplary affinity domains include His5 (HHHHH; SEQ ID NO:40), HisX6 (HHHHHH; SEQ ID NO:41), c-myc (EQKLISEEDL; SEQ ID NO:39), Flag (DYKDDDDK; SEQ ID NO:38), Strep tag (WSHPQFEK; SEQ ID NO:42), hemagglutinin (e.g., HA tag (YPYDVPDYA; SEQ ID NO:37)), GST, thioredoxin, cellulose binding domain, RYIRS (SEQ ID NO:43), Phe-His-His-Thr (SEQ ID NO:44), chitin binding domain, S peptide, T7 peptide, SH2 domain, C-terminal RNA tag, WEAAAREACCRECCARA (SEQ ID NO:45), SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65 ID NO: 45), a metal binding domain, e.g., a zinc binding domain or a calcium binding domain, such as those from calcium binding proteins, e.g., calmodulin, troponin C, calcineurin B, myosin light chain, recoverin, S-regulin, cone opsin, VILIP, calcineurin, hippocampal calcium binding protein, agrin, caltractin, calpain large subunit, S100 protein, parvalbumin, calbindin D9K, calbindin D28K and calretinin, intein, biotin, streptavidin, MyoD, Id, leucine zipper sequence, and maltose binding protein.
[0269] Suitable detectable signal-generating proteins include, for example, fluorescent proteins, enzymes that catalyze a reaction that produces a detectable signal as a product, and the like.
[0270] Suitable fluorescent proteins include, but are not limited to, green fluorescent protein (GFP) or variants thereof, a blue fluorescent variant of GFP (BFP), a cyan fluorescent variant of GFP (CFP), a yellow fluorescent variant of GFP (YFP), enhanced GFP (EGFP), enhanced CFP (ECFP), enhanced YFP (EYFP), GFPS65T, Emerald, Topaz (TYFP), Venus, Citrine, mCitrine, GFPuv, destabilized EGFP (dEGFP), destabilized ECFP (dECFP), destabilized EYFP (dEYFP), mCFPm, Cerulean, T-Sapphire, CyPet, Ypet, mKO, HcRed, t-HcRed, DsRed, DsRed2, DsRed-monomer, J-Red, Dimer 2, t-Dimer 2 (12), mRFP1, coral, Renilla GFP, Monster GFP, paGFP, Kaede protein and kindling protein, phycobiliproteins and phycobiliprotein conjugates, including B-phycoerythrin, R-phycoerythrin and allophycocyanin. Other examples of fluorescent proteins include mHoneydew, mBanana, mOrange, dTomato, tdTomato, mTangerine, mStrawberry, mCherry, mGrapel, mRaspberry, mGrape2, mPlum (Shaner et al. (2005) Nat. Methods 2:905-909), and the like. Any of a variety of fluorescent and colored proteins from Anthozoan species are suitable for use, as described, for example, in Matz et al. (1999) Nature Biotechnol. 17:969-973.
[0271] Suitable enzymes include, but are not limited to, horseradish peroxidase (HRP), alkaline phosphatase (AP), β-galactosidase (GAL), glucose-6-phosphate dehydrogenase, β-N-acetamido glucosidase, β-glucuronidase, invertase, xanthine oxidase, firefly luciferase, glucose oxidase (GO), and the like.
[0272] Identify domains and / or eliminate domains
[0273] Any of the replication-deficient recombinant retroviral particles provided herein may include a nucleic acid encoding a recognition domain or an elimination domain, which is part of or separated from a nucleic acid encoding any of the engineered signaling polypeptides provided herein. Therefore, any of the engineered signaling polypeptides provided herein may include a recognition domain or an elimination domain. For example, any of the CARs disclosed herein may include a recognition domain or an elimination domain. In addition, the recognition domain or the elimination domain may be expressed together with any of the lymphoproliferative components disclosed herein, or even fused therewith. The recognition domain or the elimination domain is expressed on T cells and / or NK cells, but not on replication-deficient recombinant retroviral particles.
[0274] In some embodiments, the recognition domain or elimination domain may be derived from the herpes simplex virus-derived enzyme thymidine kinase (HSV-tk) or inducible caspase 9. In some embodiments, the recognition domain or elimination domain may include a modified endogenous cell surface molecule, such as disclosed in U.S. Patent No. 8,802,374. The modified endogenous cell surface molecule may be any cell surface-associated receptor, ligand, glycoprotein, cell adhesion molecule, antigen, integrin, or modified cluster of differentiation (CD). In some embodiments, the modified endogenous cell surface molecule is a truncated tyrosine kinase receptor. In one aspect, the truncated tyrosine kinase receptor is a member of the epidermal growth factor receptor (EGFR) family, such as ErbB1, ErbB2, ErbB3, or ErbB4. In some embodiments, the recognition domain may be a polypeptide recognized by an antibody that recognizes the extracellular domain of an EGFR member. In some embodiments, the recognition domain may be at least 20 consecutive amino acids of an EGFR family member, or, for example, between 20 and 50 consecutive amino acids of an EGFR family member. For example, SEQ ID NO: 78 is an exemplary polypeptide that is bound by an antibody that recognizes the extracellular domain of an EGFR member and is recognized under appropriate conditions. Such extracellular EGFR antigenic determinants are sometimes referred to herein as eTags. In illustrative embodiments, such antigenic determinants are recognized by commercially available anti-EGFR monoclonal antibodies.
[0275] The epidermal growth factor receptor, also known as EGFR, ErbB1, and HER1, is a cell surface receptor for a member of the epidermal growth factor family of extracellular ligands. Alterations in EGFR activity have been implicated in certain cancers. In some embodiments, a gene encoding an EGFR polypeptide comprising the human epidermal growth factor receptor (EGFR) is constructed by removing a nucleic acid sequence encoding a polypeptide comprising a membrane-remote EGF binding domain and a cytoplasmic signaling tail, but retaining an extracellular membrane-proximal antigenic determinant recognized by an anti-EGFR antibody. Preferably, the antibody is a known commercially available anti-EGFR monoclonal antibody, such as cetuximab, matuzumab, necitumumab, or panitumumab.
[0276] Others have shown that biotinylated cetuximab combined with anti-biotin microbeads was used for immunomagnetic selection to successfully enrich T cells that had been lentivirally transduced with a construct containing EGFRt from as low as 2% of the population to a purity greater than 90% without observable toxicity to the cell preparation. In addition, others have shown that constitutive expression of this inert EGFR molecule did not affect T cell phenotype or effector function such as that directed by the coordinately expressed chimeric antigen receptor (CAR), CD19R. In addition, others have shown that EGFR was successfully used as an in vivo tracking marker for T cell transplantation in mice via flow cytometry analysis. In addition, it has been shown that The antibody-dependent cellular cytotoxicity (ADCC) pathway mediated by EGFR demonstrates its potential as a suicide gene. The inventors of the present invention have successfully expressed eTag in PBMC using a lentiviral vector and have found that PBMC exposed to cetuximab express eTag in vitro, providing an effective mechanism for the elimination of PBMC. Therefore, EGFR can be used as a non-immune gene selection tool, tracking marker, and suicide gene for transduced T cells with immunotherapeutic potential. EGFR nucleic acid can also be detected by methods well known in the art.
[0277] In some embodiments provided herein, EGFR is expressed as part of a single polypeptide also including CAR or as part of a single polypeptide including a lymphoproliferative component lymphoproliferative component. In some embodiments, the amino acids encoding the EGFR recognition domain can be separated from the amino acids encoding the chimeric antigen receptor by a cleavage signal and / or a ribosome skipping sequence. The ribosome skipping and / or cleavage signal can be any ribosome skipping and / or cleavage signal known in the art. Without being limited by theory, the ribosome skipping sequence can be, for example, T2A (also known as 2A-1) having the amino acid sequence GSGEGRGSLLTCGDVEENPGP (SEQ ID NO: 77). Without being limited by theory, other examples of cleavage signals and ribosome skipping sequences include FMDV 2A (F2A), equine rhinovirus A 2A (abbreviated as E2A), porcine teschovirus 12A (P2A), and thoseaasigna virus 2A (T2A). In some embodiments, the polynucleotide sequence encoding the recognition domain can be on the same transcript as the CAR or lymphoproliferative component, but separated from the polynucleotide sequence encoding the CAR or lymphoproliferative component by an internal ribosome entry site.
[0278] In other embodiments, as exemplified herein, the recognition domain can be expressed as part of a fusion polypeptide fused to a lymphoproliferative component. Such constructs offer the advantage of taking up less genomic space on the RNA genome compared to individual polypeptides, particularly in combination with other "space-saving" components provided herein. In one illustrative embodiment, the eTag is expressed as a fusion polypeptide fused to an IL7Rα mutant, as experimentally demonstrated herein.
[0279] Chimeric antigen receptor
[0280] In some aspects of the present invention, the engineered signaling polypeptide is a chimeric antigen receptor (CAR) or a polynucleotide encoding a CAR, which for simplicity is referred to herein as "CAR". The CAR of the present invention includes: a) at least one antigen-specific targeting region (ASTR); b) a transmembrane domain; and c) an intracellular activation domain. In illustrative embodiments, the antigen-specific targeting region of the CAR is the scFv portion of an antibody directed against a target antigen. In illustrative embodiments, the intracellular activation domain is from CD3Z, CD3D, CD3E, CD3G, CD79A, CD79B, DAP12, FCER1G, FCGR2A, FCGR2C, DAP10 / CD28 or ZAP70, and in some other illustrative embodiments, from CD3z. In illustrative embodiments, CAR further includes a costimulatory domain, such as any one of the costimulatory domains provided above in the regulatory domain chapters and sections, and in other illustrative embodiments, the costimulatory domain is the intracellular costimulatory domain of 4-1BB (CD137), CD28, ICOS, OX-40, BTLA, CD27, CD30, GITR and HVEM. In certain embodiments, CAR includes any one of the transmembrane domains listed above in the transmembrane domain chapters and sections.
[0281] The CAR of the present invention may be present in the plasma membrane of a eukaryotic cell (e.g., a mammalian cell), wherein suitable mammalian cells include, but are not limited to, cytotoxic cells, T lymphocytes, stem cells, progeny of stem cells, progenitor cells, progeny of progenitor cells, and NK cells, NK-T cells, and macrophages. When present in the plasma membrane of a eukaryotic cell, the CAR of the present invention is activated in the presence of one or more target antigens (under certain conditions, bound to an ASTR). The target antigen is the second member of the specific binding pair. The target antigen of the specific binding pair may be a soluble (e.g., not bound to a cell) factor; a factor present on the surface of a cell such as a target cell; a factor present on the surface of an entity; a factor present on a lipid bilayer; and the like. When the ASTR is an antibody and the second member of the specific binding pair is an antigen, the antigen may be a soluble (e.g., not bound to a cell) antigen; an antigen present on the surface of a cell such as a target cell; an antigen present on the surface of an entity; an antigen present on a lipid bilayer; and the like.
[0282] In some cases, the CAR of the present invention increases the expression of at least one nucleic acid in the cell when present in the plasma membrane of a eukaryotic cell and activated by one or more target antigens. For example, in some cases, the CAR of the present invention increases the expression of at least one nucleic acid in the cell by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 75%, at least about 2 times, at least about 2.5 times, at least about 5 times, at least about 10 times, or more than 10 times when present in the plasma membrane of a eukaryotic cell and activated by one or more target antigens, compared to the transcription level of the nucleic acid in the absence of one or more target antigens.
[0283] As an example, a CAR of the present invention may include an intracellular signaling polypeptide containing an immunoreceptor tyrosine-based activation motif (ITAM).
[0284] In some cases, the CAR of the present invention, when present in the plasma membrane of a eukaryotic cell and activated by one or more target antigens, can increase the production of one or more cytokines by the cell. For example, when the CAR of the present invention is present in the plasma membrane of a eukaryotic cell and activated by one or more target antigens, the cell can produce an increase in cytokines by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 75%, at least about 2 times, at least about 2.5 times, at least about 5 times, at least about 10 times, or more than 10 times. Cytokines whose production can be increased include, but are not limited to, interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-a), IL-2, IL-15, IL-12, IL-4, IL-5, IL-10; chemokines; growth factors; and the like.
[0285] In some cases, the CARs of the present invention, when present in the plasma membrane of a eukaryotic cell and activated by one or more target antigens, can result in both increased transcription of nucleic acids in the cell and increased production of cytokines by the cell.
[0286] In some cases, the CAR of the present invention, when present in the plasma membrane of a eukaryotic cell and activated by one or more target antigens, produces a cytotoxic activity of the cell toward the target cell, the target cell expressing an antigen on its cell surface, the antigen binding domain of the first polypeptide of the CAR. For example, when the eukaryotic cell is a cytotoxic cell (e.g., NK cell or cytotoxic T lymphocyte), the CAR of the present invention, when present in the plasma membrane of a eukaryotic cell and activated by one or more target antigens, increases the cytotoxic activity of the cell toward the target cell, the target cell expressing one or more target antigens on its cell surface. For example, when the eukaryotic cell is a NK cell or a T lymphocyte, the CAR of the present invention, when present in the plasma membrane of the eukaryotic cell and activated by one or more target antigens, increases the cytotoxic activity of the cell by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 75%, at least about 2-fold, at least about 2.5-fold, at least about 5-fold, at least about 10-fold, or more than 10-fold compared to the cytotoxic activity of the cell in the absence of the one or more target antigens.
[0287] In some cases, the CARs of the present invention, when present in the plasma membrane of a eukaryotic cell and activated by one or more target antigens, can produce events associated with other CAR activation, such as proliferation and expansion (due to enhanced cell division or anti-apoptotic responses).
[0288] In some cases, the CARs of the present invention, when present in the plasma membrane of a eukaryotic cell and activated by one or more target antigens, can produce other CAR activation-related events, such as intracellular signaling regulation, cell differentiation, or cell death.
[0289] In some cases, the CARs of the present invention are microenvironmentally restricted. This property is generally a result of the microenvironmentally restricted nature of the ASTR domain of the CAR. Thus, the CARs of the present invention may have lower binding affinity or, in illustrative embodiments, may have higher binding affinity for one or more target antigens under conditions of the microenvironment than under conditions of the normal physiological environment.
[0290] Lymphoproliferative component Lymphoproliferative component
[0291] Despite the continuous increase in cells, the number of peripheral T lymphocytes remains at a very stable level throughout adulthood, due to the proliferation of cells removed from the thymus and in response to antigen encounters, and due to the loss of cells that remove antigen-specific effects after antigen clearance (Marrak, P. et al. 2000. Nat Immunol 1: 107-111; Freitas, AA et al. 2000. Annu Rev Immunol 18: 83-111). The size of the peripheral T cell compartment is regulated by multiple factors that affect both proliferation and survival. However, in the context of lymphopenia, T lymphocytes divide independently of cognate antigens due to the "acute constant proliferation" mechanism that maintains the size of the peripheral T cell compartment. The conditions of lymphopenia have been established in individuals or patients during adoptive cell therapy by in vivo proliferation of T cells and their introduction into individuals with lympho-depletion, resulting in enhanced implantation and anti-tumor function of transferred T cells. However, lymphodepletion of an individual is undesirable because it can cause serious side effects, including immune disorders and death.
[0292] Studies have shown that lymphodepletion removes endogenous lymphocytes that serve as reservoirs for stabilizing cytokines, thereby releasing cytokines to induce survival and proliferation of adoptively transferred cells. Some cytokines, such as IL-7 and IL-15, are known to mediate antigen-independent proliferation of T cells and are therefore able to induce stable proliferation in a non-lymphopenic environment. However, these cytokines and their receptors have inherent control mechanisms that prevent lymphoproliferative diseases in the steady state.
[0293] Many aspects provided herein include lymphoproliferative elements, or nucleic acids encoding them, typically as part of engineered signaling polypeptides. Thus, in some aspects of the present invention, the engineered signaling polypeptide is a lymphoproliferative element (LE), such as a chimeric lymphoproliferative element (CLE). Typically, a LE comprises an extracellular domain, a transmembrane domain, and at least one intracellular signaling domain that drives proliferation, and in illustrative embodiments, comprises a second intracellular signaling domain. As illustrated herein (see, e.g., Examples 11 and 12), wherein there are first and second intracellular signaling domains of a CLE, the first intracellular signaling domain is positioned between a membrane-associated motif and a second intracellular domain. In illustrative embodiments, the intracellular domain of LE or the first intracellular domain having two or more intracellular domains in LE is not a functional intracellular activation domain from an ITAM intracellular domain, such as an intracellular domain from CD3Z, CD3D, CD3E, CD3G, CD79A, CD79B, DAP12, FCER1G, FCGR2A, FCGR2C, DAP10 / CD28 or ZAP70, and in other illustrative sub-embodiments, the intracellular domain of CD3z. In illustrative embodiments, the second intracellular domain of LE is not a costimulatory domain of 4-1BB (CD137), CD28, ICOS, OX-40, BTLA, CD27, CD30, GITR and HVEM. In illustrative embodiments, the extracellular domain of LE does not include a single-chain variable fragment (scFv). In other illustrative embodiments, the extracellular domain of LE that activates LE when bound to a binding partner does not include a single-chain variable fragment (scFv).
[0294] CLE does not comprise both an ASTR and an activation domain from: CD3ζ, CD3D, CD3E, CD3G, CD79A, CD79B, DAP12, FCER1G, FCGR2A, FCGR2C, DAP10 / CD28, or ZAP70. Without being limited by theory, it is believed that the extracellular and transmembrane domains play a supporting role in the LE, ensuring that the intracellular signaling domain is in an effective conformation / orientation / positioning for driving proliferation. Thus, it is believed that the ability of the LE to drive proliferation is provided by the intracellular domain of the LE, and it is believed that the extracellular and transmembrane domains play a secondary role relative to the intracellular domain. The lymphoproliferative component includes an intracellular domain that is a signaling polypeptide capable of driving proliferation of membrane-associated T cells or NK cells via a membrane-associated motif (e.g., a transmembrane domain) and is oriented in an active conformation or capable of being oriented into an active conformation. In illustrative embodiments, the ASTR of the LE does not comprise a scFv. Provided herein are strategies for associating the intracellular domain with the membrane, such as by including a transmembrane domain, a GPI anchor, a myristoylated region, a palmitoylated region, and / or a prenylated region. In some embodiments, the lymphoproliferative component does not include an extracellular domain.
[0295] The extracellular domain, transmembrane domain, and intracellular domain of the LE can vary in their respective amino acid lengths. For example, for embodiments comprising replication-defective recombinant retroviral particles, there are limitations on the length of the polynucleotide that can be packaged into the retroviral particle, such that a LE with a shorter amino acid sequence may be advantageous in certain illustrative embodiments. In some embodiments, the total length of the LE may be between 3 and 4000 amino acids, for example, between 10 and 3000 amino acids, 10 and 2000 amino acids, 50 and 2000 amino acids, 250 and 2000 amino acids, and in illustrative embodiments, between 50 and 1000 amino acids, 100 and 1000 amino acids, or 250 and 1000 amino acids. When present to form an extracellular domain and a transmembrane domain, the extracellular domain may be between 1 and 1000 amino acids, and typically between 4 and 400 amino acids, between 4 and 200 amino acids, between 4 and 100 amino acids, between 4 and 50 amino acids, between 4 and 25 amino acids, or between 4 and 20 amino acids. In one embodiment, for the extracellular domain and transmembrane domain of this aspect of the invention, the extracellular region is GGGS. The transmembrane domain or the transmembrane region of the extracellular domain and transmembrane domain may be between 10 and 250 amino acids, and more typically at least 15 amino acids in length, and may be, for example, between 15 and 100 amino acids, 15 and 75 amino acids, 15 and 50 amino acids, 15 and 40 amino acids, 15 and 30 amino acids in length. The intracellular signaling domain can be, for example, between 10 and 1000 amino acids, 10 and 750 amino acids, 10 and 500 amino acids, 10 and 250 amino acids, or 10 and 100 amino acids. In illustrative embodiments, the intracellular signaling domain can be at least 30 amino acids, or between 30 and 500 amino acids, 30 and 250 amino acids, 30 and 150 amino acids, 30 and 100 amino acids, 50 and 500 amino acids, 50 and 250 amino acids, 50 and 150 amino acids, or 50 and 100 amino acids. In some embodiments, the intracellular signaling domain of a particular gene is at least 90%, 95%, 98%, 99%, 100% identical to at least 10, 25, 30, 40, or 50 amino acids from a sequence of that intracellular signaling domain, such as a sequence provided herein for that intracellular domain, up to the size of the entire intracellular domain sequence, and may include, for example, up to an additional 1, 2, 3, 4, 5, 10, 20, or 25 amino acids, provided that such sequence is still capable of providing any of the LE properties disclosed herein.
[0296] In Examples 10, 11, and 12 herein, it was identified that CLE promotes proliferation of PBMC cell cultures transduced with lentiviral particles encoding CLE between days 7 and 21, 28, 35, and / or 42 after transduction. These examples provide tests and / or criteria that can be used to identify whether any test polypeptide, including LE or a test domain of LE, such as the first intracellular domain or the second intracellular domain, or both the first and second intracellular domains, is indeed LE or an effective intracellular domain of LE, or a particularly effective LE or intracellular domain of LE. Thus, in certain embodiments, any aspect or other embodiment provided herein comprising LE or a polynucleotide or nucleic acid encoding LE may state that the LE satisfies or provides the following properties, or is capable of providing and / or possessing the following properties: properties of any one or more of the identified tests or criteria for identifying LE provided herein, or that cells genetically modified and / or transduced with retroviral particles (such as lentiviral particles encoding LE) are capable of providing, adapting to, possessing, and / or modified to achieve the results of one or more of the stated tests. In one embodiment, the LE provides, is capable of providing, and / or possesses the following properties (or cells genetically modified and / or transduced with retroviral particles encoding the LE are capable of, are suitable for, possess, and / or are modified to provide for): increased expansion of pre-activated PBMCs transduced with a lentivirus comprising a nucleic acid encoding the LE and an anti-CD19 CAR comprising a CD3 zeta intracellular activation domain but not a co-stimulatory domain, between day 7 and day 21, day 28, day 35, and / or day 42 of culture in vivo after transduction in the absence of exogenously added cytokines, compared to a control retroviral particle (e.g., a lentiviral particle) under the same conditions. In some embodiments, a lymphoproliferative component assay for improved or enhanced survival, expansion, and / or proliferation of cells transduced with retroviral particles (e.g., lentiviral particles) having a genome encoding a test construct encoding a putative LE (test cell) can be performed based on comparison to control cells, which can be, for example, untransduced cells, or cells transduced with a control retroviral (e.g., lentiviral) particle identical to the lentiviral particle, comprising nucleic acid encoding a lymphoproliferative component but lacking the lymphoproliferative component, or lacking one or more intracellular domains of the test polypeptide construct, but comprising the same extracellular domain (if present) and the same transmembrane region or membrane targeting region of the respective test polypeptide construct. In some embodiments, control cells are transduced with retroviral particles (e.g., lentiviral particles) having a genome encoding a lymphoproliferative component or an intracellular domain thereof identified as an exemplified lymphoproliferative component herein.In this embodiment, the test criteria can include at least sufficient enrichment, survival, and / or expansion, or the absence of a statistical difference in enrichment, survival, and / or expansion when tested using retroviral particles (e.g., lentiviral particles) having a genome encoding the test construct relative to that encoding a control lymphoproliferative component, typically by analyzing cells transduced therewith. In some embodiments, the exemplary or illustrative embodiments of lymphoproliferative components herein are illustrative embodiments of control lymphoproliferative components for such testing.
[0297] In some embodiments, this test for inferring or testing the improved properties of the lymphoproliferative component is performed by performing replication and / or performing statistical tests. The skilled artisan will recognize that many statistical tests can be used for this lymphoproliferative component test. It is envisioned that this test in these embodiments will be any such test known in the art. In some embodiments, the statistical test can be a T test or a Mann-Whitney-Wilcoxon test. In some embodiments, the normalized enrichment level of the test construct is significant at a p-value of less than 0.1, or less than 0.05, or less than 0.01.
[0298] In another embodiment, the LE provides, is capable of providing, and / or possesses the following properties (or cells genetically modified and / or transduced with the LE are capable of providing, are suitable for, possess, and / or are modified to provide): at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold expansion of pre-activated PBMCs transduced with a nucleic acid encoding the LE, or between 1.5-fold and 25-fold expansion, or between 2-fold and 20-fold expansion, or between 2-fold and 15-fold expansion, or between 5-fold and 25-fold expansion, or between 5-fold and 20-fold expansion, or between 5-fold and 15-fold expansion, between day 7 and day 21, day 28, day 35, and / or day 42 of in vivo culture when transduced with an anti-CD19 CAR comprising a CD3 zeta intracellular activation domain but not a costimulatory domain, in the absence of exogenously added cytokines. In some embodiments, the test is performed in the presence of PBMCs, for example, at a 1:1 ratio of transduced cells to PBMCs (which can be, for example, from a matched donor), and in some embodiments, the test is performed in the absence of PBMCs. In some embodiments, amplification analysis of any of these tests is performed as provided in Example 11 or Example 12. In some embodiments, the test may include other statistical tests and cutoffs, such as a p-value below 0.1, 0.05, or 0.01, where the test polypeptide or nucleic acid encoding the test polypeptide is required to meet one or both thresholds (i.e., fold amplification and statistical cutoff).
[0299] For any one in the lymphoproliferative component test provided herein, between the 7th day and the 14th day, the 21st day, the 28th day, the 35th day, the 42nd day or the 60th day after transduction, the number of test cells and the number of control cells are compared. In certain embodiments, the number of test and control cells can be measured by sequencing DNA and counting the identifier present in each construct. In certain embodiments, the number of test and control cells can be directly counted with a hemocytometer or a cell counter. In certain embodiments, all test cells and control cells can be grown in the same container, hole or flask. In certain embodiments, test cells can be inoculated in one or more holes, flasks or containers, and control cells can be inoculated in one or more flasks or containers. In certain embodiments, test and control cells can be inoculated in holes or flasks separately, for example, one cell in every hole. In certain embodiments, the number of test cells and control cells can be compared using enrichment levels. In some embodiments, the enrichment level of a test or control construct can be calculated by dividing the number of cells at a later time point (day 14, day 21, day 28, day 35, or day 45) by the number of cells at day 7 for each construct. In some embodiments, the enrichment level of a test or control construct can be calculated by dividing the number of cells at a time point (day 14, day 21, day 28, day 35, or day 45) by the number of cells at that time point for untransduced cells. In some embodiments, the enrichment level of each test construct can be normalized to the enrichment level of the respective control construct to produce a normalized enrichment level. In some embodiments, the LE encoded in the test construct provides (or cells genetically modified and / or transduced with retroviral particles (e.g., lentiviral particles) having a genome encoding the LE are capable of providing, suitable for, possess the following characteristics and / or are modified to provide) at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold or 10-fold normalized enrichment level, or between 1.5-fold and 25-fold normalized enrichment level, or between 3-fold and 20-fold normalized enrichment level, or between 5-fold and 25-fold normalized enrichment level, or between 5-fold and 20-fold normalized enrichment level, or between 5-fold and 15-fold normalized enrichment level. Enrichment can be measured, for example, by direct cell counting. The cutoff value can be based on a single test, or two, three, four or five replicates, or based on a plurality of replicates. The cutoff value can be met when the lymphoproliferative component meets the cutoff value for one or more replicates, or meets or exceeds the cutoff value for all replicates. In some embodiments, enrichment is measured as log2((normalized count data on the testing day + 1) / (normalized count data on day 7 + 1)).
[0300] As demonstrated in Examples 10, 11, and 12, CLE was identified from a library of constructs including constructs encoding a test chimeric polypeptide designed to include an intracellular domain believed to induce proliferation and / or survival of lymphoid or myeloid cells and an anti-CD19 CAR including an intracellular activation domain but not a co-stimulatory domain. TM CTS TM The cells were preactivated in a preactivation reaction mixture containing 500 IU / ml of T-cell expansion SFM), recombinant human interleukin-2 (100 IU / ml) and anti-CD3 Ab (OKT3) (50 ng / ml), which was performed overnight at 37°C. After preactivation, the test and control lentiviral particles were added to the preactivation reaction mixture and then transduced at 37°C with a multiplicity of infection (MOI) of 5 overnight. Some control lentiviral particles contained constructs encoding polypeptides with extracellular and transmembrane domains but no intracellular domains. In contrast, the test lentiviral particles contained constructs encoding polypeptides with extracellular and transmembrane domains and one or two intracellular domains. After transduction, the complete OpTmizer was added. TM CTS TM T-cell expansion SFM was used to dilute the reaction mixture 5-fold to 20-fold, and the cells were cultured at 37°C for up to 45 days. After the 7th day after transduction, the cultures were either "fed" or not ("unfed") with additional non-transduced donor-matched PBMCs. After the initial formation of the transduction reaction mixture, no additional cytokines (e.g., IL-2, IL-7, or IL-15 and no other lymphoid mitogens) were added to these cultures that were not present in the commercial medium. Amplification was measured by analyzing the enrichment of cell counts that were actually counted as nucleic acid sequence counts of the unique identifiers of each construct in the mixed cultured PBMC cell population, such that enrichment was positive, calculated as the logarithm to the base 2 of the ratio between the normalized count plus one on the last day of analysis and the count plus one on the 7th day. Additional details on the tests performed to identify LE are provided in Examples 10, 11, and 12, including experimental conditions.
[0301] As shown in Examples 10, 11, and 12, constructs were identified as CLEs because they induced proliferation / expansion in these fed or unfed cultures without the need for the addition of cytokines (such as IL-2) between day 7 and day 21, day 28, day 35, and / or day 42. For example, Example 10 identified effective CLEs by identifying test CLEs that provided increased expansion of these in vitro cultures between day 7 and day 21, day 28, day 35, and / or day 42 after transduction, compared to control constructs that did not include any intracellular domain, regardless of whether or not non-transduced PBMCs were fed. Example 10 revealed that, in contrast to each control construct (not including an intracellular domain) present on day 7 after transduction, at least one, and typically more than one, test CLEs that included an intracellular domain from a test gene provided more expansion. Example 10 further provides a statistical method for identifying exceptionally effective genes for the first intracellular domain and one or more exemplary intracellular domains from these genes. The method uses a Mann-Whitney-Wilcoxon test and a false discovery cutoff rate of less than 0.1 or less than 0.05. Example 12 identifies particularly effective genes for the first intracellular domain or the second intracellular domain, for example, by analyzing the gene score calculated as the combined score of all constructs having the gene. As shown in some of the tests performed in Example 12, such analysis can use the following cutoff values: greater than 1, or greater than a negative control construct without any intracellular domain, or greater than 2.
[0302] As shown by the examples herein, in exemplary aspects and embodiments comprising LEs (which typically comprise CARs), such as those provided herein for genetically modifying and / or transducing, methods for genetically modifying and / or transducing cells, and uses thereof, the genetically modified cells are modified so as to possess new properties that the cells did not possess prior to genetic modification and / or transduction. This property can be provided by genetic modification using nucleic acids encoding CARs or LEs (and in illustrative embodiments, both CARs and LEs). For example, in certain embodiments, the genetically modified and / or transduced cells are capable of, adapted for, possess, and / or modified to survive and / or proliferate in ex vivo culture for at least 7, 14, 21, 28, 35, 42, or 60 days, or between day 7 and day 14, 21, 28, 35, 42, or 60 after transduction, in the absence of added IL-2 or in the absence of added cytokines such as IL-2, IL-15, or IL-7, and in certain illustrative embodiments, in the presence of an antigen recognized by a CAR, wherein the method comprises genetically modifying and / or transducing with retroviral particles having a pseudotyping element and, optionally, an isolated or fused activation domain on their surface, and generally without the need for pre-activation.
[0303] By capable of enhancing survival and / or proliferation, in certain embodiments, is meant that the genetically modified and / or transduced cells exhibit, are capable of, are suitable for, possess, and are modified for improved survival or expansion in culture ex vivo or in vitro in the absence of one or more added cytokines (such as IL-2, IL-15, or IL-7) or added lymphocyte mitogens, as compared to the genetically modified and / or transduced cells before they were genetically modified and / or transduced, or to control cells that were transduced with retroviral particles that are identical to the tested retroviral particles comprising LE or a putative LE but without LE or the intracellular domain of LE, wherein said survival or proliferation of said control cells is promoted by said one or more cytokines (such as IL-2, IL-15, or IL-7) or said lymphocyte mitogens added to the culture medium. By added cytokines or lymphocyte mitogens, it is meant that the cytokines or lymphocyte mitogens are added exogenously to the culture medium such that the concentration of the cytokines or lymphocyte mitogens in the culture medium increases during the culturing of the cells compared to the initial culture medium, and in some embodiments, the initial culture medium may not be present prior to such addition. By "addition" or "exogenously added," it is meant that such cytokines or lymphocyte mitogens are added to the lymphocyte medium used to culture genetically modified and / or transduced cells following genetic modification and / or transduction, wherein the culture medium may or may not already possess the cytokines or lymphocyte mitogens. In the absence of exogenously added cytokines or lymphocyte mitogens, all or part of the medium, comprising a mixture of various medium components, is typically stored and, in illustrative embodiments, transported to the site where the culture occurs. In some embodiments, the lymphocyte medium is purchased from a supplier, and a user, such as a technician who is not employed by the supplier and is not located within the supplier's facility, adds exogenously added cytokines or lymphocyte mitogens to the lymphocyte medium and then cultures the genetically modified and / or transduced cells in the presence or absence of such exogenously added cytokines or lymphocyte mitogens.
[0304] In some embodiments, improved or enhanced survival, expansion, and / or proliferation can be demonstrated as an increase in cell number as determined by sequencing DNA from cells transduced with retroviral particles (e.g., lentiviral particles) having a genome encoding a CLE and counting the occurrence of sequences present in the unique identifier from each CLE. In some embodiments, improved survival and / or increased expansion can be determined by directly counting cells at each time point using a hemocytometer or cell counter. In some embodiments, improved survival and / or improved expansion and / or enrichment can be calculated by dividing the number of cells at a later time point (day 21, day 28, day 35, and / or day 45) by the number of cells at day 7 for each construct. In some embodiments, cells can be counted using a hemocytometer or cell counter. In some embodiments, the enrichment level determined using nucleic acid counts or cell counts for each specific test construct can be normalized to the enrichment level of a respective control construct (i.e., a construct having the same extracellular and transmembrane domains but lacking the intracellular domain present in the test construct). In these embodiments, the LE encoded in the construct provides (or cells genetically modified and / or transduced with retroviral particles (e.g., lentiviral particles) having a genome encoding the LE are capable of, suitable for, possess, and / or modified to provide) at least a 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold normalized enrichment level, or between 1.5-fold and 25-fold normalized enrichment level, or between 3-fold and 20-fold normalized enrichment level, or between 5-fold and 25-fold normalized enrichment level, or between 5-fold and 20-fold normalized enrichment level, or between 5-fold and 15-fold normalized enrichment level.
[0305] In the illustrative embodiments herein, one or more lymphoproliferative components are introduced into T cells and / or NK cells, typically by genetically modifying and / or transducing T cells and / or NK cells with replication-deficient recombinant retroviral particles whose genome encodes the lymphoproliferative component as part of an engineered signaling polypeptide. Lymphoproliferative components Lymphoproliferative components can include a signaling intracellular domain or can include more than one intracellular domain. In certain illustrative embodiments, the lymphoproliferative component includes two intracellular domains. Tables 8 to 25 provided herein and discussed in Examples 10, 11, and 12 provide one intracellular domain for a CLE and two intracellular domains identified using the experimental methods provided herein. For CLEs comprising two intracellular signaling domains in these examples, the first intracellular signaling domain is between the transmembrane domain and the second intracellular signaling domain. The "intracellular signaling domain" of an LE is sometimes referred to herein as the "intracellular domain" of the LE. These examples confirm that the vast majority of the first intracellular domains tested (P3 moieties) enhance the proliferation / expansion effect of genetically modified PBMCs, and all of the second intracellular domains tested (P4 moieties) were found in at least one and generally more potent CLE construct (e.g., see Table 25). Some of these P4 moieties were identified as being able to promote the proliferation / expansion of genetically modified PBMCs that do not have a P3 moiety, and thus capable of serving as the first intracellular signaling domain of LE. In addition, the candidate chimeric polypeptides tested included different combinations of extracellular and intracellular domains identified in Table 7 and shown to be present in at least one of the top 100 constructs (Table 25). In some embodiments, the lymphoproliferative component intracellular domain may include any of the intracellular portions (S036 to S216) listed in Table 7, including the P3 portion of Example 10, Example 11, or Example 12, or, in the absence of the P3 portion, any P4 portion identified in Example 10, Example 11, or Example 12 as having activity in inducing expansion between day 7 and day 21 or later. Without being limited by theory, in a CLE containing two intracellular signaling domains, the first intracellular signaling domain (Example 10, Example 11, or Example 12 and Figures 15 to 18 The second intracellular signaling domain (Example 10, Example 11 and Example 12 and Example 13) is selected to have a greater effect on the ability of CLE to induce proliferation of transduced cells and can be referred to as the core or primary signaling domain of CLE. Figures 15 to 18 P4 in (Example 11 and) is selected as the costimulatory domain of the first intracellular signaling domain. In addition, the extracellular domain and the transmembrane domain (Example 11 and Figures 16 and 17 P1 / 2 in Example 10 and Example 12 and Figures 15 to 18In some embodiments, the intracellular signaling domain may have at least 80%, 90%, or 95%, or may have 100% sequence identity to any one of SEQ ID NOs: 404 to 509. In some embodiments, the intracellular signaling domain may have at least 80%, 90%, or 95%, or may have 100% sequence identity to an intracellular domain from BTLA, CD2, CD3D, CD3E, CD3G, CD3Z, CD4, CD8A, CD8B, CD27, mutant δLck, or a combination thereof. CD28, CD28, CD40, CD79A, CD79B, CD137, CRLF2, CSF2RB, CSF2RA, CSF3R, DAP10 / CD28, DAP12, EPOR, FCER1G, FCGR2A, FCGR2C, FCGRA2, GHR, ICOS, IFNAR 1. IFNAR2, IFNGR1, IFNGR2, IFNLR1, IL1R1, IL1RAP, IL1RL1, IL1RL2, IL2RA, IL2RB, IL2RG, IL3RA, IL4R, IL5RA, IL6R, IL6ST, IL7RA, IL9R, IL10RA, IL 10RB, IL11RA, IL12RB1, IL12RB2, IL13RA1, IL13RA2, IL15RA, IL17RA, IL17RB, IL17RC, IL17RD, IL17RE, IL18R1, IL18RAP, IL20RA, IL20RB, IL21R, IL22RA1, IL23R, IL27RA, IL31RA, LEPR, LIFR, LMP1, MPL, MYD88, OSMR, PRLR, TNFRSF4, TNFRSF8, TNFRSF9, TNFRSF14, TNFRSF18 or ZAP70, or a variant or fragment that promotes signaling.In some embodiments, the intracellular domain may have at least 80%, 90%, or 95%, or may have 100% sequence identity to an intracellular domain from CD2, CD4, CD8A, CD8B, CD40, CD79B, CRLF2, CSF2RB, CSF2RA, CSF3R, EPOR, FCGR2C, FCGR2A, GHR, IFNAR1, IFNAR2, IFNGR1, IFNGR2, IFNLR1, IL1R1, IL1RAP, IL1RL1, IL1RL2, IL2RA, IL2RB, I L2RG, IL3RA, IL4R, IL5RA, IL6R, IL6ST, IL9R, IL10RA, IL10RB, IL11RA, IL13RA1, IL13RA2, IL17RA, IL17RB, IL17RC, IL17RD, IL17RE, IL18R1, IL18RAP, IL20RA, IL20RB, IL22RA1, IL31RA, LEPR, LIFR, LMP1, MPL, MYD88, OSMR, and PRLR, or variants or fragments thereof that promote signaling.
[0306] In some illustrative embodiments, the lymphoproliferative component lymphoproliferative component can be or can include a cytokine, or in other illustrative embodiments, a cytokine receptor, or a fragment including its signaling domain, which activates a STAT3 path, a STAT4 path, or even in other illustrative embodiments, a Jak / STAT5 path. Therefore, in non-limiting examples, the lymphoproliferative component lymphoproliferative component can be a cytokine receptor or an active fragment including its signaling domain, such as an interleukin receptor, or an active fragment including its signaling domain that activates STAT5. Therefore, the lymphoproliferative component lymphoproliferative component is a polypeptide that promotes proliferation and optionally survives (anti-apoptosis) and optionally provides a costimulatory signal that enhances the differentiation state of lymphocytes, the proliferation potential, or the resistance to cell death. In illustrative embodiments, the lymphoproliferative component lymphoproliferative component is a polypeptide that induces the proliferation of T cells and / or NK cells. The illustrative lymphoproliferative component lymphoproliferative component induces proliferation by activating STAT5. Thus, fragments of this lymphoproliferative component retain, in illustrative embodiments, the ability to induce proliferation of T cells and / or NK cells by activating STAT5.
[0307] In illustrative embodiments, the lymphoproliferative component, when present in genetically modified PBMCs, lymphocytes, or genetically modified T cells and / or NK cells, is capable of promoting lymphocyte proliferation / expansion and survives in culture, optionally ex vivo or in vitro, for 6, 7, 14, 21, or 35 days in culture, in the absence of exposure of the cells to cytokines (such as IL-15, IL-7, or, in illustrative embodiments, IL-2), in some illustrative embodiments, further in the absence of the target of the ASTR of the CAR expressed by the cells, or in certain illustrative embodiments, in the presence of an antigen recognized by the CAR (wherein the method comprises genetically and / or transducing using retroviral particles having a pseudodifferentiation component and, optionally, a separate or fused activation domain on their surface, and generally without the need for pre-activation).
[0308] In some of the methods and compositions presented herein, the lymphoproliferative component is used to promote the proliferation or expansion of genetically modified T cells in vivo without having to deplete individual lymphocytes. Thus, the non-limiting illustrative embodiments of the methods provided herein (including inserting the lymphoproliferative component into the resting T cells and / or NK cells of an individual, typically by transducing such T cells and / or NK cells) can be performed without depleting individual lymphocytes before, during, and / or after performing the method, or before, during, and / or after collecting blood from an individual before performing this method, or before, during, and / or after genetically modifying T cells and / or NK cells from an individual in vitro, and / or before, during, and / or after reintroducing the genetically modified T cells and / or NK cells into an individual, depleting individual lymphocytes. Factors that promote the proliferation of T cells in vivo include cytokines and their receptors, wherein the receptors typically include a ligand binding domain and a signaling domain. In some embodiments, the lymphoproliferative element used in the methods and compositions disclosed herein is a cytokine and / or a cytokine receptor. The cytokine may be an interleukin, and the cytokine receptor may be an interleukin receptor. The lymphoproliferative element may be a functional fragment of a cytokine and / or a functional fragment of a cytokine receptor (such as a signaling domain thereof), wherein the fragment is capable of promoting T cell proliferation, for example, by activating STAT5.
[0309] In some embodiments, the cytokine lymphoproliferative component of the methods and compositions herein comprises one or more of the following: interleukin-7 (IL-7) or its receptor (IL-7R), or its signaling domain; interleukin-12 (IL-12) or its receptor (IL-12R), or its signaling domain; interleukin-23 (IL-23) or its receptor consisting of IL-12Rβ1 and IL-23R, or its signaling domain; interleukin-2 In some embodiments, the lymphoproliferative element is IL-12R or a TGFβ decoy receptor (TGFβ-dominant-negative receptor II (DNRII)).
[0310] IL-7 binds to the IL-7 receptor (a heterodimer composed of IL-7Rα and a common γ chain). Binding initiates a signaling cascade that is crucial for T cell development in the thymus and survival in the periphery. It is known that binding of IL-7 to the IL-7 receptor activates the Jak / STAT5 pathway.
[0311] IL-12 is involved in the differentiation of naive T cells into Th1 cells (Hsieh CS et al. 1993. Science. 260 (5107): 547-9) and is called a T cell stimulatory factor. IL-12 binds to the IL-12 receptor (which is a heterodimeric receptor formed by IL-12R-β1 and IL-12R-β2). IL12 can act by activating STAT4, but has been shown to also activate STAT5 in T cells (Ahn, H. et al. 1998. J. Immun. 161: 5893-5900). The IL-12 family consists of cytokines IL-12, IL-23, and IL-27. The receptor for IL-23 consists of IL-12Rβ1 and IL-23R. IL-27 is a heterodimeric cytokine composed of two different genes (Epstein-Barr virus-induced gene 3 (EBI3) and IL-27p28). IL-27 interacts with the IL-27 receptor.
[0312] IL-15 is a T cell and NK cell stimulator similar in structure and function to IL-2. Both cytokines induce T cell proliferation; their shared function is believed to arise from the use of two receptors, IL-2 / IL-15Rβ and a common γ chain. The IL-15 signaling pathway begins by binding to the IL-15Rα receptor and subsequent presentation to surrounding cells with the IL-15Rβγc complex on their cell surface. Upon binding to IL-15β, the subunit activates Janus kinase 1 (Jak1) and the γc subunit Janus kinase 3 (Jak3), which leads to the phosphorylation and activation of STAT3 and STAT5.
[0313] IL-21 is expressed in activated human CD4+T cells and NK T cells, and IL-21 expression is upregulated in Th2 and Th17 subsets of T helper cells. IL-21 receptor (IL-21R) is expressed on the surface of T cells, B cells and NK cells and is structurally similar to the receptors of other type I cytokines such as IL-2R or IL-15. IL-21R needs to be dimerized with common gamma chains (γc) in order to combine IL-21. When being attached to IL-21, IL-21 receptor works via Jak / STAT path, thereby activating STAT1, STAT3 and STAT5.
[0314] The TGFβ decoy receptor, TGFβ dominant-negative receptor II (DNRII), blocks TGFβ signaling by competing with the native receptor for TGFβ binding. TGFβ-DNRII is a kinase-inactive, truncated form of RII that contains the extracellular TGFβ binding domain and transmembrane domain of RII. TGFβ-DNRII binds ligand but does not phosphorylate and activate RI, thereby reducing or eliminating Smad phosphorylation.
[0315] Mutations that increase the functionality of IL-7Rα have been identified in individuals with B-cell and T-cell acute lymphoblastic leukemia (B-ALL and T-ALL) (Zenatti PP et al. 2011. Nat Genet 43:932-939; Snochat, C. et al. 2011. J Exp Med 208:901-908; McElroy, CA et al. 2012. PNAS 109(7):2503-2508). Mutations include insertions and deletions in the N-terminal region of the IL-7Rα TMD, wherein almost all sequences contain an additional Cys residue, and an S165 to C165 mutation. Cysteine results in constitutive activation of the receptor. Some of the mutations in all T groups activate JAK1. These IL-7R mutants with increased functionality can be used as one of the lymphoproliferative components in any of the aspects provided herein.
[0316] Thus, in some embodiments, the lymphoproliferative component is a mutated IL-7 receptor. In other embodiments, the mutated IL-7 receptor is constitutively active, thereby activating the JAK-STAT5 pathway in the absence of cytokine ligands. In yet other embodiments, the mutated IL-7 receptor comprises an insertion of 1 to 10 amino acids at a position between 237 and 254, the insertion comprising a cysteine residue comprising the ability to constitutively activate the STAT5 pathway. In some embodiments, the mutated IL-7 receptor is IL-7Rα-insPPCL (represented by SEQ ID NO: 82). In addition, in some chimeric lymphoproliferative component lymphoproliferative component (CLE) embodiments provided herein, one or more (but not all) of the domains are from IL-7Rα-insPPCL.
[0317] In some embodiments, the lymphoproliferative component is a chimeric cytokine receptor, such as, but not limited to, a cytokine connected to its receptor, which typically constitutively activates the same STAT pathway as the corresponding activated wild-type cytokine receptor (such as STAT3, STAT4, and in illustrative embodiments, STAT5). In some embodiments, the chimeric cytokine receptor is an interleukin or a fragment thereof, which is connected to or covalently connected to its cognate receptor via a connector. In some embodiments, the chimeric cytokine receptor is the IL-7 connected to IL-7Rα. In other embodiments, the chimeric cytokine receptor is the IL-7 connected to the IL-7Rα domain, such as the extracellular domain of IL-7Rα and / or the transmembrane domain of IL-7Rα. In some embodiments, the lymphoproliferative component is a cytokine receptor that is not connected to a cytokine, and in fact, in some embodiments, the lymphoproliferative component provided herein is a constitutively active cytokine receptor that is not connected to a cytokine. These chimeric IL-7 receptors typically constitutively activate STAT5 when expressed.
[0318] In the illustrative embodiments of any of the methods and compositions comprising a lymphoproliferative component provided herein, wherein the lymphoproliferative component is a cytokine or cytokine receptor polypeptide or a fragment thereof comprising a signaling domain, the lymphoproliferative component may comprise a portion covalently linked to its cognate interleukin receptor polypeptide via a connector. Typically, this portion of a cognate interleukin receptor comprises a functional portion of an extracellular domain and a transmembrane domain capable of binding an interleukin cytokine. In some embodiments, the intracellular domain is an intracellular portion of a cognate interleukin receptor. In some embodiments, the intracellular domain is an intracellular portion of a different interleukin receptor capable of promoting lymphocyte proliferation. In some embodiments, the lymphoproliferative component is an interleukin polypeptide covalently linked to its full-length cognate interleukin receptor polypeptide via a connector.
[0319] In illustrative embodiments of any of the methods and compositions provided herein that include a lymphoproliferative component, the intracellular domain can be derived from the intracellular portion of the transmembrane protein CD40. The CD40 protein contains several binding sites for TRAF proteins. Without being limited by theory, the binding sites for TRAF1, TRAF2, and TRAF3 are located in the distal membrane domain of the intracellular portion of CD40 and include the amino acid sequence PXQXT (SEQ ID NO: 522), where each X can be any amino acid (corresponding to amino acids 35 to 39 of SEQ ID NO: 416) (Elgueta et al., Immunol Rev. 2009 May;229(1):152-72). TRAF2 has also been shown to bind to the consensus sequence SXXE (SEQ ID NO: 523), where each X can be any amino acid (corresponding to amino acids 57 to 60 of SEQ ID NO: 416) (Elgueta et al., Immunol Rev. 2009 May;229(1):152-72). The significant binding site for TRAF6 is located in the membrane proximal domain of the intracellular portion of CD40 and comprises the consensus sequence QXPXEX (SEQ ID NO: 524), where each X can be any amino acid (corresponding to amino acids 16 to 21 of SEQ ID NO: 416) (Lu et al., J Biol Chem. 2003 Nov 14;278(46):45414-8). In an illustrative embodiment, the intracellular portion of the transmembrane protein CD40 may include all binding sites for TRAF proteins. TRAF binding sites are known in the art, and a skilled artisan will be able to identify corresponding TRAF binding sites in similar CD40 polypeptides. In some embodiments, suitable intracellular domains may include domains having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to at least 10, 15, 20, or all of the amino acids in SEQ ID NO: 416 or SEQ ID NO: 417. In some embodiments, the intracellular domain derived from CD40 has a length of about 30 amino acids (aa) to about 35 aa, about 35 aa to about 40 aa, about 40 aa to about 45 aa, about 45 aa to about 50 aa, about 50 aa to about 55 aa, about 55 aa to about 60 aa, or about 60 aa to about 65 aa. In illustrative embodiments, the intracellular domain derived from CD40 has a length of about 30 aa to about 66 aa, e.g., 30 aa to 65 aa or 50 aa to 66 aa.In illustrative embodiments of a lymphoproliferative element comprising a first intracellular domain derived from CD40, the second intracellular domain may not be an intracellular domain derived from MyD88, a CD28 family member (e.g., CD28, ICOS), a pattern recognition receptor, a C-reactive protein receptor (i.e., Nod1, Nod2, PtX3-R), a TNF receptor (i.e., CD40, RANK / TRANCE-R, OX40, 4-1BB), an HSP receptor (Lox-1 and CD91), or CD28. Pattern recognition receptors include, but are not limited to, endocytic pattern recognition receptors (i.e., mannose receptor, scavenger receptors (i.e., Mac-1, LRP, peptidoglycan, teichoic acid, toxins, CD1 1c / CR4)); external signal pattern recognition receptors (Toll-like receptors (TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10), peptidoglycan recognition protein (PGRP binds bacterial peptidoglycan and CD14)); external signal pattern recognition receptors (i.e., NOD receptors 1 and 2) and RIG1.
[0320] In illustrative embodiments of any of the methods and compositions provided herein that include a lymphoproliferative component, the intracellular domain can be derived from an intracellular portion of CD27. Serine at amino acid 219 of full-length CD27 (corresponding to serine at amino acid 6 of SEQ ID NO: 413) is shown to be phosphorylated. In some embodiments, a suitable intracellular domain may include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 413 or at least 10, 15, 20 or all of the amino acids in SEQ ID NO: 413. In some embodiments, the intracellular domain derived from CD27 has a length of about 30 amino acids (aa) to about 35 aa, about 35 aa to about 40 aa, about 40 aa to about 45 aa, or about 45 aa to about 50 aa.
[0321] In illustrative embodiments of any of the methods and compositions provided herein that include a lymphoproliferative component, the intracellular domain can be derived from the intracellular portion of CSF2RB. Full-length CSF2RB contains a Box 1 motif at amino acids 474 to 482 (corresponding to amino acids 14 to 22 of SEQ ID NO: 421). Tyrosine at amino acid 766 of full-length CSF2RB (corresponding to tyrosine at amino acid 306 of SEQ ID NO: 421) is shown to be phosphorylated. In some embodiments, a suitable intracellular domain can include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to at least 10, 15, 20, or all of the amino acids in SEQ ID NO: 421. In some embodiments, the intracellular domain derived from CSF2RB has a length of about 30 aa to about 35 aa, about 35 aa to about 40 aa, about 40 aa to about 45 aa, about 45 aa to about 50 aa, about 50 aa to about 55 aa, about 55 aa to about 60 aa, about 60 aa to about 65 aa, about 65 aa to about 70 aa, about 70 aa to about 100 aa, about 100 aa to about 125 aa, about 125 aa to 150 aa, about 150 aa to about 175 aa, about 175 aa to about 200 aa, about 200 aa to about 250 aa, about 250 aa to 300 aa, about 300 aa to 350 aa, about 350 aa to about 400 aa, or about 400 aa to about 450 aa.
[0322] In illustrative embodiments of any of the methods and compositions provided herein that include a lymphoproliferative component, the intracellular domain can be derived from the intracellular portion of IL2RB. Full-length IL2RB contains a Box 1 motif at amino acids 278 to 286 (corresponding to amino acids 13 to 21 of SEQ ID NO: 448). In some embodiments, a suitable intracellular domain can include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the amino acids in SEQ ID NO: 448. In some embodiments, the intracellular domain derived from IL2RB has a length of about 30 aa to about 35 aa, about 35 aa to about 40 aa, about 40 aa to about 45 aa, about 45 aa to about 50 aa, about 50 aa to about 55 aa, about 55 aa to about 60 aa, about 60 aa to about 65 aa, about 65 aa to about 70 aa, about 70 aa to about 100 aa, about 100 aa to about 125 aa, about 125 aa to 150 aa, about 150 aa to about 175 aa, about 175 aa to about 200 aa, about 200 aa to about 250 aa, or about 250 aa to 300 aa.
[0323] In illustrative embodiments of any of the methods and compositions provided herein that include a lymphoproliferative component, the intracellular domain can be derived from the intracellular portion of IL6ST. Full-length IL6ST contains a Box 1 motif at amino acids 651 to 659 (corresponding to amino acids 10 to 18 of SEQ ID NO: 455). Serine at amino acids 661, 667, 782, 789, 829, and 839 of full-length IL6ST (corresponding to serine at amino acids 20, 26, 141, 148, 188, and 198 of SEQ ID NO: 455, respectively) has been shown to be phosphorylated. In some embodiments, a suitable intracellular domain may comprise a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the amino acids in SEQ ID NO: 454 or SEQ ID NO: 455. In some embodiments, the intracellular domain derived from IL6ST has a length of about 30 aa to about 35 aa, about 35 aa to about 40 aa, about 40 aa to about 45 aa, about 45 aa to about 50 aa, about 50 aa to about 55 aa, about 55 aa to about 60 aa, about 60 aa to about 65 aa, about 65 aa to about 70 aa, about 70 aa to about 100 aa, about 100 aa to about 125 aa, about 125 aa to 150 aa, about 150 aa to about 175 aa, about 175 aa to about 200 aa, about 200 aa to about 250 aa, or about 250 aa to 300 aa.
[0324] In illustrative embodiments of any of the methods and compositions provided herein that include a lymphoproliferative component, the intracellular domain can be derived from the intracellular portion of IL17RE. The full-length IL17RE contains a TIR domain at amino acids 372 to 495 (corresponding to amino acids 13 to 136 of SEQ ID NO: 473). In some embodiments, a suitable intracellular domain can include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to at least 10, 15, 20, or all of the amino acids in SEQ ID NO: 473. In some embodiments, the intracellular domain derived from IL17RE has a length of about 30 aa to about 35 aa, about 35 aa to about 40 aa, about 40 aa to about 45 aa, about 45 aa to about 50 aa, about 50 aa to about 55 aa, about 55 aa to about 60 aa, about 60 aa to about 65 aa, about 65 aa to about 70 aa, about 70 aa to about 100 aa, about 100 aa to about 125 aa, about 125 aa to 150 aa, about 150 aa to about 175 aa, or about 175 aa to about 200 aa.
[0325] In illustrative embodiments of any of the methods and compositions provided herein that include a lymphoproliferative component, the intracellular domain can be derived from the intracellular portion of IL2RG. Full-length IL2RG contains a box 1 motif at amino acids 286 to 294 (corresponding to amino acids 3 to 11 of SEQ ID NO: 449). In some embodiments, a suitable intracellular domain can include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the amino acids in SEQ ID NO: 449. In some embodiments, the intracellular domain derived from IL2RG has a length of about 30 amino acids (aa) to about 35 aa, about 35 aa to about 40 aa, about 40 aa to about 45 aa, about 45 aa to about 50 aa, about 50 aa to about 55 aa, about 55 aa to about 60 aa, about 60 aa to about 65 aa, about 65 aa to about 70 aa, or about 70 aa to about 100 aa.
[0326] In illustrative embodiments of any of the methods and compositions provided herein that include a lymphoproliferative component, the intracellular domain can be derived from the intracellular portion of IL18R1. Full-length IL18R1 contains a TIR domain at amino acids 222 to 364 (corresponding to amino acids 28 to 170 of SEQ ID NO: 474). In some embodiments, a suitable intracellular domain can include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to at least 10, 15, 20, or all of the amino acids in SEQ ID NO: 474. In some embodiments, the intracellular domain derived from IL18R1 has a length of about 30 aa to about 35 aa, about 35 aa to about 40 aa, about 40 aa to about 45 aa, about 45 aa to about 50 aa, about 50 aa to about 55 aa, about 55 aa to about 60 aa, about 60 aa to about 65 aa, about 65 aa to about 70 aa, or about 70 aa to about 100 aa.
[0327] In illustrative embodiments of any of the methods and compositions provided herein that include a lymphoproliferative component, the intracellular domain can be derived from the intracellular portion of IL27RA. Full-length IL27RA contains a box 1 motif at amino acids 554 to 562 (corresponding to amino acids 17 to 25 of SEQ ID NO: 481). In some embodiments, a suitable intracellular domain can include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to at least 10, 15, 20, or all of the amino acids in SEQ ID NO: 481 or SEQ ID NO: 482. In some embodiments, the intracellular domain derived from IL27RA has a length of about 30 aa to about 35 aa, about 35 aa to about 40 aa, about 40 aa to about 45 aa, about 45 aa to about 50 aa, about 50 aa to about 55 aa, about 55 aa to about 60 aa, about 60 aa to about 65 aa, about 65 aa to about 70 aa, or about 70 aa to about 100 aa.
[0328] In illustrative embodiments of any of the methods and compositions provided herein that include a lymphoproliferative component, the intracellular domain can be derived from the intracellular portion of IFNGR2. Full-length IFNGR2 contains a dileucine internalization motif at amino acids 276 to 277 (corresponding to amino acids 8 to 9 of SEQ ID NO: 438). In some embodiments, a suitable intracellular domain can include a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to at least 10, 15, 20, or all of the amino acids in SEQ ID NO: 438. In some embodiments, the intracellular domain derived from IFNGR21 has a length of about 30 aa to about 35 aa, about 35 aa to about 40 aa, about 40 aa to about 45 aa, about 45 aa to about 50 aa, about 50 aa to about 55 aa, about 55 aa to about 60 aa, about 60 aa to about 65 aa, or about 65 aa to about 70 aa.
[0329] In illustrative embodiments of any of the methods and compositions provided herein that include a lymphoproliferative component, the intracellular domain can be derived from the intracellular portion of MyD88. The MyD88 protein has an N-terminal death domain (corresponding to amino acids 29 to 106 of SEQ ID NO: 492) that mediates interaction with other death domain-containing proteins, an intermediate domain (corresponding to amino acids 107 to 156 of SEQ ID NO: 492) that interacts with IL-1R-associated kinases, and a C-terminal TIR domain (corresponding to amino acids 160 to 304 of SEQ ID NO: 492) that associates with the TLR-TIR domain (Biol Res. 2007; 40(2): 97-112). MyD88 also has a canonical nuclear localization and export motif. Point mutations have been identified in MyD88 and include loss-of-function mutations L93P and R193C (corresponding to L93P and R196C in SEQ ID NO: 492) and gain-of-function mutation L265P (corresponding to L260P in SEQ ID NO: 492) (Deguine and Barton. F1000 Prime Rep. 2014 Nov 4;6:97). In some embodiments, the portion of the protein MyD88 may include all of the domains disclosed herein. The domains, motifs, and point mutations of MyD88 are known in the art, and a skilled artisan will be able to identify corresponding domains, motifs, and point mutations in similar MyD88 polypeptides. In some embodiments, a suitable intracellular domain may comprise a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a stretch of at least 10, 15, 20 or all of amino acids in SEQ ID NOs: 492 to 501. In some embodiments, the intracellular domain derived from MyD88 has a length of about 30 aa to about 35 aa, about 35 aa to about 40 aa, about 40 aa to about 45 aa, about 45 aa to about 50 aa, about 50 aa to about 55 aa, about 55 aa to about 60 aa, about 60 aa to about 65 aa, about 65 aa to about 70 aa, about 70 aa to about 100 aa, about 100 aa to about 125 aa, about 125 aa to 150 aa, about 150 aa to about 175 aa, about 175 aa to about 200 aa, about 200 aa to about 250 aa, about 250 aa to 300 aa, or about 300 aa to 350 aa. In illustrative embodiments, the intracellular domain derived from MyD88 has a length of about 30 aa to about 350 aa, e.g., 50 aa to 350 aa, or 100 aa to 350 aa, 100 aa to 304 aa, 100 aa to 296 aa, 100 aa to 251 aa, 100 aa to 191 aa, 100 aa to 172 aa, 100 aa to 146 aa, or 100 aa to 127 aa.In illustrative embodiments of a lymphoproliferative element comprising a first intracellular domain derived from MyD88, the second intracellular domain may not be an intracellular domain derived from a CD28 family member (e.g., CD28, ICOS), a pattern recognition receptor, a C-reactive protein receptor (i.e., Nod1, Nod2, PtX3-R), a TNF receptor (i.e., CD40, RANK / TRANCE-R, OX40, 4-1BB), an HSP receptor (Lox-1 and CD91), or CD28.
[0330] In illustrative embodiments of any of the methods and compositions provided herein that include a lymphoproliferative component, the intracellular domain can be derived from a portion of the transmembrane protein MPL. The transmembrane MPL protein contains a Box 1 motif, PXXP (SEQ ID NO: 525), and a Box 2 motif, which is a region with increased serine and glutamate content (corresponding to amino acids 46 to 64 in SEQ ID NO: 491), where each X in PXXP can be any amino acid (corresponding to amino acids 17 to 20 in SEQ ID NO: 491) (Drachman and Kaushansky. Proc Natl Acad Sci USA. 1997 Mar 18;94(6):2350-5). Even though the presence of the Box2 motif is not always required for a proliferative signal, both Box1 and Box2 motifs are involved in binding to JAKs and signal transduction (Murakami et al., Proc Natl Acad Sci USA. 1991 Dec 15;88(24):11349-53; Fukunaga et al., EMBO J. 1991 Oct;10(10):2855-65; and O'Neal and Lee. Lymphokine Cytokine Res. 1993 Oct;12(5):309-12). Many cytokine receptors have hydrophobic residues at positions -1, -2, and -6 relative to the Box 1 motif (corresponding to amino acids 16, 15, and 11 of SEQ ID NO: 491), which form a "switch motif" that requires cytokine-induced JAK2 activation but does not require JAK2 binding (Constantinescu et al., Mol Cell. 2001 Feb;7(2):377-85; and Huang et al., Mol Cell. 2001 Dec;8(6):1327-38). A deletion encompassing amino acids 70 to 95 in SEQ ID NO: 491 was shown to support viral conversion in the context of v-mpl (Benit et al., J Virol. 1994 Aug;68(8):5270-4), indicating that this region is not essential for mpl function in this context. Morello et al., Blood 1995 Jul;86(8):557-71, using the same deletion, showed that this region is not required for stimulating transcription of an erythropoietin receptor-responsive CAT receptor gene construct, and further showed that this deletion resulted in slightly enhanced transcription, which is expected to remove non-essential and negative elements in this region as suggested by Drachman and Kaushansky. Thus, in some embodiments, the MPL intracellular signaling domain does not include the region comprising amino acids 70 to 95 of SEQ ID NO: 491.In full-length MPL, lysine K553 (corresponding to K40 of SEQ ID NO: 491) and K573 (corresponding to K60 of SEQ ID NO: 491) have been shown to be negative regulatory sites that act as part of a ubiquitination targeting motif (Saur et al., Blood 2010 Feb 11; 115(6): 1254-63). Thus, in some embodiments herein, the MPL intracellular signaling domain does not contain these ubiquitination targeting motif residues. In full-length MPL, tyrosines Y521 (corresponding to Y8 of SEQ ID NO: 491), Y542 (corresponding to Y29 of SEQ ID NO: 491), Y591 (corresponding to Y78 of SEQ ID NO: 491), Y626 (corresponding to Y113 of SEQ ID NO: 491), and Y631 (corresponding to Y118 of SEQ ID NO: 491) were shown to be phosphorylated (Varghese et al., Front Endocrinol (Lausanne). 2017 Mar 31;8:59). Y521 and Y591 of full-length MPL are negative regulatory sites that serve as a lysosomal targeting motif (Y521) or through interaction with the adaptor protein AP2 (Y591) (Drachman and Kaushansky, Proc Natl Acad Sci USA. 1997 Mar 18;94(6):2350-5; and Hitchcock et al., Blood. 2008 Sep 15;112(6):2222-31). Y626 and Y631 of full-length MPL are positive regulatory sites (Drachman and Kaushansky, Proc Natl Acad Sci USA. 1997 Mar 18;94(6):2350-5), and the murine homolog of Y626 is required for cell differentiation and phosphorylation of Shc (Alexander et al., EMBO J. 1996 Dec 2;15(23):6531-40), and Y626 is also required for constitutive signaling in MPL using the W515A mutation described below (Pecquet et al., Blood. 2010 Feb 4;115(5):1037-48).MPL contains a binding motif NXXY (SEQ ID NO: 526) that binds to Shc phosphotyrosine, where each X can be any amino acid (corresponding to amino acids 110 to 113 of SEQ ID NO: 491). This tyrosine is phosphorylated and is essential for TPO-dependent phosphorylation of Shc, SHIP, and STAT3 (Laminet et al., J Biol Chem. 1996 Jan 5;271(1):264-9; and van der Geer et al., Proc Natl Acad Sci USA. 1996 Feb 6;93(3):963-8). MPL also contains a STAT3 consensus binding sequence YXXQ (SEQ ID NO: 527), where each X can be any amino acid (corresponding to amino acids 118 to 121 of SEQ ID NO: 491) (Stahl et al., Science. 1995 Mar 3;267(5202):1349-53). The tyrosine residues in this sequence are phosphorylated, and MPL is capable of partial STAT3 recruitment (Drachman and Kaushansky, Proc Natl Acad Sci USA. 1997 Mar 18;94(6):2350-5). MPL also contains the sequence YLPL (SEQ ID NO:528) (corresponding to amino acids 113 to 116 of SEQ ID NO:491), which is similar to the consensus binding site for STAT5 recruitment of pYLXL (SEQ ID NO:529), where pY is a phosphotyrosine residue and X can be any amino acid (May et al., FEBS Lett. 1996 Mar 30;394(2):221-6). Using computer simulations, Lee et al. found that clinically relevant mutations in the transmembrane domain of MPL should activate MPL in the following order of activation effect: W515K (corresponding to the amino acid substitution W2K of SEQ ID NO: 491) > S505A (corresponding to the amino acid substitution S14A of SEQ ID NO: 395) > W515I (corresponding to the amino acid substitution W2I of SEQ ID NO: 491) > S505N (corresponding to the amino acid substitution S14N of SEQ ID NO: 395, which was tested as T075 (SEQ ID NO: 396) in Example 12) (PLoS One. 2011; 6(8): e23396). It is predicted that simulation of these mutations may result in constitutive activation of JAK2, the kinase partner of MPL. In some embodiments, the intracellular portion of MPL may include all of the domains and motifs described herein that are present in SEQ ID NO: 491. In some embodiments, the transmembrane portion of MPL may include all of the domains and motifs described herein that are present in SEQ ID NO: 395.The domains, motifs, and point mutations of MPL provided herein are known in the art, and the skilled artisan will recognize that the intracellular signaling domains of MPL herein will include, in illustrative embodiments, corresponding domains, motifs, and point mutations that have been shown to promote proliferative activity, and will not include those that have been shown to inhibit MPL proliferative activity. In some embodiments, suitable intracellular domains may include domains having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the amino acids in SEQ ID NO: 491. In some embodiments, the intracellular domain derived from MPL has a length of about 30 aa to about 35 aa, about 35 aa to about 40 aa, about 40 aa to about 45 aa, about 45 aa to about 50 aa, about 50 aa to about 55 aa, about 55 aa to about 60 aa, about 60 aa to about 65 aa, about 65 aa to about 70 aa, about 70 aa to about 100 aa, about 100 aa to about 125 aa, about 125 aa to 150 aa, In some embodiments, the intracellular domain of MPL has a length of about 150 aa to about 175 aa, about 175 aa to about 200 aa, about 200 aa to about 250 aa, about 250 aa to 300 aa, about 300 aa to 350 aa, about 350 aa to about 400 aa, about 400 aa to about 450 aa, about 450 aa to about 500 aa, about 500 aa to about 550 aa, about 550 aa to about 600 aa, or about 600 aa to about 635 aa. In illustrative embodiments, the intracellular domain derived from MPL has a length of about 30 aa to about 200 aa, such as 30 aa to 150 aa, 30 aa to 119 aa, 30 aa to 121 aa, 30 aa to 122 aa, or 50 aa to 125 aa.
[0331] In illustrative embodiments of any of the methods and compositions provided herein that include a lymphoproliferative component, the intracellular domain can be derived from a portion of the transmembrane protein CD79B, also known as B29; IGB; AGM6. CD79B contains an ITAM motif at residues 193 to 212 (corresponding to amino acids 16 to 30 of SEQ ID NO: 419). CD79B has two tyrosines, Y196 and Y207, known to be phosphorylated (corresponding to Y16 and Y27 of SEQ ID NO: 419). In some embodiments, the intracellular portion of the transmembrane protein CD79B can include the ITAM motifs and known phosphorylation sites described herein. The motifs and phosphorylatable tyrosines of CD79B are known in the art, and a skilled artisan will be able to identify corresponding motifs and phosphorylatable tyrosines in similar CD79B polypeptides. In some embodiments, suitable intracellular domains may include domains having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to at least 10, 15, 20, or all of the amino acids in SEQ ID NO: 419. In some embodiments, the intracellular domain derived from CD79B has a length of about 30 aa to about 35 aa, about 35 aa to about 40 aa, about 40 aa to about 45 aa, or about 45 aa to about 50 aa. In illustrative embodiments, the intracellular domain derived from CD79B has a length of about 30 aa to about 50 aa. In some embodiments, a suitable CD79B intracellular activation domain may comprise a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a stretch of at least 10, 15, 20 or all amino acids of the following sequence: LDKDDSKAGMEEDHT[YEGLDIDQTATYEDI]VTLRTGEVKWSVGEHPGQE (SEQ ID NO: 419), wherein the ITAM motif is set forth in parentheses.
[0332] In illustrative embodiments of any of the methods and compositions provided herein that include a lymphoproliferative component, the intracellular domain can be derived from a portion of the transmembrane protein OSMR. OSMR contains a Box 1 motif at amino acids 771 to 779 of isoform 3 (corresponding to amino acids 16 to 30 of SEQ ID NO: 502). OSMR has two serines at amino acids 829 and 890 of isoform 3 that are known to be phosphorylated (serines at amino acids 65 and 128 of SEQ ID NO: 502). In some embodiments, the intracellular portion of protein OSMR can include the box 1 motif and known phosphorylation sites described herein. The motifs and phosphorylatable tyrosines of OSMR are known in the art, and a skilled artisan will be able to identify corresponding motifs and phosphorylatable serines in similar OSMR polypeptides. In some embodiments, a suitable intracellular domain may comprise a domain having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a stretch of at least 10, 15, 20 or all of the amino acids in SEQ ID NO:502. In some embodiments, the intracellular domain derived from OSMR has a length of about 30 aa to about 35 aa, about 35 aa to about 40 aa, about 40 aa to about 45 aa, about 45 aa to about 50 aa, about 50 aa to about 55 aa, about 55 aa to about 60 aa, about 60 aa to about 65 aa, about 65 aa to about 70 aa, about 70 aa to about 100 aa, about 100 aa to about 125 aa, about 125 aa to 150 aa, about 150 aa to about 175 aa, about 175 aa to about 200 aa, or about 200 aa to about 250 aa.
[0333] In the illustrative embodiments of any one of the methods and compositions comprising lymphoproliferative components provided herein, the intracellular domain can be derived from the part of transmembrane protein PRLR.PRLR contains the growth hormone receptor binding domain at amino acid 185 to 261 (corresponding to amino acid 28 to 104 of SEQ ID NO:503) of isoform 6. The growth hormone receptor binding domain of PRLR is known in the art, and the technician will be able to identify the corresponding domain in similar PRLR polypeptides. In certain embodiments, the intracellular domain suitable for can include and SEQ ID NO:503 amino acid at least 10,15,20 or all of a section have at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity. In some embodiments, the intracellular domain derived from PRLR has a length of about 30aa to about 35aa, about 35aa to about 40aa, about 40aa to about 45aa, about 45aa to about 50aa, about 50aa to about 55aa, about 55aa to about 60aa, about 60aa to about 65aa, about 65aa to about 70aa, about 70aa to about 100aa, about 100aa to about 125aa, about 125aa to 150aa, about 150aa to about 175aa, about 175aa to about 200aa, about 200aa to about 250aa, about 250aa to 300aa, about 300aa to 350aa, or about 350aa to about 400aa.
[0334] In illustrative embodiments of any of the methods, uses, and composition aspects provided herein that include a lymphoproliferative component, the intracellular domain can be, or the lymphoproliferative component can include, an intracellular domain comprising a signaling domain from: CSF2RB, CRLF2, CSF2RA, CSF3R, EPOR, GHR, IFNAR1, IFNAR2, IFNGR1, IFNGR2, IFNLR1, IL1R1, IL1RAP, IL1RL1, IL1RL2, IL2RA, IL2RB, IL2RG, IL3RA, IL5 RA, IL6R, IL6ST, IL7RA, IL9R, IL10RA, IL10RB, IL11RA, IL12RB1, IL12RB2, IL13RA1, IL13RA2, IL15RA, IL17RB, IL17RC, IL17RD, IL18R1, IL18RAP, IL20RA, IL20RB, IL21R, IL22RA1, IL23R, IL27RA, IL31RA, LEPR, LIFR, LMP1, MPL, MyD88, OSMR or PRLR. Each of these genes has an intracellular domain that is present at the P3 position on at least one construct in the top 100 hits of at least one of the copies of library 3.1. In some embodiments, the lymphoproliferative component may comprise an intracellular domain or fragment thereof comprising a signaling domain from CSF2RB, CRLF2, CSF2RA, CSF3R, EPOR, GHR, IFNAR1, IFNAR2, IFNGR1, IFNGR2, IFNLR1, IL1R1, IL1RAP, IL1RL1, IL1RL2, IL2RA, IL2RB, IL2RG, IL3RA, IL5RA, IL6R, IL6ST, IL9R, IL10RA, IL10RB, IL11RA, IL13RA1, IL13RA2, IL17RB, IL17RC, IL17RD, IL18R1, IL18RAP, IL20RA, IL20RB, IL22RA1, IL31RA, LEPR, LIFR, LMP1, MPL, MyD88, OSMR, or PRLR.In some embodiments, the lymphoproliferative component may comprise an intracellular domain or fragment thereof comprising a signaling domain from CSF2RB, CSF2RA, CSF3R, EPOR, IFNGR1, IFNGR2, IL1R1, IL1RAP, IL1RL1, IL2RA, IL2RG, IL5RA, IL6R, IL9R, IL10RB, IL11RA, IL12RB1, IL12RB2, IL13RA2, IL15RA, IL17RD, IL21R, IL23R, IL27RA, IL31RA, LEPR, MPL, MyD88, or OSMR. Each of these genes has an intracellular domain present at the P3 position on at least one construct that does not have an intracellular domain in the P4 position and in the top 100 hits of at least one of the replicates of library 3.1. In some embodiments, the lymphoproliferative component may comprise an intracellular domain or fragment thereof comprising a signaling domain from CSF2RB, CSF2RA, CSF3R, EPOR, IFNGR1, IFNGR2, IL1R1, IL1RAP, IL1RL1, IL2RA, IL2RG, IL5RA, IL6R, IL9R, IL10RB, IL11RA, IL13RA2, IL17RD, IL31RA, LEPR, MPL, MyD88, or OSMR. In some embodiments, the lymphoproliferative component may include an intracellular domain or a fragment thereof that includes a signaling domain from CSF2RB, CSF3R, IFNAR1, IFNGR1, IL2RB, IL2RG, IL6ST, IL10RA, IL12RB2, IL17RC, IL17RE, IL18R1, IL22RA1, IL27RA, IL31RA, MPL, MyD88, OSMR, or PRLR (Table 1). Each of these genes has an intracellular domain that is significantly enriched at the P3 position across the replicates of library 3.1 (p < 0.1). In some embodiments, the lymphoproliferative component may comprise an intracellular domain or fragment thereof comprising a signaling domain from CSF2RB, CSF3R, IFNAR1, IFNGR1, IL2RB, IL2RG, IL6ST, IL10RA, IL17RC, IL17RE, IL18R1, IL22RA1, IL31RA, MPL, MyD88, OSMR, or PRLR.In some embodiments, the lymphoproliferative component may include an intracellular domain or a fragment thereof, which includes a signaling domain from: CSF2RB, CSF3R, IFNGR1, IL2RB, IL2RG, IL6ST, IL10RA, IL12RB2, IL17RE, IL18R1, IL22RA1, IL27RA, IL31RA, MPL, MyD88, OSMR or PRLR (Table 1). Each of these genes has an intracellular domain that is significantly enriched (p < 0.05) at the P3 position of the repetition across library 3.1. In some embodiments, the lymphoproliferative component may include an intracellular domain or a fragment thereof, which includes a signaling domain from: CSF2RB, CSF3R, IFNGR1, IL2RB, IL2RG, IL6ST, IL10RA, IL17RE, IL18R1, IL22RA1, IL31RA, MPL, MyD88, OSMR or PRLR. In some embodiments, the lymphoproliferative component may comprise an intracellular domain or fragment thereof comprising a signaling domain from CSF2RB, CSF3R, IL2RB, IL2RG, IL6ST, IL27RA, IL31RA, MPL, or MyD88. Each of these genes has an intracellular domain that is significantly enriched (p < 0.05) at the P3 position across at least 2 repeats of library 3.1. In some embodiments, the lymphoproliferative component may comprise an intracellular domain or fragment thereof comprising a signaling domain from CSF2RB, CSF3R, IL2RB, IL2RG, IL6ST, IL31RA, MPL, or MyD88.
[0335] In some embodiments, the lymphoproliferative component may include the following sequence: S054, S057, S058, S059, S062, S063, S064, S069, S072, S077, S081, S082, S083, S084, S085, S086, S087, S098, S099, S100, S101, S102, S103, S104, S105, S106, S109, S115, S116, S117, S120, S121, S126, S129, S130, S135, S136, S137 7, S138, S141, S142, S143, S145, S147, S148, S154, S155, S156, S157, S158, S161, S165, S168, S169, S170, S171, S174, S175, S176, S177, S180, S183, S186, S189, S190, S191, S192, S193, S194, S195, S196, S197, S198, S199 or S202 (as shown in Table 7), or any fragment thereof that includes a signaling domain. Each of these portions was present at the P3 position on at least one construct in the top 100 hits of at least one of the replicates of library 3.1. In some embodiments, the lymphoproliferative component may comprise the sequence of S057, S058, S059, S064, S069, S072, S084, S085, S099, S100, S101, S102, S104, S106, S115, S116, S126, S130, S135, S137, S138, S142, S143, S148, S158, S165, S168, S169, S170, S171, S174, S175, S176, S177, S186, S190, S191, S192, S193, S197, S198, or S199 (as shown in Table 7), or any fragment thereof that includes a signaling domain. Each of these portions is present at the P3 position on at least one construct that does not have the intracellular domain in the P4 position and is among the top 100 hits of at least one of the repeats of library 3.1. In some embodiments, the lymphoproliferative component may include the following sequences as shown in Table 7: S057, S062, S063, S064, S081, S084, S105, S106, S117, S129, S138, S149, S161, S168, S169, S170, S186, S190, S191, S192, S194, S196, S197, S198, S199, or S202 (Table 1), or any fragment thereof that includes a signaling domain.Each of these fractions was significantly enriched at the P3 position across the repeats of library 3.1.
[0336] In illustrative embodiments of any of the methods, uses, and composition aspects provided herein that include a lymphoproliferative component, the intracellular domain can include an intracellular domain or fragment thereof that includes a signaling domain from CD3D, CD3E, CD3G, CD27, CD28, CD40, CD79A, CD79B, FCER1G, FCGR2C, FCGRA2, ICOS, TNFRSF4, TNFRSF8, TNFRSF9, TNFRSF14, or TNFRSF18. Each of these genes has an intracellular domain that is present at the P4 position on at least one construct in the top 100 hits of at least one of the replicates of library...
Claims
1. Use of a replication-deficient recombinant retroviral particle in the preparation of a kit for genetically modifying T cells or NK cells of an individual, wherein the use of the kit comprises: The T cell or the NK cell is contacted with the replication-deficient recombinant retroviral particle ex vivo, wherein the replication-deficient recombinant retroviral particle comprises a pseudotyping component on its surface, wherein the replication-deficient recombinant retroviral particle comprises a polynucleotide comprising one or more transcription units operably linked to a promoter active in T cells and / or NK cells, wherein, The one or more transcription units encode a first polypeptide comprising a lymphoproliferative element (LE), or a first polypeptide comprising an LE and a second polypeptide comprising a chimeric antigen receptor (CAR), and wherein the contacting is performed for between 15 minutes and 18 hours to facilitate membrane fusion of the T cell or the NK cell with the replication-defective recombinant retroviral particle, wherein the LE comprises an intracellular signaling domain from: CD2, CD4, CD8A, CD8B, CD40, CD79B, CRLF2, CSF2RB, CSF2RA, CSF3R, EPOR, FCGR2C, FCGR2A, GHR, IFNAR1, IFNAR2, IFNGR1, IFNGR2, IFNLR1, IL1R1, IL1RAP, IL1RL1, IL1RL2, IL2RA, IL2RB, IL2RG, IL3RA, IL4R, IL5RA, IL6R, IL6ST, IL9R, IL10RA, IL10RB, IL11RA, IL13RA1, IL13RA2, IL17RA, IL17RB, IL17RC, IL17RD, IL17RE, IL18R1, IL18RAP, IL20RA, IL20RB, IL22RA1, IL31RA, LEPR, LIFR, LMP1, MPL, MYD88, OSMR or PRLR, thereby producing genetically modified T cells or genetically modified NK cells.
2. A genetically modified T cell or NK cell, which is made by genetically modifying a T cell or NK cell according to a method comprising contacting the T cell or NK cell ex vivo with a replication-deficient recombinant retroviral particle, wherein the replication-deficient recombinant retroviral particle comprises a pseudotyped component on its surface, wherein the replication-deficient recombinant retroviral particle comprises a polynucleotide comprising one or more transcription units operably linked to a promoter active in the T cell and / or NK cell, wherein the one or more transcription units encode a first polypeptide comprising a lymphoproliferative element (LE), or a first polypeptide comprising an LE and a second polypeptide comprising a chimeric antigen receptor (CAR), and wherein the contacting is performed for between 15 minutes and 18 hours to facilitate membrane fusion of the T cell or the NK cell with the replication-deficient recombinant retroviral particle, wherein the LE comprises an intracellular signaling domain from: CD2, CD4, CD8A, CD8B, CD40, CD79B, CRLF2, CSF2RB, CSF2RA, CSF3R, EPOR, FCGR2C, FCGR2A, GHR, IFNAR1, IFNAR2, IFNGR1, IFNGR2, IFNLR 1. IL1R1, IL1RAP, IL1RL1, IL1RL2, IL2RA, IL2RB, IL2RG, IL3RA, IL4R, IL5RA, IL6R, IL6ST, IL9R, IL10RA, I L10RB, IL11RA, IL13RA1, IL13RA2, IL17RA, IL17RB, IL17RC, IL17RD, IL17RE, IL18R1, IL18RAP, IL20RA, IL20RB, IL22RA1, IL31RA, LEPR, LIFR, LMP1, MPL, MYD88, OSMR or PRLR, thereby producing the genetically modified T cells or the genetically modified NK cells.
3. A method for genetically modifying and / or transducing T cells or NK cells, comprising contacting the T cells or NK cells ex vivo with replication-defective recombinant retroviral particles comprising a pseudotyped component on their surface, wherein the replication-defective recombinant retroviral particles comprise a polynucleotide comprising one or more transcription units operably linked to a promoter active in the T cells and / or NK cells, wherein the one or more transcription units encode a first polypeptide comprising a lymphoproliferative element (LE), or a first polypeptide comprising an LE and a second polypeptide comprising a chimeric antigen receptor (CAR), and wherein the contacting is performed for between 15 minutes and 18 hours to facilitate membrane fusion of the T cells or NK cells by the replication-defective recombinant retroviral particles, wherein the LE comprises an intracellular signaling domain from: CD2, CD4, CD8A, CD8B, CD40, CD79B, CRLF 2. CSF2RB, CSF2RA, CSF3R, EPOR, FCGR2C, FCGR2A, GHR, IFNAR1, IFNAR2, IFNGR1, IFNGR2, IFNLR1, IL1R1, IL1RAP, IL1RL1, IL1RL2, IL2RA, IL2RB, IL2RG, IL3RA, IL4R, IL5RA, IL6R, IL6ST, IL9R, IL10RA, IL10RB, IL11RA, IL13RA1, IL13RA2, IL17RA, IL17RB, IL17RC, IL17RD, IL17RE, IL18R1, IL18RAP, IL20RA, IL20RB, IL22RA1, IL31RA, LEPR, LIFR, LMP1, MPL, MYD88, OSMR and PRLR, thereby producing genetically modified T cells or NK cells.
4. The use, genetically modified T cells or NK cells, or method for genetically modifying and / or transducing T cells or NK cells according to any of the preceding claims, wherein the LE is capable of promoting cell survival and / or cell proliferation of T cells during culture without the need for the addition of IL-2.
5. Use of a replication-deficient recombinant retroviral particle in the manufacture of a kit for genetically modifying T cells or NK cells of an individual, wherein the use of the kit comprises: The T cells or the NK cells are contacted ex vivo with the replication-deficient recombinant retroviral particles, wherein the replication-deficient recombinant retroviral particles comprise a pseudotyping component on their surface, wherein the replication-deficient recombinant retroviral particles comprise a polynucleotide comprising one or more transcription units operably linked to a promoter active in T cells and / or NK cells, wherein the one or more transcription units encode a first polypeptide comprising a chimeric antigen receptor (CAR), a first polypeptide comprising a lymphoproliferative element (LE), or a first polypeptide comprising an LE and a second polypeptide comprising a CAR, wherein the one or more transcription units further comprise one or more of a Kozak-related sequence, a WPRE component, and a triple termination sequence, wherein the LE is capable of promoting cell survival and / or cell proliferation of T cells during culture without the need for the addition of IL-2, and wherein the contacting is performed for between 15 minutes and 18 hours to facilitate membrane fusion of the T cells or the NK cells with the replication-deficient recombinant retroviral particles, thereby producing genetically modified T cells or genetically modified NK cells.
6. A genetically modified T cell or NK cell, which is made by genetically modifying a T cell or NK cell according to a method comprising contacting the T cell or NK cell ex vivo with a replication-deficient recombinant retroviral particle, wherein the replication-deficient recombinant retroviral particle comprises a pseudotype component on its surface, wherein the replication-deficient recombinant retroviral particle comprises a polynucleotide, wherein the polynucleotide comprises one or more transcription units operably linked to a promoter active in T cells and / or NK cells, wherein the one or more transcription units encode a first polypeptide comprising a chimeric antigen receptor (CAR), a first polypeptide comprising a lymphocyte antigen receptor (IL-1), a second polypeptide comprising a cytokine receptor (CCR ... A first polypeptide comprising a tissue proliferative element (LE), or a first polypeptide comprising an LE and a second polypeptide comprising a CAR, wherein the one or more transcription units further comprise one or more of a Kozak-related sequence, a WPRE element, and a triple termination sequence, wherein the LE is capable of promoting cell survival and / or cell proliferation of T cells during culture without the need for the addition of IL-2, and wherein the contacting is performed for between 15 minutes and 18 hours to facilitate membrane fusion of the T cells or the NK cells with the replication-deficient recombinant retroviral particles, thereby producing the genetically modified T cells or the genetically modified NK cells.
7. A method for genetically modifying and / or transducing T cells or NK cells, comprising contacting the T cells or NK cells ex vivo with replication-deficient recombinant retroviral particles comprising a pseudotyped component on their surface, wherein the replication-deficient recombinant retroviral particles comprise a polynucleotide comprising one or more transcription units operably linked to a promoter active in T cells and / or NK cells, wherein the one or more transcription units encode a first polypeptide comprising a chimeric antigen receptor (CAR), a first polypeptide comprising a lymphoproliferative element (LE), or a first polypeptide comprising an LE and a second polypeptide comprising a CAR, wherein the one or more transcription units further comprise one or more of a Kozak-related sequence, a WPRE component, and a triple termination sequence, wherein the LE is capable of promoting cell survival and / or cell proliferation of T cells during culture without the need for the addition of IL-2, and wherein the contact is performed for between 15 minutes and 18 hours to facilitate membrane fusion of the T cells or NK cells through the replication-deficient recombinant retroviral particles, thereby producing genetically modified T cells or NK cells.
8. The use according to claim 5, the genetically modified T cell or NK cell according to claim 6, or the method for genetically modifying and / or transducing T cells or NK cells according to claim 7, wherein the LE comprises an intracellular signaling domain from: BTLA, CD2, CD3D, CD3E, CD3G, CD3Z, CD4, CD8A, CD8B, CD27, mutant δLck CD28, CD28, CD40, CD79A, CD79B, CRLF2, CSF2RB, CSF2RA, CSF3R, DAP10 / CD28, DAP12, EPOR, FCER1G, FCGR2A, FCGR2C, FCGRA2, GHR, ICOS, IFNAR1 , IFNAR2, IFNGR1, IFNGR2, IFNLR1, IL1R1, IL1RAP, IL1RL1, IL1RL2, IL2RA, IL2RB, IL2RG, IL3RA, IL4R, IL5RA, IL6R, IL6ST, IL7RA, IL9R, IL10R A. IL10RB, IL11RA, IL12RB1, IL12RB2, IL13RA1, IL13RA2, IL15RA, IL17RA, IL17RB, IL17RC, IL17RD, IL17RE, IL18R1, IL18RAP, IL20RA, IL20RB , IL21R, IL22RA1, IL23R, IL27RA, IL31RA, LEPR, LIFR, LMP1, MPL, MYD88, OSMR, PRLR, TNFRSF4, TNFRSF8, TNFRSF9, TNFRSF14, TNFRSF18, or ZAP70.
9. The use according to claim 5, the genetically modified T cell or NK cell according to claim 6, or the method for genetically modifying and / or transducing T cells or NK cells according to claim 7, wherein the LE comprises an intracellular signaling domain from the following: CD2, CD4, CD8A, CD8B, CD40, CD79B, CRLF2, CSF2RB, CSF2RA, CSF3R, EPOR, FCGR2C, FCGR2A, GHR, IFNAR1, IFNAR2, IFNGR1, IFNGR2, IFNLR1, IL1R1, IL 1RAP, IL1RL1, IL1RL2, IL2RA, IL2RB, IL2RG, IL3RA, IL4R, IL5RA, IL6R, IL6ST, IL9R, IL10RA, IL10RB, IL11RA, IL13RA1, IL13RA2, IL1 7RA, IL17RB, IL17RC, IL17RD, IL17RE, IL18R1, IL18RAP, IL20RA, IL20RB, IL22RA1, IL31RA, LEPR, LIFR, LMP1, MPL, MYD88, OSMR and PRLR.
10. The use, genetically modified T cells or NK cells, or method for genetically modifying and / or transducing T cells or NK cells according to any of the preceding claims, wherein the use or the method is performed without prior ex vivo stimulation.
